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The impact of chronic kidney disease (CKD) on drug disposition is essential to opti-
mize drug dosing in CKD. Clarifying the role of drug transporters and metabolic enzymes
for nonrenally cleared drugs has been an emerging clinical interest for dose optimization.
Physiologically-based pharmacokinetic (PBPK) modeling can provide valuable insight in
this research area. The primary aim of this dissertation was to develop a novel PBPK
approach and measurement procedure, called individualized PBPK modeling of rate data
(iPBPK-R) to simultaneously estimate parameters for nonrenal elimination pathways in in-
dividuals and evaluate the effect of CKD on these pathways. We first described iPBPK-R
which is a signal processing based indirect measurement method for measuring enzyme and
transporter activities for individuals. In two subsequent studies, iPBPK-R was applied to
14CO2 production rate data of erythromycin breath test (EBT) in healthy subjects and pa-
tients with end-stage renal disease (ESRD) receiving hemodialysis, respectively. Rate data
for 14CO2 production, as the approximate first derivative of
14CO2 concentration data, al-
lows iPBPK-R to successfully estimate parameters for nonrenal elimination pathways using
the single phenotypic probe 14C-erythromycin regardless of rate-limiting steps. iPBPK-R
analysis indicated that CYP3A4 activity is much lower than the baseline IVIVE input in
healthy subjects, and females had a higher CYP3A4 activity than males. In ESRD patients,
estimated adjustment factors indicated that hemodialysis increased CYP3A4 activity mini-
mally while OATPs activity varied among patients without improvement across hemodialy-
sis. BUN was not correlated with any of the nonrenal elimination pathways suggesting that
BUN is not a good candidate biomarker. Lastly, iPBPK-R was extended to its application to
multiple concentration datasets of temsirolimus and its metabolite sirolimus in healthy sub-
jects. Both temsirolimus and sirolimus are substrates of CYP3A4 and P-gp, and the effect
iv
of concomitantly administered rifampin on these elimination pathways was evaluated. The
findings showed that rifampin did not affect CYP3A4 activity on temsirolimus but increased
it for sirolimus by 73%. Rifampin did not affect P-gp activity. Collectively, iPBPK-R may
facilitate drug dosing based on personalized parameter estimates of nonrenal elimination
pathways. iPBPK-R may enable uremic toxin-based biomarker research towards precision
dosing in CKD as sketched with hierarchical cluster analysis.
Keywords: PBPK, CYP3A4, drug transporters, kidney disease, hemodialysis, uremic tox-
ins, physiologically based pharmacokinetics, erythromycin, temsirolimus, sirolimus, indi-
rect measurement, non-linear parameter estimation, breath test, precision medicine.
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1.1 Introduction
In the United States approximately 37 million adults, representing more than 10% of
the population, are estimated to have chronic kidney disease (CKD) [1], [2]. CKD patients
frequently exhibit altered pharmacokinetics (PK) and pharmacodynamics (PD), and thus
require special attention to the dosing of their medications in order to optimize safety and
efficacy. Hospitalized patients with impaired kidney function often receive medications that
are known to be nephrotoxic or require dose adjustment [3]. Unfortunately, CKD patients
are commonly prescribed numerous drugs concurrently and are also at high risk for med-
ication related problems in the outpatient setting. Hence, medication selection and dose
optimization are critically important for protecting a large segment of the U.S. population
and has direct implications to public health.
Drug studies in patients with kidney disease are complex, requiring effort from a multi-
disciplinary team of stakeholders, typically including pharmaceutical scientists, pharmacol-
ogists, regulatory scientists, and clinicians among others [4]. Yet, pharmacokinetics (PK),
the quantitative study of drug movement over time in terms of absorption, distribution,
metabolism, and excretion (ADME), provides all stakeholders with core principles for re-
fining drug dosing [5] [6]. Kidney function generally declines as kidney disease progresses.
Similarly, many factors related to ADME also change as the disease progresses, all of which
should be evaluated using PK principles to determine whether systemic exposure is altered,
requiring corresponding dose optimization. In addition to the glomerular filtration rate
(GFR), factors to be considered include hepatic metabolism, transport, plasma protein bind-
ing, and fraction unbound in plasma. These factors may affect not only renal clearance but
also nonrenal clearance pathways [7].
In the application of PK modeling it is common to use empirical equations to model
ADME and simulate drug concentration–time curve profiles to fit clinically observed con-
centration–time curve profiles. Parameter estimates obtained via this “top-down” popu-
lation PK approach are used to adjust drug dosing by comparing subjects with normal
kidney function and impaired kidney function [6]. However, physiologically-based pharma-
cokinetic (PBPK) modeling as a “bottom-up” approach is an alternative option to model
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drug concentration-time curves. Since the physiological and drug-specific parameters are
included in the model structure, PBPK modeling is at least partially mechanistic. This is
advantageous because the factors that are potentially altered in kidney disease can be evalu-
ated via modeling and simulation of drug exposure. A recent Food and Drug Administration
(FDA) guidance for industry acknowledges the strengths of PBPK modeling and encourages
its use during drug development [8].
We present an overview of PBPK modeling based dose optimization in kidney disease.
Several examples of PBPK models incorporating kidney function are provided, and appli-
cations and broad opportunities of PBPK modeling for dose optimization in patients with
kidney disease are discussed.
1.2 Dose Optimization in Kidney Disease
1.2.1 Evaluation of kidney function and the impact of kidney disease on drug
disposition
Optimal drug dosing in kidney disease requires both an accurate evaluation of the kid-
ney function and a mechanistic understanding of the impact of altered kidney function on
drug disposition. The current clinical practices of evaluation of kidney function are based
on research findings in 1960s to 1970s [9]. By 1970s it became known that patients with
kidney disease are more likely to experience adverse drug reactions compared to patients
with normal kidney function. It was also recognized that a decline in kidney function will
decrease clearance of renally cleared drugs and increase drug exposures [9]. Dettli et al. used
creatinine clearance (CLcr) to not only measure kidney function but also estimate nonrenal
elimination fraction and presented a dose calculation method [10]. Using serum creatinine
concentration Cockcroft and Gault developed a simplified equation (called the CG equation)
to estimate CLcr for dose individualization [11].
Accurate evaluation of GFR is one of the essential steps for dose optimization in kidney
disease. GFR can be approximately estimated with CLcr using the aforementioned CG
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equation. This surrogate measurement is commonly used in clinical practice. CLcr can
be alternatively calculated using urinary creatinine concentration but collection of required
urine samples is challenging in terms of accuracy and completeness. More recently, several
equations to estimate GFR were developed based on large epidemiological studies such as the
Modification of Diet in Renal Disease (MDRD) study [12] and the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) study [13]. Evaluation of kidney function for dose
adjustment may need to be further improved since clinical data in subpopulations such as
pediatrics and on new molecular entities are not sufficiently available or analyzed [14] [15]
[16] [17].
In terms of the impact of kidney disease on drug disposition, Reidenberg et al. recognized
that nonrenal metabolism of sulfisoxazole slowed in kidney disease as early as 1969 [18] and
later organized a list of drugs based on metabolic pathways [19]. By 1970s drug distribution
(e.g., digoxin), drug-protein binding (e.g., phenytoin), and drug sensitivity (e.g., atropine)
were also found to be affected in kidney disease [20] [21] [22] [23]. These early findings were
used to inform dose optimization of many drugs in kidney disease.
Glomerular filtration, tubular secretion and reabsorption in the nephron collectively de-
termine an individual’s kidney funcion. It is known that tubular secretion is a more efficient
mechanism of drug elimination and its dysfunction is associated with a great risk of death
independent of estimated GFR [24]. Given these complex clearance processes in the kidney,
deeper investigations of the underlying mechanism of altered kidney function and the extent
of impact of kidney disease on drug disposition are also warranted [24] [25] [26]. However,
accurate and non-invasive evaluation of the impact of kidney disease is not an easy task.
Modeling and simulations may be used to investigate the underlying mechanism of altered
kidney function and for predicting the impact of kidney disease on drug exposures in rel-
atively inexpensive and non-invasive fashion. The cost-effectiveness of modeling should be
validated at some point, for example, in terms of the time spent for collecting preclinical
data and modeling and simulation, predictability of the modeling, and the cost to hire sci-
entists versus the time spent for designing and conducting all necessary clinical studies, and
recruiting patients with kidney disease, analyzing the clinical data, and the cost to recruit
patients and hire operational staff and clinical scientists.
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1.2.2 Factors that may affect drug exposure in kidney disease
Multiple patient characteristics (i.e., demographic covariates) can be used for dose op-
timization in kidney disease. For example, evaluation of kidney function using MDRD and
CKD-EPI equations require age, serum creatinine clearance, sex, and race as intrinsic pa-
tient information [13] [27] [28]. In recent years, other factors also have been shown to
affect drug exposure in kidney disease. First, certain metabolism-mediated and transporter-
mediated pathways are known to be altered in kidney disease and this contributes to changes
in drug exposure of nonrenally cleared drugs as well as renally cleared drugs [29]. Zhang
et al. reported that between 2003 and 2007 [23], NDA submissions for nonrenally cleared
drugs included PK data in patients with impaired kidney function, and a quarter of these
showed about 2-fold increase in AUC [16]. In addition, the extent of altered nonrenal
elimination may vary based on the etiology of CKD (e.g., glomerulonephritis versus non-
glomerulonephritis) [30] [31]. Second, accumulated uremic toxins in the systemic circulation
may impact enzymatic metabolism and drug transporter function [7]. Uremic toxins are ni-
trogenous and other waste products accumulated in the blood in chronic kidney disease [7],
and they are classified into three groups based on physicochemical properties: (i) small, water
soluble compounds with a molecular mass less than 500 Da (ii) middle size compounds with
a molecular mass greater than 500 Da, and (iii) protein bound compounds [32]. Identifying
a particular uremic toxin out of more than 100 known uremic toxins as a cause of altered
drug disposition is difficult [33] [34]. A high concentration of uremic toxin does not neces-
sarily elicit a strong biologic effect [32]. However, some uremic toxins (e.g., hippuric acid,
indoxyl sulfate, incole-3-acetic acid, p-cresol, and CMPF) inhibit in vitro CYP3A4-mediated
metabolism [35]. Hsueh et al. identified that 12 and 13 out of 72 uremic solutes were in-
hibitors of renal OAT1 and OAT3 transporters in in vitro studies using a fluorescent probe
substrate, 6-carboxylfluorescein1, respectively [36]. Other uremic toxins have been reported
to directly or indirectly affect enzymatic metabolism and drug transport in experimental
models of end-stage renal disease (ESRD) [7]. PBPK modeling could facilitate research on
the effect of uremic toxins on metabolizing enzyme- and transporter-mediated pathways of
1For both OAT1 and OAT3 transporters 6-carboxylfluorescein was commonly used as a substrate.
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drug clearance in kidney disease. For example, evaluation of correlations between the plasma
concentrations of uremic toxins and the impact of altered enzyme or transporter activities
on drug exposure can provide clinical insights and serve as a hypothesis-generating analysis
for subsequent targeted biomarker research (i.e., facilitation of research).
1.2.3 Disease- and population-specific heterogeneity should be accounted for in
dose adjustment in kidney disease
Patients with kidney disease tend to have multiple comorbidities [2]. The leading cause
of death in ESRD is cardiovascular disease, though many other causes are also reported
including malignancy [2]. Accordingly, it is important to consider dose optimization for kid-
ney disease in a cross-disciplinary manner. For example, inclusion of patients with impaired
kidney function in oncology clinical trials requires special attention due to the potential for
increased risk of toxicity [37] [38]. In PK and dose escalation studies in oncology, safety
and clinical data are collected from cancer patients to determine maximum tolerated dose
(MTD). These patients may or may not have kidney impairment, and evaluation of the im-
pact of the kidney disease on drug disposition can be more complex compared to evaluation
of the impact of the kidney disease on disposition of drugs for treating other diseases. For
example clinical trials for anticancer drugs often employ unique study designs (e.g., adap-
tive designs, sequential designs, etc.) and sample sizes for evaluating the impact of kidney
disease may not be sufficient when such a study objective is not accounted for in the study
design and inclusion/exclusion criteria. In addition, the choice of method to evaluate kidney
function requires clinical judgement and affects eligibility to enroll patients [38]. This choice
may in particular introduce a bias in dose optimization of narrow therapeutic index drugs,
many of which are taken by cancer patients [39].
Evaluation of kidney function and dose adjustment in kidney disease need to be carefully
conducted in accordance with the target disease, sex, and age group to treat, not only in
oncology but also in geriatrics, pediatrics, hepatic impairment, among others [15] [40] [41]
[42] [43]. Target drug classes may include antibiotics and small biologics (< 60 kDa) [44] [45].
If drugs are orally administered, the effect of gut absorption needs to be accounted for in
6
the evaluation of the effect of kidney function. Crosstalk between the liver and kidneys
and particularly the gut-liver-kidney-axis is an emerging research area [46]. Gut-derived
uremic toxins are reported to lead to not only kidney disease but also liver disease. The
relationship between uremic toxins and these diseases may not be simple. Lin et al. showed
a relationship between liver disease and serum concentrations of the uremic toxins indoxyl
sulfate and p-cresyl sulfate independent of CKD severity [47]. Accordingly, drug disposition
may need to be evaluated by severity of liver disease and/or a choice of uremic toxins (as a
candidate biomarker) in the same CKD cohort. It is imperative to account for disease- and
population-specific heterogeneity in drug dosing as part of precision medicine, which can be
achieved via modeling and simulation [48] [49].
1.2.4 FDA guidance on PK studies in kidney disease
In its 1998 guidance and 2010 revision, the FDA recommends evaluating the effect of
kidney disease on PK/PD of investigational drugs to inform dosing recommendations. This
guidance provides a decision algorithm for conducting PK studies in kidney disease and
describes appropriate study designs where PK/PD data and other clinical factors should
be collected. In addition, the revised FDA guidance notably recommends: (1) using the
4-variable MDRD equation in addition to the CG equation to evaluate kidney function, (2)
conducting PK studies in kidney disease regardless of route of elimination of drugs (i.e.,
both renally and nonrenally cleared drugs), and (3) conducting PK studies in hemodialysis
(HD) patients [50] [51]. Since the original guidance was issued, a substantial number of
approved drugs include dose recommendations for kidney disease in the label [52] [53] [54].
It is anticipated that future revisions to the guidance will further streamline PK research in
drug development programs and enable more informed drug regimens for CKD patients [55].
PBPK modeling is a powerful tool to investigate the differential PK/PD of drugs in kidney
disease, as it also facilitates evaluation of multiple effects of extrinsic and intrinsic factors
on drug exposures and effects in kidney disease in an integral manner.
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1.2.5 Quantitative approaches for dosing evaluation
The effect of kidney disease on PK/PD and its variability by physiological, intrinsic, and
extrinsic factors are quantitatively evaluated using PK modeling [17]. With noncompartmen-
tal approaches, typical PK parameters such as the area under the plasma concentration-time
curve (AUC), Cmax, apparent clearance (CL/F), volume of distribution at a steady state
(Vss), and half-life (t1/2) are estimated. However, compartmental population approaches
are more useful to evaluate the effects of multiple factors that may be altered in kidney
disease [50]. A model-based dosing strategy is typically proposed based on population PK
modeling [56], and prediction of drug exposures by population PK modeling can be enhanced
by advanced techniques such as machine learning algorithms [57]. Population PK modeling
is usually considered a “top-down” approach as it is constructed on observed data [58]. In
contrast, PBPK models generally employ a “bottom-up” approach whereby a set of math-
ematical equations describe physiological and anatomical structures and drug flows in the
system using system-specific and drug properties as parameters [59]. Thus, PBPK modeling
is mechanistic in nature and therefore valuable for evaluating unique physiological factors
in a special population, such as kidney disease. This mechanistic approach may translate
to good precision dosing in the special population, and for this reason PBPK modeling has
garnered much attention in clinical pharmacology and drug dosing research [15] [60] [61] [62].
1.3 PBPK Modeling and Simulations
The concept of PBPK modeling is not new, but over the past two decades it has emerged
as an essential tool in drug development and regulation [59]. Two main reasons for this trend
are (1) development of specialized PBPK software in conjunction with increased computing
power, and (2) in vitro – in vivo extrapolation (IVIVE) techniques, by which some parameter
inputs necessary for simulation are taken from in vitro data [59], have become an integral
part of PBPK modeling. PBPK modeling can be used to predict variability in ADME for
different populations prior to conducting clinical trials [63].
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The power of PBPK modeling comes from its use of biological variables that facilitate
simulation and prediction of drug behaviors over time in virtual populations [58] [59]. This
in silico approach consists of three main parts. First, a structural model describing the
anatomical arrangement of organs and tissues connected by blood vessels is built for a hu-
man body system. Second, parameters for system-specific properties are collected and used
as model inputs. Third, parameters for drug properties are collected and used as model in-
puts. Examples of drug-specific properties are tissue affinity, plasma-protein binding affinity,
enzymatic stability, and transporter activity.
IVIVE techniques can further improve PBPK modeling by enabling calculation of a
necessary parameter value like intrinsic metabolic clearance, for a large population based
on in vitro data, such as that from human liver microsome experiments. Resulting PBPK-
IVIVE linked models increase the impact of preclinical data and aid in prediction of clinical
variability by utilizing both preclinical and mechanistic information [64].
Traditionally, human PK predictions have been based on an allometric approach, which
assumes that the only difference between human and other mammals is size; however, such
predictions have been shown to be imprecise [65]. Compared to the allometric approach, the
IVIVE approach improves the predictability of plasma concentrations for several drugs [59].
The improved predictability is likely due to PBPK-IVIVE linked models that account for
underlying biological variability between species as well as in a population. However, overall
predictability of PBPK models needs to be further improved by accounting for intervariability
of intrinsic and extrinsic factors of in vitro samples since in vitro experimental data are used
to calculate IVIVE values [66]. Intrinsic factors may be genetic polymorphism, smoking, or
alcohol drinking of humans from whom hepatocyte samples are obtained. Extrinsic factors
may be preparation process and/or storage condition of human liver samples.
PBPK-IVIVE linked models have been particularly useful to investigate variability in
hepatic clearance caused by differential drug metabolism and/or transporter activity in a
special population [64], which may facilitate PBPK model-based dose optimization. Several
equations have been proposed to calculate IVIVE values depending on the type of preclinical
experiments [67] [68] [69]. For example, calculating intrinsic metabolic clearance for the
whole liver using data from recombinantly expressed CYP enzymes incorporates not only
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the maximum velocity (Jmax) and Michaelis-Menten constant (Km) of each CYP enzyme
in the drug’s metabolic pathways, but also the amount of microsomal protein per gram of
liver (MPPGL), the liver weight, and a scaling factor per unit of enzyme from recombinant
systems to hepatic enzymes (ISEF) for each enzymatic activity and pathway.
A summary querying PBPK publications on PubMed between January 2008 and May
2015 [70] reported the most common uses of published PBPK models to be prediction of DDI,
followed by predictions of interindividual variability and dose exposure. Population PBPK
modeling has also been utilized for complex analyses of enzyme-transporter interplay [71].
PBPK modeling has been considered to be a key innovation in personalized medicine and dose
optimization as it alleviates some of the ethical and methodological hurdles of conducting
clinical trials by simulating clinical scenarios and elucidating mechanistic insights in special
populations [72] [73].
Applications of PBPK modeling in kidney disease can be aligned with drug development
[74]. The FDA issued guidance for PBPK analyses discussed that “throughout a drug’s life
cycle, PBPK model predictions can be used to support decisions on whether, when, or how
to conduct certain clinical pharmacology studies, and to support dosing recommendations
in product labeling” [8]. In light of the FDA guidances related to PBPK documentation
and conduction of PK studies in kidney impairment [8] [75], it is well envisioned that PBPK
modeling will increasingly be used to evaluate dose-exposure relationships and support dose
recommendation decision-making in the kidney disease population. PBPK-based findings
that are informative for dose optimization in kidney disease have been presented in the past
decade both within and beyond drug development [60].
1.4 Examples of PBPK Modeling in Kidney Disease
1.4.1 PBPK modeling for renally cleared drugs in CKD
Accurate evaluation of renal clearance is important for predicting drug exposure of renally
cleared drugs. Renal clearance is a net result of glomerular filtration, reabsorption, and
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secretion.
A 35-compartment PBPK model verified with 46 test compounds [76] described detailed
mechanisms underlying passive reabsorption processes (e.g., tubular water reabsorption, dy-
namic tubular flow, tubular pH, and microvilli) contributing to renal clearance. The pre-
dicted renal clearance was within 2-fold of the observed renal clearance in 87% of drugs
tested, showcasing the value of mechanistic PBPK studies in assessing tubular reabsorption
and its contribution to renal elimination of xenobiotics.
Renal secretion has been evaluated in multiple PBPK modeling studies. Renal trans-
porters are major contributors to renal secretion, and as such it is essential to understand
the mechanism of transporter-mediated activities. Hsu et al. evaluated the utility of a
PBPK model incorporating both renal uptake and efflux transporters for three renally cleared
drugs: oseltamivir carboxylate, cidofovir, and cefuroxime [77]. Incorporating manual sensi-
tivity searches, they explored the association between drug exposure in kidney disease and
both renal transport activity and a system-specific parameter (proximal tubular cells per
gram kidney or PTCPGK). Transporter-mediated activity was investigated by ranging the
apparent inhibition constant Ki of probenecid in DDI simulations. When the transporter-
mediated secretion was modeled, the simulated mean AUC ratio (AUCR) between renally
impaired patients and healthy controls improved model predictability for all three drugs.
One should note that in this study, no common threshold of PTCPGK across the drugs (i.e.,
to differentiate drug exposure in kidney impairment from healthy subjects) was determined.
This suggests that inhibition of drug transporters is not solely based on the reduction of
PTCPGK, but may depend on the relative magnitude of intrinsic transporter clearance of
each drug. When simulations for each drug were conducted with probenecid (i.e., DDI sim-
ulations), approximate ranges of in vivo Ki were identified for oseltamivir carboxylate and
cefuroxime. However, the range of Ki could not be identified for cidofovir since in DDI sim-
ulations Ki was not sensitive to the AUC ratio of cidofovir with probenecid versus cidofovir
without probenecid. While the authors evaluated a range of 1-100µM for Ki in the sensi-
tivity analysis based on in vitro data, the clinical concentration of probenecid can increase
up to 520µM in healthy subjects. [78] In this sense, a well-designed follow-up sensitivity
analysis may provide further insights on Ki for cidofovir. Hsu et al. also simulated renal cell
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concentrations of cidofovir by inhibiting uptake and/or efflux transporters and elucidated a
plausible mechanism of the DDI for cidofovir. This in turn contributed to understanding
nephrotoxicity, which is believed to be caused by increased renal exposure of cidofovir. This
assumed mechanism can be investigated only through modeling and simulation.
Posoda et al. conducted similar PBPK modeling of DDI studies for baricitinib in healthy
subjects [79]. In this PBPK application, an IC50 value extrapolated from in vitro data
was used to simulate inhibition of nonlinear renal transporter OAT3. The study cohort
was composed of healthy subjects. However, this PBPK modeling approach may inform
subsequent drug development work for determining dose recommendation in kidney diseases
as it evaluated the alteration of renal OAT3 activity. At the same time, one limitation in
the PBPK modeling is that extrapolated in vivo parameter inputs may not be sensitive or
accurate because of simple assumptions used to derive parameter equations [77] [80] [81] [82].
Scotcher et al. discussed renal drug transport and uncertainty in system- and drug-
specific parameters that are used for developing PBPK models for renal drug disposition
[83]. In PBPK kidney models of digoxin in healthy subjects, geriatrics, and kidney disease
patients, the predicted renal clearance relative to observed renal clearance was improved after
renal transporters OATP4C1 and P-gp were added to the model [84]. Furthermore, using
sensitivity analyses in PBPK modeling and simulations, it was concluded that either reduced
PTCPGK or abundance of OATP4C1 (but not P-gp) is a potential cause of decreased renal
secretion of digoxin. Based on this PBPK work, it is anticipated that improving the search
algorithm and optimization method for system- and drug-specific parameters will facilitate
the utility of PBPK modeling of renal cleared drugs.
In addition to assessing the contribution of renal clearance on exposure of renally cleared
drugs, PBPK modeling and simulation may be used to evaluate whether renally cleared
drugs affect exposure of concomitant drugs in kidney disease via metabolic inhibition or
induction.
Lu et al. applied PBPK modeling to evaluate a potential drug-drug interaction (DDI) of
the renally cleared drug orteronel, a weak in vitro inhibitor of CYP1A2, 2C8, 2C9, and 2C19,
using data from human liver microsomal studies [85]. PBPK modeling demonstrated that
the AUC of four CYP substrates did not significantly differ (AUCR < 1.25) in the presence
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and absence of orteronel. This indicated that orteronel is a ‘non-inhibitor’ as per FDA DDI
guidance [86], avoiding the cost for conducting clinical DDI studies before the drug approval.
1.4.2 PBPK modeling for nonrenally cleared drugs in CKD
About 75% of currently approved drugs undergo CYP-mediated metabolism [87] [88]
[89] and more than half of nonrenally cleared drugs present altered PK profiles in kidney
impaired patients [16]. In CKD patients when metabolic enzymes and drug transporters are
involved in drug disposition, the magnitude of altered nonrenal clearance may not be easily
determined [73]. PBPK modeling allows us to account for a potential interplay between
enzymatic and drug transporter activity in nonrenal clearance, and to evaluate the impact
of kidney disease on disposition of nonrenally cleared drugs.
In a simulation study, the impact of kidney disease on repaglinide exposure was evaluated
by varying kidney function (down to GFR < 30 mL/min/1.73 m2) and comparing it to the
mean exposure in healthy subjects [60]. Incorporating intrinsic metabolism by CYP3A4 and
CYP2C8 and transporter clearance (OATP1B1 uptake) into the PBPK model, the predicted
results were relatively consistent with the observed exposure in each population. However,
more validation of the model was considered to be necessary.
Zhao et al. evaluated the utility of PBPK modeling for three nonrenally cleared drugs:
sildenafil, repaglinide, and telithromycin [90]. Physiological parameters known to be differ-
entially expressed in kidney impaired patients versus healthy subjects, including abundance
of CYP3A4 (metabolizing sildenafil, telithromycin, and repaglinide), CYP2C8 (metaboliz-
ing repaglinide), and CYP2C9 (metabolizing sildenafil), were incorporated into the model.
Predicted and observed AUCR of kidney impaired patients to healthy subjects correlated
reasonably well for sildenafil and telithromycin. The predicted AUCR for repaglinide was
lower than the observed value (1.2 vs 3.0), but this difference improved after OATP1B1
activity in the model was decreased for the kidney impaired patients. This study emphasizes
the importance of incorporating patient-specific system-dependent parameters (such as rel-
ative abundance of CYP enzymes) in special population PBPK models. The knowledge gap
regarding the effect of kidney disease on hepatic transporter OATP1B1 was also improved
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via the PBPK modeling work.
PBPK modeling also demonstrates that the effect of kidney disease on physiological pro-
cesses, including hepatic clearance, may not be linear to the disease severity [90]. A series of
studies investigated the effect of CKD on nonrenal elimination pathways to elucidate whether
changes are enzyme and/or transporter specific [91] [92] [93]. Yoshida et al. conducted a sys-
tematic evaluation of the effect of CKD on CYP2D6- and CYP3A4/5-mediated clearance of
13 and 18 substrates, respectively, in increasing disease severity: mild, moderate, and severe
CKD, and dialysis-independent ESRD [91]. The study concluded that CYP2D6-mediated
clearance decreased in parallel with the severity of CKD while there was no apparent re-
lationship between CYP3A-mediated clearance and the severity of CKD. Similarly, Tan
et al. conducted a systematic evaluation of CYP1A2-, CYP2C8-, CYP2C9-, CYP2C19-,
and OATP-mediated clearances in CKD [92]. The results suggested that CYP2C8- and
OATP-mediated clearance decline according to disease severity, but the effect of CKD on
the activities of CYP1A2, CYP2C9, and CYP2C19 was variable and minimal.
Subsequent work by Tan et al. utilized PBPK modeling to delineate CYP2C8 and
OATP1B activities in CKD using substrates of CYP2C8 (rosiglitazone and pioglitazone),
OATP1B (pitavastatin), or both (repaglinide) [93]. PK profiles for severe CKD patients
were simulated with altered GFR, plasma protein binding, and activity of CYP2C8 and/or
OATP1B in a stepwise fashion. The PBPK analysis suggested that OATP1B activity could
be reduced in severe CKD but CYP2C8 activity is not affected by CKD. PBPK modeling
was shown to be useful for interrogating elimination pathways of nonrenally cleared drugs.
The reported decreases in pathway-specific nonrenal clearance are informative for clinical
pharmacologists and drug developers, as the information may be used to anticipate the need
for dose optimization of corresponding drug substrates in patients with kidney disease. One
limitation of the systematic evaluations evaluations by Yoshida et al. and Tan et al. (2017)
may be a lack of generalizability due to small numbers of model drugs and sample sizes of
the studies included (i.e., small sample sizes without pre-planned power calculation) [29]. In
addition, statistical analysis did not account for data dependency across disease stages for
each drug. Data was not uniformly available across all disease stages and drugs. Although
these systematic evaluations require confirmatory studies, it is clear that the subsequent
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PBPK modeling and simulation work by Tan et al. (2018) is an advantageous tool for
evaluating the complex interplay of multiple nonrenal elimination pathways in kidney disease.
1.4.3 Top-down PBPK approaches to evaluate altered drug exposure and its
causes in kidney disease
Uremic toxins accumulate in kidney disease and are suggested to be causes of altered
transcription, expression, and activity of CYPs and transporters [73] [94] [95] [96]. To under-
stand the effect of the toxic waste product creatinine on the MATE1 efflux transporter, Al-
mukainzi et al. performed PBPK modeling of the renally-cleared drug metformin in healthy
and kidney impaired subjects along with cell culture inhibition studies [97]. The model in-
cluded OCT2 uptake, and MATE1 and MATE2 efflux transporters in the kidney, OCT1 and
MATE1 transporters in the liver, and literature-based differences in system-specific prop-
erties (hematocrit, renal blood flow, gastric pH, and GFR value). The study concluded
that increased metformin exposure in kidney disease patients could be explained by down-
regulation of MATE1 in the kidney and liver in the PBPK analysis. This increased exposure
may be mediated by creatinine but creatinine concentration was not statistically associated
with the change of metformin uptake in the cell culture studies. The authors discussed
that high capacity of MATE1 towards creatinine may be a possible reason that accumulated
creatinine did not affect the PK profile of metformin in kidney disease. This finding based
on PBPK modeling added to the previous work showing that metformin exposure is altered
by decreased OCT2 activity [98]. To further understand the role of uremic toxins on drug
disposition, a novel middle-out PBPK approach may be effective.
The above PBPK modeling was a semi top-down approach where levels of transporter
(OCT2 and MATE1) expression was varied to find the best values to fit the model to the
observed PK profile in kidney disease. Generally, bottom-up PBPK modeling is common.
However, a top-down PBPK approach is also possible for the purpose of parameter esti-
mation rather than prediction of PK profiles. Top-down PBPK approaches typically use
reduced order models. In reduced order models the number of organ/tissue compartments is
limited [59] so that a set of parameters can be estimable with a limited number of observed
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samples [99]. Sayama et al. used a variant top-down approach where some PK parameter
inputs for CKD patients were statistically obtained from their compiled clinical datasets of
151 compounds (i.e., interquartile ranges were obtained) [100]. The collected PK parameters
were: unbound fraction in plasma (fp, fraction excreted unchanged in urine (fe), apparent
volume of distribution at steady-state, clearance (CL), AUC after oral dosing, and elimina-
tion t1/2. Relative percentages (RPs) of these PK parameters and scaling factors (SFs) of
unbound intrinsic clearance in the liver (CLH,u), and renal clearance (CLR) were calculated
to scale PK parameters of healthy subjects to those of patients with kidney disease for any
compounds in the same category (basic, acidic, and neutral drugs). SFs calculated with the
dataset were derived in a top-down approach. Using SFs as inputs for moderate and severe
CKD patients, PBPK modeling of 12 compounds were performed and PK profiles were sim-
ulated. The 12 compounds were selected from the 151 compounds. As a result of PBPK
modeling, the predicted range of CL contained the observed CL in 83% and 58% of the 12
compounds in moderate and severe CKD conditions, respectively. Although the prediction
in moderate CKD seems to be reasonable, the predicted ranges were broad. Furthermore,
synthesizing SFs of all different types of drugs and extrapolating them in mechanistic model-
ing of a particular drug is likely to lead to statistical biases, especially when individual drugs’
in vivo parameters are available without extrapolation. In the model structures, detailed
renal and nonrenal elimination pathways were not included. Thus, this PBPK top-down
method may require some improvement.
1.4.4 A middle-out PBPK approach to simultaneously evaluate hepatic trans-
port and metabolism pathways
In this dissertation research, we develop a top-down + bottom-up or ‘middle out’ PBPK
approach, namely, individualized PBPK modeling of rate data (iPBPK-R) using a reduced
order model and apply it to 14CO2 production rate data. We also apply iPBPK-R to multiple
coupled drug concentration data of parent drug temsirolimus and its metabolite sirolimus to
evaluate the feasibility of the method. iPBPK-R enable simultaneous evaluation of hepatic
transport and metabolism pathways and exploration of uremic toxin-mediated alterations of
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drug disposition in individuals. We describe the details of the development and applications
of iPBPK-R in Chapter 2 to Chapter 5.
1.4.5 Predictability and interpretation of PBPK modeling and simulation in
kidney disease
During PBPK modeling and simulation it is important to inspect the model for pre-
dictability and to conduct careful interpretation. Generally, the decision criterion for ac-
ceptable model predictability is simulated PK profiles (AUC, Cmax, etc,) within 2-fold of the
observed PK profiles [76, 90, 93, 101, 102]. Among the PBPK applications discussed above,
poor predictability during model development was observed when either essential parameters
for intrinsic clearance were not incorporated in the model or uncertainty of the parameter
input (e.g., IVIVE value) was likely to be high. For example, Hsu et al. described that
when only altered GFR is considered in DDI simulations for severe renal impairment, pre-
dicted AUCR between kidney impairment and normal kidney function were between 3- to
5.5-fold [77]. This low predictability was resolved by incorporating the transporter-mediated
secretion with reduced PTCPGK in the model. As another example, Scotcher et al. reported
that varying IVIVE values of OATP4C1-mediated clearance based on different in vitro data
led to 8-fold difference in simulated renal clearance. As illustrated in these examples, to
improve the model predictability it is essential to identify impactful system-specific and/or
drug-specific property parameters. This can be conducted through sensitivity analysis vary-
ing parameters of interest within a clinically relevant range. Also, collecting quality in vitro
experimental data for IVIVE is often challenging. In the case of kidney disease, using in vivo
parameters which are pre-estimated using a CKD patient database may be one alternative
approach as in top-down PBPK modeling. Regardless, good predictability is not guaranteed
and PBPK modeling and simulation needs to be carefully designed, improved, and vali-
dated. Knowledge may also be gained on system- and drug-specific properties by estimating
individual in vivo parameters using a middle-out approach to supplement model prediction.
When interpreting the predicted results from PBPK modeling and simulation, it is essen-
tial to pay close attention to parameter dependency. PBPK modeling incorporates various
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system-specific and drug-specific properties and they should be dependent with each other
within the system. Consequently, the effects of these properties may not be obvious and
may be mathematically indistinguishable in simulations. This was observed as unidentified
properties of PTCPGK and intrinsic transporter clearance in DDI studies and the unidenti-
fiable range of Ki for cidofovir in the study by Hsu et al [77]. At times, it may be necessary
to treat multiple transporter phenotypes as a global- or meta-transporter. Understanding
mathematical relationships among property parameters and conducting sensitivity analysis
on them is essential to have confidence in interpretation.
While kidney function (i.e., GFR) has been included as a covariate in many PBPK
applications, the effect of kidney disease itself on physiological parameters (e.g., renal trans-
porters, renal filtration/secretion processes) that impact PK have not been extensively ex-
plored using PBPK to date. Another unique aspect of exploring kidney disease in PBPK
applications is the ability to evaluate its effect on nonrenal elimination pathways, mainly
metabolism-mediated pathways and transporter-mediated pathways in the liver. In addi-
tion, the top-down PBPK example used in vivo parameter estimates collected from CKD
patients, and one middle-out PBPK approach evaluate the effect of hemodialysis in Chap-
ter 4. A variety of applications of PBPK modeling of renally and nonrenally cleared drugs in
kidney disease and unique PBPK approaches for evaluating PK parameters mechanistically
are presented in Table 1. Table 2 lists potential factors for evaluation based on these appli-
cations. In the next section we summarize challenges and opportunities of PBPK modeling
for dose optimization in kidney disease.
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Table 1: Examples of PBPK modeling including parameters related to kidney function
Applicationa Substrates Inhibitors Model features Observationsc Software or
platform
Ref.
Renal clearance 46 compoundsb NA A 35-compartment kidney




tubular flow, tubular pH, and
microvilli).
Renal clearance in 87% of
drugs was predicted within a










Probenecid Renal uptake and efflux trans-
porters were modeled; The
role of transporters was ex-
plored with PTCPGK andKi.
The simulated mean AUC ra-
tio between renally impaired
patients and healthy controls
improved model predictabil-
ity for all three drugs. Ap-
proximate ranges of in vivo
Ki of probenecid were iden-





Baricitinib Probenecid Nonlinear renal transporter
OAT3 was modeled; IC50 was
used to evaluate the trans-
porter inhibition.
The role of OAT3 and its po-
tential DDI were predicted.
Simcyp [79]
Renal clearance Digoxin NA Kidney models for healthy
subjects, an elderly cohort,
and patients with kidney im-
pairment; Modeled renal up-
take and efflux transporters
with varying PTCPGK or
abundance of transporters.
Parameters causing a decrease




Table 1: Examples of PBPK modeling including parameters related to kidney function (continued)









CYP1A2, 2C8, 2C9, and 2C19
were modeled; Inhibition of
CYPs was evaluated with Ki
of each inhibitor.
Orteronel was identified as a
non-inhibitor for CYPs evalu-
ated. Simulated AUC for kid-








NA CYP2D6 for paroxetine,
CYP3A4 for diltiazem, and
OATP1B1 for repaglinide
were included in models;
Drug exposures were simu-
lated for moderate and/or
severe CKD (30-59 and <
30ml/min/1.73m2, respec-
tively) vs. healthy subjects.
Incorporating enzyme- and
transporter-mediated clear-
ance into the PBPK model,
the predicted results were
relatively consistent with the
observed exposure in each
population. For repaglinide,
in vitro data OATP1B1 was
limited to use in PBPK
modeling, and simulated PK











NA CYP3A4, 2C8, 2C9, and
OATP1B1 were modeled de-
pending on the substrate
specificity; effect of decreased
abundance of CYPs with KI
was evaluated.
PK profiles were well pre-
dicted against observed data
in healthy and KI cohorts ex-
cept for repaglinide. This was






Table 1: Examples of PBPK modeling including parameters related to kidney function (continued)









NA CYP2C8 and/or OATP1B1
were modeled in a stepwise
fashion with altered GFR and
plasma protein binding for
CKD patients
OATP1B1 activity but not
CYP2C8 was found to de-





Metformin Renal transporters OCT2,
MATE1, and MATE2 were
modeled. Hepatic OCT1 and
MATE1 were also included;
Hematocrit, renal blood flow,
Gatric pH, and GFR were
altered in KI. The results




in kidney and liver was found
to explain the altered PK pro-
file of metformin in KI. Crea-








12 compoundsb RPs of fp, fe, Vss, CL, t1/2,
and AUC between healthy
subjects and CKD patients
were statistically obtained
from 151 compounds in clin-
ical database. SFs of CLH,u
and CLR were calculated to
use in PBPK models. Model
predictability was assessed
for moderate and severe CKD
conditions.
Hepatic and renal clearance
were well predicted in half to
2/3 of the model compounds




Table 1: Examples of PBPK modeling including parameters related to kidney function (continued)








14C-erythromycin NA A reduced order model with
CYP3A4 and hepatic trans-
porters was fit to 14CO2 pro-
duction rate data in healthy
individuals; impactful PBPK
parameters were estimated.
Parameters related to nonre-
nal elimination pathways were
correlated with uremic toxins.
CYP3A4 and hepatic trans-
porter activities were esti-
mated in healthy individuals.
Correlations of parameter es-











14C-erythromycin NA A reduced order model with
CYP3A4 and hepatic trans-
porters was fit to 14CO2 pro-
duction rate data in individ-
ual patients across hemodialy-
sis; impactful PBPK parame-
ters were nested co-estimated.
The effect of hemodialysis on
CYP3A4 and OATPs activi-
ties was evaluated. These pa-
rameters were correlated with
uremic toxins
The effect of hemodialysis on
multiple nonrenal clearance
pathways was individually es-
timated. Correlations of pa-
rameter estimates with ure-




NA, not applicable. a. Renal clearance denotes that renal clearance was evaluated for renally cleared substrate(s) while nonrenal
clearance denotes that nonrenal clearance was evaluated for nonrenally cleared substrate(s) unless it is further indicated.
b. Model compounds included both renally cleared and nonrenally cleared substrates. c. The column includes dose-related if the
research problem is related to dose-optimization for kidney disease.
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1.5 Opportunities for PBPK Modeling in Kidney Disease
While many PBPK applications have included kidney function as a parameter, kidney
disease per se has not been extensively explored by PBPK modeling. Several opportunities
in PBPK modeling for dose optimization in kidney disease are presented in Table table 3.
First, accurate evaluation of kidney function is a challenge because renal clearance is
an elimination process consisting of GFR, active secretion, and reabsorption in the complex
structure of the kidney. Each renal elimination pathway cannot be easily measured separately
in a clinical setting. In this situation, PBPK modeling can provide mechanistic insights
regarding renal elimination of xenobiotics. Several PBPK studies have shown reasonable
predictability of drug exposures when the renal clearance was modeled in detail, such as by
incorporating relevant renal transporter and metabolic enzyme intrinsic clearance in PBPK
model equations. Detailed kidney models can be developed to simulate and predict drug
exposures. Alternatively, reduced order models may be considered to employ top-down
and middle-out PBPK approaches and to elucidate a dominant elimination pathway for a
particular drug.
Second, there has been great interest regarding the effect of CKD on drug exposure, espe-
cially for nonrenally cleared drugs. Evaluating intrinsic clearance by hepatic transporters and
metabolic enzymes using PBPK modeling is likely to fill knowledge gaps in drug disposition
at different stages of kidney disease. PBPK modeling has also proven to be useful in identi-
fying impactful changes in systemic- and drug-dependent parameters and their association
with CKD progression. At the same time, there is still room to improve overall predictability
of PBPK-IVIVE linked models, and thus advancing in vitro experimental techniques may
partly eliminate biases in parameter inputs.
Third, PBPK modeling and simulation can be applied to prevent DDI-related toxicity
in kidney disease. Both perpetrator drugs and victim drugs can be evaluated by PBPK
modeling to assess whether a DDI is mediated by renal transporters, hepatic enzymes, or
any interplay of transporters and enzymes under the varying condition of kidney impairment.
PBPK modeling has proven to be advantageous relative to simple in vitro experiments for
DDI studies since it can evaluate various DDI scenarios by ranging parameter values.
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Fourth, causes of interindividual variability in kidney disease are important to investigate
prior to considering precision dosing. Focusing on a sub-cohort of CKD patients in PBPK
modeling may facilitate discovery of factors that contribute to inter-individuality. Sub-
cohorts may be CKD-specific (i.e. hemodialysis-independent ESRD patients, administration
of drugs pre- and post-hemodialysis, patients with glomerulonephritis versus CKD of non-
glomerular etiology) or extrarenal (i.e. various comorbidities, different stages of the human
life cycle, and specific classes of drugs).
Fifth, in vivo parameter inputs can be explored in combination with top-down and
middle-out PBPK approaches to supplement IVIVE techniques. Related examples were
reviewed above: a large clinical database study where PBPK parameter inputs in kidney
disease were collected and extrapolated into PBPK modeling [100]. As another study, indi-
vidualized PBPK model fitting can be conducted to indirectly estimate multiple parameters
on nonrenal elimination pathways utilizing reduced order models like this dissertation re-
search.
Sixth, PBPK modeling is a dynamic mechanistic approach that enables exploration of
the association of uremic toxins as potential causes of altered drug disposition and parameter
estimates related to drug elimination pathways. Uremic toxins can be treated as perpetrator
drugs in PBPK DDI modeling. Furthermore, PBPK modeling can be co-implemented with in
vitro cell culture experiments with an increasing concentration of uremic toxins as reviewed
above [97]. Correlation analysis combined with a middle-out PBPK approach is another
method to explore the impact of uremic toxins on transporter- and metabolism-mediated
pathways. We present such correlation analysis in Chapters 3 and 4.
Lastly, to maximally benefit from PBPK modeling, clinical trial designs may need to
be designed and coordinated with subsequent PBPK analyses in mind in order to optimize
the clinical information available for subsequent modeling (i.e., optimal sampling times to
enhance PBPK modeling) [107].
In summary, PBPK modeling and simulation provides exciting opportunities to support
quantitative studies in pharmacology, pharmacokinetics, and drug dosing in the setting of
kidney disease. PBPK modeling and simulation enables the integration of data from both
in vitro and clinical work pertaining to drug-specific parameters, system-specific parameters
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and model structure to make mechanistic inferences on drug exposure. PBPK modeling may
be used to accurately evaluate kidney function and to mechanistically understand the impact
of kidney disease on drug disposition. FDA guidance related to PBPK and conduction of
PK studies in kidney impairment will further incentivize model-based dose finding research
in kidney disease.
Table 2: Potential factors for evaluation in PBPK modeling in kidney disease
Type of factors Factors for evaluation in kidney disease PBPK modelingab
Kidney function/renal
clearancec
GFR, passive reabsorption processes (e.g., tubular water reabsorp-
tion, dynamic tubular flow, tubular pH, and microvilli), secretion
processes (e.g., renal transporter intrinsic clearance such as OAT1,
OAT3, OCT2, OATP4C1, MATE1, MATE2, and P-gp), PTCPGK
Nonrenal elimination
pathwaysc
Intrinsic clearance of hepatic enzymes (e.g., CLint, or Jmax and Km
of CYP3A4 and CYP2C8) and transporters (e.g., OATP1B, P-gp,
OCT1, and MATE1), SF of intrinsic clearance, ISEF
System-specific proper-
ties
Organ mass or volume (e.g., hepatocyte volume), blood flow, and
tissue composition
Drug-specific properties Tissue affinity, plasma-protein binding affinity, enzymatic stability




IC50, Ki (e.g., CYP2C8, CYP2C9, CYP3A4 inhibitors), uremic toxin
concentrations (e.g., creatinine, IS, and PCS)
a. The list is not comprehensive but it summarizes factors discussed in the examples of
PBPK modeling in kidney disease. b. The factors which cannot be parameterized in non-
compartmental analysis and population PK modeling may be captured by PBPK modeling.
c. These are of particular of interest in kidney disease modeling and part of either systemic-
or drug-specific properties.
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Table 3: Key challenges and opportunities in PBPK modeling for dose optimization in kidney disease
Challenges Opportunities Examples and considerations
Accurate evaluation of kid-
ney function
• To model detailed components of kidney
function [76,83]
• Reabsorption [108], active secretion, re-
nal tubule, renal enzyme- and/or re-
nal transporter-mediated pathways such as
OAT1 and OAT3 may be considered.
Evaluation of the effect of
CKD on renally and nonre-
nally cleared drugs [91] [92]
• To model relevant drug transporters,
metabolic enzymes, and/or interplay of
transporters and enzymes in CKD and com-
pare it to normal kidney function [93,97]
• To advance in vitro experimental tech-
niques [109]
• To evaluate influential system- and drug-
dependent parameters in sensitivity analy-
sis
• Interplay between CYP3A4 and P-
glycoprotein is well-known for many
substrates [110] and whether such interplay
affects drug exposure in CKD may be
considered.
• Experiments with Caco-2 cells modified to
express CYP3A4 may be designed and cor-
responding IVIVE equations may be devel-
oped.
Evaluation of enzyme- and
transporter-mediated DDI
in kidney disease
• To incorporate intrinsic clearance
(metabolic enzyme and/or transporter
activities) and model a perpetrator
drug and/or victim drug in kidney dis-
ease [79] [82] [81]
• DDI PBPK modeling in new drug develop-
ment may be routinely conducted in kidney
disease to develop dose recommendations in




based dose selection for a
sub-population of CKD
• To model ADME in a subpopulation of kid-
ney disease
• To conduct parameter estimation via
PBPK model fitting in kidney disease and
correlation analysis of parameter estimates
and disease stage/type
• Altered drug disposition in ESRD (off-
dialysis), hemodialysis [49, 106], kidney
transplant, glomerulonephritis [31] may be
modeled and evaluated.
• Individualized PBPK modeling of rate data
(iPBPK-R) in CKD may be adopted [106].
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Table 3: Key challenges and opportunities in PBPK modeling for dose optimization in kidney disease (continued)
Challenges Opportunities Examples and considerations
Evaluation of the effect




different life stages) [112]
• To model ADME in a relevant special pop-
ulation [62] and/or for a particular class of
drugs with and without kidney impairment
• Examples of special populations are: CKD
patients in oncology [38,42], pediatrics, [15]
pregnancy, [113] and geriatrics [41]; CKD
patients with hepatic impairment [46, 47,
114], antibiotics, and small biologics (<
60kDa) [45].
• Ontogeny information may be incorporated
into a PBPK model in kidney impairment
[43,115].
Development of a mecha-
nistic rationale for dose op-
timization in kidney dis-
ease
• To conduct top-down PBPK modeling and
sensitivity analysis to define impactful pa-
rameters (system- and drug-dependent pa-
rameters) in CKD patients
• To use a synthetic modeling approach in in
vitro experiments [116] [59] and obtain in-
put parameters for PBPK modeling in kid-
ney disease
• To incorporate machine learning/AI into
PBPK modeling in kidney disease
• To collaborate with engineers and computer
scientists to conduct efficient modeling and
simulations
• Partition coefficients [117], plasma protein
binding [93], PTCPGK [77,84], among oth-
ers may be investigated as potentially influ-
ential parameters.
• Alternatively, consider collecting in vivo
parameter estimates from a large drug
database to conduct top-down PBPK mod-
eling in kidney disease [100].
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Table 3: Key challenges and opportunities in PBPK modeling for dose optimization in kidney disease (continued)
Challenges Opportunities Examples and considerations
Estimation of PBPK pa-
rameters towards personal-
ized dosing in kidney dis-
ease
• To conduct middle-out PBPK model fitting
with a reduced order models
• To individualized PBPK model develop-
ment [105] [99]
• To use of more sensitive data than concen-
tration data
• Production rate data in breath samples us-
ing volatile organic compounds (e.g., iso-
prene and trimethylamine) may be inves-
tigated with iPBPK-R modeling [118]; in
vivo parameters for nonrenally elimination
pathways may be individually estimated to
inform future personalized dosing in CKD.
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Table 3: Key challenges and opportunities in PBPK modeling for dose optimization in kidney disease (continued)
Challenges Opportunities Examples and considerations
Evaluation of the effect of
uremic toxins [119] as po-
tential mechanism of al-
tered drug disposition in
kidney disease
• To conduct PBPK modeling to select can-
didate uremic toxins for designing in vitro
inhibition experiments
• To estimate personalized parameters via in-
dividualized PBPK model fitting (iPBPK-
R) and conduct correlation analysis of pa-
rameter estimates with uremic toxins
• Uremic toxins indoxyl sulfate (IS) and p-
cresyl (PCS) sulfate have been found to in-
crease with CKD severity while liver disease
is an independent factor to determine the
levels of IS and PCS [47]. Inhibition exper-
iments with IS and PCS may inform PBPK
modeling for CKD patients with varying
liver disease severity.
Evaluation of exposure –
response in kidney disease
for dose optimization
• To incorporate a PD model into PBPK
modeling in kidney disease, develop and
validate PBPK models for model-informed
precision dosing at the bedside [120]
• PBPK/PD models for drugs to treat dia-
betes and cancers and antibiotics may be
practical examples for CKD patients given
their comorbidities, narrow therapeutic in-
dex, and PK/PD literature [121].
Development of opti-
mal clinical designs for
studying drug exposure
via PBPK modeling and
simulation
• To conduct research on sampling time
points to optimize a PK study design in kid-
ney disease using PBPK modeling, which
may influence parameter estimates
• Research to optimize sampling time points
for designing clinical trials in CKD may
be conducted using Simcyp simulation sim-
ilarly to Durmont et al [107].
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1.6 Hypothesis
We aim to develop a novel PBPK model and measurement procedure, called iPBPK-R, to
simultaneously estimate parameters for various hepatic drug elimination pathways in individ-
uals and evaluate the effect of kidney impairment on these pathways. We hypothesized that
utilizing a multi-compartment PBPK model with a nested co-optimization procedure, which
is a middle-out PBPK-R approach, we can differentiate multiple hepatic elimination path-
ways and estimate the effects of kidney impairment on these elimination pathways through
high time resolution measurements. Application of iPBPK-R method could be further ex-
tended to drug concentration data when the data are observed in multiple compartments.
To evaluate these hypotheses the following specific aims have been proposed by chapter.
Specific Aim 1. To describe a novel PBPK methodology, iPBPK-R, for indirectly measur-
ing enzyme and transporter properties that are not directly measurable for individuals
Specific Aim 2. To apply iPBPK-R to 14CO2 production rate in the erythromycin breath
test (EBT) in individual healthy subjects and simultaneously estimate multiple non-renal
elimination pathways
Specific Aim 3. To apply iPBPK-R to 14CO2 production rate in the EBT in individual
patients with CKD and simultaneously estimate multiple non-renal elimination pathways
and evaluate the effect of hemodialysis
Specific Aim 4. To evaluate the ability of iPBPK by extending its application to multiple
coupled concentration data of temsirolimus and sirolimus in healthy individuals and estimate
multiple non-renal elimination pathways and the effect of rifampin on these pathways
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2.0 Indirect Measurement of Hepatic Drug Clearance by Fitting Dynamical
Models
2.1 Abstract
We present an indirect signal processing-based measurement method for biological quan-
tities in humans that cannot be directly measured. We develop the method by focusing
on estimating hepatic enzyme and drug transporter activity through breath-biopsy samples
clinically obtained via the erythromycin breath test (EBT): a small dose of radio-labeled
drug is intravenously administered and the subsequent content of radio-labeled CO2 is mea-
sured repeatedly in exhaled breath; the resulting time series is analyzed. To model EBT we
developed a 14-variable non-linear reduced order dynamical model that describes the behav-
ior of the drug and its metabolites in the human body well enough to capture all biological
phenomena of interest. Based on this system of coupled non-linear ordinary differential equa-
tions (ODEs) we treat the measurement problem as inverse problem: we estimate the ODE
parameters of individual patients from the measured EBT time series. These estimates then
provide a measurement of the liver activity of interest. The parameters are hard to estimate
as the ODEs are stiff and the problem needs to be regularized to ensure stable convergence.
A formal operator framework was developed to capture and treat the specific non-linearities
present, and perturbation analysis was performed to establish properties of the estimation
procedure and its solution. Development of the method required 150,000 CPU hours at a
supercomputing center, and a single production run takes CPU 24 hours. We introduce and
analyze the method in the context of future precision dosing of drugs for vulnerable patients
(e.g., nephrology, oncology, or pediatrics) to eventually ensure efficacy and avoid toxicity.
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2.2 Introduction
Personalized medicine and precision medicine depend on timely and accurate measure-
ment of biological quantities in patients. In particular, measurement of enzyme and drug
transporter activity is a key requirement to carefully adjust dosing of potent drugs for at-risk
populations. However, it is impossible to directly measure these activities in live humans.
In addition, multiple biological pathways such as metabolic enzyme Cytochrome P450 3A4
(CYP3A4) and drug transport (OATPs) are often interacting and their contributions are
hard to separate. They require multi-drug cocktail approaches for population-wide (but not
individual) activity estimates [122] [123]. A cocktail approach using multiple activity-specific
drugs is one way to statistically evaluate multiple biological activities, however, the cocktail
approach may be subject to statistical biases. Alternatively, it is possible to indirectly mea-
sure biological activities via modeling. Breath biopsy biomarker samples [124,125] obtained
with use of a probe drug is good candidate data for such modeling since it can be sampled
at reasonably high frequency and captures the rate of drug metabolism. Such metabolic rate
data approximates the first derivative of the concentration of the generated biomarker of
interest as function of time in a target organ where researchers are interested in evaluating
biological activities/phenotypes in individuals.
In this chapter, we introduce a signal processing based indirect measurement method for
drug clearance activities of the liver in individuals, i.e., the elimination behavior of therapeu-
tic drugs of interest. We provide the theoretical underpinning to estimate certain biological
quantities that cannot be directly measured in live humans. An additional complexity we ad-
dress arises from multiple biological processes that may dependently overlap and thus cannot
be easily separated. Our work is set in the context of future personalized medicine and pre-
cision medicine applications, and thus focusses on establishing the necessary methodological
and mathematical foundations for attempting such future applications.
More specifically, we present a signal processing-based indirect measurement method for
enzyme and drug transporter activity in the liver of individual patients, called individualized
physiologically based pharmacokinetic modeling of rate data (iPBPK-R). We set up a reduced
order physiologically based pharmacokinetic (PBPK) model of the human body, i.e., a system
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of 14 coupled non-linear ordinary differential equations (ODEs) where drug concentration in
tissues of interest are modeled as state variables. The model is accurate enough to capture
all biological effects of interest while keeping the number of model parameters low for stable
parameter estimation. A graph representation and an operator formalism are introduced
to concisely capture and analyze the particular non-linearities involved, and to perform
perturbation analysis to assess the quality of the estimation procedure.
iPBPK-R solves an inverse problem to jointly estimate a set of ODE parameters that best
fit a given measurement time series. These parameters provide indirect measurements for
enzyme and transporter activity of interest. This is a hard optimization problem that needs
to be carefully regularized via penalty terms and requires substantial computing resources,
due the stiffness and non-linearity of the coupled ODEs and constraints imposed on the
parameters by human biology. The method is implemented using R, and its development
required 150,000 CPU hours on the Bridges supercomputer at Pittsburgh Supercomputing
Center (PSC) [126].
For the development of the iPBPK-R method we leveraged data obtained in previous
clinical research [127,128], which was utilizing the erythromycin breath test (EBT): a small
dose of the radio-labeled drug erythromycin is intravenously administered, and then the
release rate of radio-labeled CO2 in the patient’s breath is measured at eleven time points over
two hours. This resolves the initial transient, the saturated maximum, and the terminal slope
of drug behavior in the human body. Further, release rate of radioactive CO2 carries higher
information content than conventional concentration data. As an aside, the original EBT
analysis procedure was simple and inconclusive, preventing clinical use of the EBT [129] [130].
We see potential future opportunities in utilizing a more advanced analysis method like
iPBPK-R for not only EBT but other breath biomarker and probe development in this
context since non-invasive breath biopsy research is emerging [124,131].
2.2.1 Related Work
Biological activity in general cannot be directly measured in human. There are many
indirect measurement methods such as MRI or PET scans where the response is captured
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with the use of magnetic fields or a radioactive tracers, and computationally processed to
estimate activities and construct the respective images. Likewise, we propose a method to
indirectly measure activities of the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and
drug transporters in the human liver by modeling breath sample data with use of a test
probe in individual subjects, and then computing an activity estimate.
In current clinical practice the interpretation of breath samples obtained with the use
of a probe drug is simple. This simplicity leads to lower-than-expected accuracy and makes
the application of probe drugs less useful despite ease of data acquisition. A key reason
is that the assumptions underlying standard criteria do not account for multiple biological
or physiological processes as parameters [132] [133]. We propose to remedy this problem
via PBPK modeling that can take these multiple parameters into account when estimating
enzyme activity from clinical samples.
This contrasts with the standard clinical research method to indirectly estimate different
biological activities in human with the use a cocktail approach. There, a subject takes
multiple activity-specific probe drugs and all drug concentrations over time are measured.
These measurements are analyzed separately to statistically estimate different biological
activities associated with respective probe drugs. While a cocktail approach is commonly
used, it uses summary statistics not accounting for inter-individual variability or missing
micro-interaction among drugs [122] [123]. This is another drawback of current practice that
our iPBPK-R approach addresses.
Population PBPK modeling has been intensively used to predict time-course drug con-
centration in the pharmaceutical industry [59]. While population PBPK may use some esti-
mation features, high-dimensional parameter estimation in individuals using PBPK modeling
has not been done. In contrast, we are interested in back-estimating multiple physiological
parameters via PBPK model fitting for individuals. In particular, we are interested in using
concentration data of metabolites (substances the drugs are converted into by its metabolism)
or by-products of metabolism. In this context metabolite production rate data measured in
breath can be used to approximate the first derivative of metabolite concentration data in
compartments of interest in the PBPK model. As the probe dose is low, detailed sampling
of the initial phase of drug concentration as function of time can reveal the characteristics of
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the system, similar to how impulse responses are used to characterize systems of interest in
signal processing theory [134]. In this sense, breath samples provide a more sensitive data set
to estimate parameters via the initial behavior after drug infusion, and thus allows us to es-
timate the multiple parameters compared to less sensitive drug concentration measurements
that are usually evaluated in PK research.
2.2.2 Contribution
This chapter introduces and analyzes the mathematical and computational engineering
framework behind iPBPK-R, our method to estimate un-observable parameters related to
drug clearance activity of the liver in individuals. iPBPK-R integrates (1) a reduced order
PBPK model that contains our parameters of interest, (2) uses IVIVE parameters as ref-
erence values in optimization, (3) fits the model to estimate the parameters of interest via
nested optimization via a specialized objective functions, (4) utilizes rate data from EBT that
resolves the early transient in the drug behavior for indirect measurement, (5) provides per
subject modeling to account for inter-individuality, and (6) is implemented in the program-
ming language and free software environment R 3.4.4 that enables features not available in
standard PK software. The iPBPK-R method applies a classical signal processing approach
in a biological setting. The purpose of this chapter is to establish the mathematical and
computational soundness of the method to enable future clinical research.
We specifically make the following contributions:
• To present both iPBPK-R’s general mathematical framework and the particular instance
parameterized for the EBT as used in a previous clinical study [127,128].
• iPBPK-R estimates in vivo biological quantities by solving a constrained optimization
problem that fits a system of non-linear ODEs to clinical rate measurement data.
• To introduce a graph representation of the coupled system of non-linear ODEs and an
operator formalism to model and linearize its state-dependent adjacency matrix.
• To utilize this formalism to provide a detailed mathematical analysis of the method, with
focus on its constraints and the quality of its parameter estimates.
Our method differs from the prevailing approach in the PBPK community since we do not
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predict drug behavior for a population, but estimate parameters for individuals given clinical
measurement (breath) data.
2.3 Background for Method Development
2.3.1 Mathematical Background
We briefly point to the mathematical concepts and methods used in this chapter. The
overall approach is following standard signal processing methodology [134]. We use graphs
[135] and non-linear ODEs [136] to model the problem and non-linear operators [137–140] to
concisely describe the ODEs. We linearize these ODEs and use the theory of linear ODEs
with constant coefficients to characterize the solutions via eigen decomposition of the system
matrix [141]. We use perturbation analysis [142] to derive bounds and constraints.
We are estimating parameters of the ODEs to fit measurement data, as discussed in
[143–147], and view the indirect measurement as inverse problem [148]. The approach leads
to non-linear optimization problems [149, 150] that need to be regularized [151] and to be
solved numerically [152,153]. We implement the optimization in R [154].
2.3.2 Pharmaceutical Science Background
In the pharmaceutical industry PBPK modeling is typically used to predict drug concen-
tration behavior over time. A system of ODEs is solved where each ODE is associated with
a specific organ/tissue compartment and describes the flows of drug concentrations for that
compartment [59]. In population PBPK, physiologically meaningful parameters related to
drug metabolism and transport, for instance in the liver compartment, can be incorporated
in the ODEs. Then they are used to predict drug concentrations of the respective compart-
ments for a population [73] [60] [101]. The prediction by PBPK modeling is informative
for designing a clinical trial and for deciding drug dosage since potential safety and efficacy
margins of drug concentrations can be statistically derived via simulations. However, all
predictive models are concerned about their out-of-samples setting, the setting where pre-
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dictions and conclusions are made outside of the data range and thus likely to be susceptible
to statistical uncertainty [155]. The physiological parameter inputs for these predictions are
out-of-samples since equations to calculate the properties are typically developed based on
multiple unrelated drug properties and thus extrapolate. The IVIVE technique described
later is one such common calculation technique [64] [156] [157].
Pharmacokinetics (PK). Pharmacokinetics (PK) is the quantitative study of drug
and its metabolites over time in the body [5]. Compartmental models are developed with
some parameters related to absorption, distribution, metabolism, and excretion (ADME)
to describe the time dependency of drug concentration in the body. The simplest model
is the one compartment model depicted in fig. 1 to describe an intravenously dosed drug
concentration C(t) at time t. For example, let ke be an elimination rate constant for the
central body compartment. Then the equation eq. (2.1) is an ordinary differential equation
(ODE) describing the change in drug mass A in the central body compartment with respect
to time t as follows:
Figure 1: A 1-compartment model.
Equation 1 (Change in drug mass A in 1-compartment model)
Ȧ = −keA (2.1)
where Ȧ = dA
dt
. The result of integration of the ODE eq. (2.1) with the initial condition
C(0) = C0 and application of a scaling factor (to convert from mass to concentration) is
given by
Equation 2 (Concentration-time curve in 1-compartment model)
C(t) = C0e
−ket, (2.2)
which describes the actual concentration-time behavior C(t).
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Depending on the route of drug dosing and ADME conditions, multiple compartments
and parameters can be used in the PK model. In the case of a two-compartment PK model
for an intravenously dosed drug (see fig. 2), the general form to describe the change in drug
concentration is given in eq. (2.3) and eq. (2.4):
Figure 2: A 2-compartment model.
Equation 3 (Change in drug concentration C1 in 2-compartment model)
Ċ1 = −(k10 + k12)C1 + k21C2, and (2.3)
Equation 4 (Change in drug concentration C2 in 2-compartment model)
Ċ2 = k12C1 − k21C2. (2.4)
The concentration in Compartment 1 as a function of time t and can be obtained by solving
eq. (2.3) and eq. (2.4) and is given by











Here A0, α, β, and V1 are administered drug mass, distribution rate constant, disposition
rate constant, and volume of distribution of Compartment 1, respectively.
Physiologically-based pharmacokinetics (PBPK). The concept of PBPK modeling
was developed in the 1930’s [158] [59]. The entire body is viewed as a system and each
organ/tissue is viewed as a compartment. The change in drug mass or concentration in each
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organ/tissue is described with an ODE. Then the system of ODEs for the entire body can
be solved to evaluate the drug concentrations over time for each compartment. The unique
feature of this modeling approach is that physiological parameters are included so that the
impact of particular physiological behavior on drug kinetics in the body can be evaluated.
As discussed in chapter 1, PBPK models require three components: (1) system-specific
properties (e.g., blood flows between compartments), (2) drug properties (e.g., fraction of
unbound drug, enzymatic and transporter activities), and (3) the assumed structure of the
system compatible with the particular research question at hand (examples are listed in
table 4). For more details, see Rowland et al. 2011 [59]. PBPK models can become quite
complex depending on the number of compartments. They are typically classified as either
full PBPK models or minimum PBPK models. According to Sager et al. [70] a PBPK model
with 7 or more compartments is defined as a full model.
fig. 3 shows an example of a simple PBPK model that consists of blood (BL) and liver
(LV) compartments with drug elimination from the liver. The changes in drug concentration
in the BL compartment and in LV compartment, ĊBL and ĊLV, are described with the ODEs
















where QLV is the blood flow into the liver, PLV is the partition coefficient of the liver to
the blood (a property of tissue affinity), and CLNR is the clearance of drug from the liver
(non-renal clearance).
In-vitro in-vivo extrapolation (IVIVE). IVIVE extrapolates the mean value of an
in vivo (clinically relevant) physiological parameter as a function of a corresponding in vitro
(experimentally/via bench work) obtained value [67] [64]. For example, metabolic clearance
activity of CYP3A4 in human (in vivo clearance) for a particular drug can be calculated
using eq. (2.8) [159] [66].
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Table 4: Properties used in PBPK modeling
System-specific proper-
ties
organ mass or volume, blood flow, and tissue composi-
tion
Drug-specific properties tissue affinity, plasma-protein binding affinity, mem-
brane permeability, enzymatic stability, and transporter
activities
The structural model a compartmental structure with relationships among
compartments for answering research questions (see
[59])
Blood (BL) Liver (LV) 
Elimination 
Figure 3: A simple PBPK model.
Equation 8 (IVIVE equation for metabolic clearance activity of CYP3A4)
CLH,int,CYP3A4 = CLint,rhCYP3A4 abundanceCYP3A4 ISEFCYP3A4 MPPGL LW. (2.8)
Here, CLint,rhCYP3A4 is the intrinsic clearance in recombinant CYP3A4 (in vitro clearance) cal-
culated from experimentally obtained enzyme kinetic parameters [µL/min pmol of CYP3A4],
abundanceCYP3A4 is the amount of CYP3A4 enzyme per unit microsomal protein
[pmol of CYP3A4/mg of protein], ISEFCYP3A4 is intersystem extrapolation factor for CYP3A4.
MPPGL is the amount of microsomal protein per unit liver [mg of protein/g of Liver], and
LW is the human liver weight(g).
Generally, a value calculated via an IVIVE method is subject to substantial variability
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on the log scale. For example, experimentally determined ISEF for CYP3A4 clearance has
a large 95% confidence interval: according to Proctor et al. 2004 [156] its upper bound is
5.2 × 103 times as high as its lower bound. Furthermore, the calculated metabolic in vivo
clearance shown in Figure 1 of Chiba et al. 2009 [66] does not have a strong correlation
with experimentally determined in vitro metabolic clearance since the correlation graph is
shown in a log-log plot that implies a non-existent (linear) correlation. (Note that a linear
regression with unit variance in a log-log plot implies a polynomial correlation with an order
of magnitude variance.) Accordingly, the relationship between IVIVE-predicted value and
the respective observed in vivo value is a unique feature of a particular drug substrate.
This indicates that the generalization of such a relationship to other drugs produces bias in
IVIVE-based predictions as this is extrapolation in an out-of-samples setting.
A scaling factor derived from regression in a log-log plot usually does not predict in
vivo metabolic clearance consistently. Therefore, it is not possible to estimate a particular
subject’s in vivo parameters using an IVIVE derived scaling factor given the low predictive
power and great variability of this scaling factor. In contrast, we are estimating an adjustment
factor via PBPK modeling that measures the size of deviation from the baseline IVIVE-based
activity in the given subject to estimate the individual’s activity of a biological process.
Prediction. As we discussed at the beginning of this section, PBPK modeling is typ-
ically used to predict drug concentration-time behavior and evaluate its PK characteristics
for particular populations. It is extensively used in the pharmaceutical industry to sup-
port decision-making in drug development. To predict drug concentration behavior PBPK
modeling requires various parameter inputs of system-specific properties and drug-specific
properties (see table 4). Furthermore, researchers can assume some distributions on those
parameters and generate distributional parameter inputs for PBPK modeling using Monte
Carlo approaches or similar methods. As a result the simulated drug concentration-time
curves will vary broadly and have to be statistically summarized. For instance, simulations
provide the mean, 95 % confidence interval (95 % CI), median, minimum, maximum, etc.
Due to the broader range of simulation curve outputs and the large number of input param-
eters, PBPK modeling is usually used to construct the statistical bounds of drug safety. In
the literature the allowed cutoff for good performance of prediction varies. Typically, mean
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ratios of predicted and observed maximum concentration, time to peak, and areas under the
concentration-time curves are often considered to be comparable in PK literature if they are
within 2 times of observed data [101] [90] [102] [93].
Standard software. A number of software tools are available to conduct PBPK sim-
ulations, including the Simcyp Simulator and NONMEM [59]. The Simcyp Simulator was
originally developed by Simcyp Ltd. and later acquired by Certara USA, Inc. [160]. This
software includes demographic, physiologic and genomic databases so that it provides PBPK
modeling for a virtual population that researchers are interested in studying. Various virtual
populations can be generated with the Simcyp simulator. This feature allows researchers to
evaluate relationships between modeled drug behavior and variability in demographic, phys-
iologic and/or genomic parameters of the interested virtual population prior to conducting
a clinical trial. For instance, using a statistical distribution of liver weight for a virtual
population, IVIVE calculation of drug property parameters can be implemented. These dis-
tributions are subsequently used to simulate drug behavior in the virtual population. Since
the Simcyp simulator allows researchers to design clinical PK studies for simulations in a
virtual population, the software is frequently used to support decision making in drug de-
velopment by pharmaceutical companies and regulatory agencies. The Simcyp simulator
has some parameter estimation features as well. However, accuracy for high-dimensional
parameter estimation is not guaranteed given the large number of parameters used in the
simulator.
NONMEM is FORTRAN-based biomathematical modeling software that allows users to
explicitly specify mathematical models [59]. It is commercialized by ICON [161]. NON-
MEM is frequently used for population PK and PK-pharmacodynamic (PD) modeling and
also can be used for PBPK modeling. Various parameter estimation methods are available in
NONMEM. NONMEM also offers many options for graphically checking model predictions.
There are limitations in the allowed number of compartments for user-defined systems of
ODEs and types of parameters supported for estimation. Furthermore, there is no flexi-
bility in specifying objective functions and conducting nested co-optimization. The speed
of computation is also limited since the software license makes it hard (expensive) to use
NONMEM in a high performance computing and batch/cloud computing environment.
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ADAPT 5 is another FORTRAN-based biomathematical modeling software. It was de-
veloped at the University of Southern California [162] [163]. It offers great flexibility in
model specifications, study design options, and parameter estimation algorithms, which en-
ables custom PK/PD modeling. Its flexibility is limited in terms of specification of objective
functions, implementation of nested optimization and co-optimization, and the type of ob-
served data.
Custom approaches. All the software discussed so far requires researchers to learn
the syntax of legacy programming languages like FORTRAN in combination with system-
specific commands and features. This hampers more customized PBPK modeling and for
method research as in our case with individualized breath sample modeling. Thus, fully
custom approaches are sometimes needed.
R is a free statistics-centered programming languages with a large library of mathemat-
ical modules [164]. While R is intensively used for data analysis, PBPK modeling can be
implemented with R. For example, ODEs for PBPK modeling need to be explicitly defined
in a R script but the set of the ODEs can be easily solved with standard solvers. General
and powerful optimization methods are available for model fitting and parameter estimation.
This in turn allows for any type of observed data to be modeled, including breath rate data
of interest to us. In addition, parameters can be co-optimized to model, for example, depen-
dent behavior across two distinct phases of an clinical intervention. In our work we use this
capability to correlate behavior before and after dialysis within patients with kidney disease
where some parameters are estimated independently and some are estimated consistently
across the two phases.
Therefore, iPBPK-R was developed in the R environment so that nested co-optimization
and advanced objective functions can be implemented, and to fine tune the configuration of
optimization and ODE integration routines. In particular, we use the deSolve package that
implements a suite of ODE solvers, including explicit and implicit solvers, adaptive solvers,
and Runge Kutta solvers [165] [166] and the R function optim that implements Nelder-Mead,
quasi-Newton, and conjugate-gradient algorithms [167]. iPBPK-R cannot be implemented
with standard PBPK software such as Simcyp and NONMEM since their degree of freedom
supported in scripts is far more limited.
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2.3.3 Erythromycin Breath Test (EBT)
EBT was originally developed to measure one type of enzyme activity that metabolizes
the radio-labeled drug 14C-erythromycin in the liver [168]. EBT is based on the premise
that as the drug undergoes the CYP3A4-mediated metabolic pathway, radio-labeled carbon
dioxide (14CO2) is released as a final by-product. A noninvasive low dose of
14C-erythromycin
is intravenously administered to a subject and breath samples containing 14CO2 are collected
over 2 hours.
In the clinical setting breath samples were collected before and after a certain change in
the subject’s state. Then, the EBT’s 14CO2 production rate data (measured as a percentage
of dose exhaled per minute) was originally interpreted via one of the following criteria as
shown in fig. 4: the CYP3A4 enzyme activity in the liver increased if (1) the time to peak
of the breath rate within 2 hours shortened, or (2) the area under the curve increased, or
(3) or the measured 14CO2 production rate at 20 minutes increased post the state change.
However, other physiological activities (not just one enzyme activity) also seemed to play in
eliminating the drug from the liver (e.g., activities in drug transporters) [169] [170] [171], and
these original criteria were inconclusively estimating did not necessarily lead to a successful
association with the drug’s overall clearance from the body [129] [130]. This led to the
consensus that (at least with the classical interpretation) the EBT was not accurate enough
for clinical measurement of CYP3A4 activity. iPBPK-R is revisiting this conclusion and
shows that with more detailed modeling and a more careful interpretation EBT data can
provide conclusive information regarding CYP3A4 activity and other physiological factors.
2.4 Mathematical Framework of iPBPK-R
In this section we describe the overall structure of the iPBPK-R approach. We discuss
the problem setup, modeling of the clinical use case, the general structure of the non-linear
reduced order model, and the parameter estimation approach. Finally, we discuss the limits
of parameter estimation in our setup. In section 2.5 and section 2.6 we will then discuss the
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CYP3A4 activity ↑ 
CYP3A4 activity ↓ 
CYP3A4 activity ↑ 
Area under the curve (AUC)↑ 
Tmax↓ 
Figure 4: 14CO2 production rate at 20 minutes (left) and for 2 hours (right).
instantiation of the general method described in this section for the EBT and the enzyme
CYP3A4 activity as used in the results discussed in section 2.7.
2.4.1 Problem Description and Approach
The key idea of iPBPK-R is to develop an indirect measurement method to measure (or
estimate) values in a particular patient for physiological parameters that cannot be measured
directly. The indirectly measured values are maximally compatible with the underlying model
and samples, i.e., they are model parameters that minimize the mismatch between (noisy)
data and a model that is rich enough to capture the measured behavior but simple enough
so the estimation is a well-posed inverse problem. Statistically speaking, we are interested
in estimating parameters in a within sampling setting as opposed to out-of-samples setting:
given clinically observed breath rate data due to a single probe drug (i.e., EBT), PBPK model
fitting (but not prediction) will be used to inversely solve for physiologically meaningful
parameters.
Approach. iPBPK-R integrates several methods for conducting multiple-parameter
estimation. It is based on a reduced order PBPK model, which is parameterized by our
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physiological parameters of interest. IVIVE parameters are utilized as initial guesses that are
adjusted for individual subjects based on their measurement data. These IVIVE parameters
are also used as constraints in the estimation procedure to ensure biological plausibility.
The actual parameter estimation is implemented via optimization to fit the measurements
to the reduced model by varying the physiological parameters of interest to minimize the
discrepancy between noisy measurement data and the model. Estimation is done via nested
optimization or nested co-optimization and utilizes a specialized metric and bias terms.
Estimating parameters via the specialized nested optimization approach based on measured
breath rate data allows us to resolve the early transient in the drug behavior at both rate-
limiting and non-rate limiting steps of the multiple elimination pathways.
Software system. Standard optimization software packages are too general to adapt to
a particular pharmacokinetics optimization problem, and there is no guarantee that the pa-
rameter estimates are physiologically meaningful solutions even when they are ever obtained
by fitting a system of ODEs to measured data using standard metrics. Further, iPBPK-R
cannot be implemented in standard PK or PBPK software since multiple-parameter opti-
mization must be carefully tailored to the estimation problem by developing a specialized
objective function and constraint terms. Thus, we implemented the iPBPK-R in the R sys-
tem. However, any high-level computer language can be used to implement iPBPK-R and
its modeling and optimization components.
Highly sensitive indirect measurement. PBPK modeling is rarely used for parame-
ter estimation of individual subjects, partly since clinically obtained drug concentration data
is too noisy to capture sensitive changes in the physiological parameters needed to estimate
the physiological parameters of interest. We overcome this issue by borrowing the idea of
parameter estimation by fitting data to a reduced order model from signal processing and
indirect physics measurements as we developed iPBPK-R for high-dimensional parameter es-
timation in our use case. We utilize observed concentration change data (rate data), which
at the same sampling rate and accuracy has higher information contents compared to drug
concentration data. iPBPK-R enables us to estimate per-person physiological parameters
which are otherwise difficult to capture. The enabling idea is model fitting to measured
rate data of individual subject that was collected with a single probe. We anticipate that
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iPBPK-R is useful for estimating parameters related to in vivo drug elimination pathway
activities simultaneously, and that these estimates are useful for determining individualized
drug dosage. This is a step towards personalized medicine that utilizes current biological
activity in individuals as decision criterium.
2.4.2 Clinical data: EBT
General background of EBT was provided in section 2.3.3. We now discuss how EBT
is modeled in our reduced order model. Recall that a subject receives a single 0.074 mmol
short-time intravenous (IV) bolus dose of 14C-erythromycin. This is modeled as a constant-
rate influx of drug into the patient. Breath samples are collected at 11 time points within
two hours of IV dosing, including the baseline time point prior to dosing [128] [127] (see
fig. 5). The sampling time points are unequally spaced: breath is measured more often at
early on and then at a lower sampling rate towards the end of the 2 hours. The contents of
14CO2 in the breath samples is measured and
14CO2 production rates are calculated at each
time point from the exhaled volume and 14CO2 content.
14CO2 production rate data in an individual’s breath is approximately proportional to
the first derivative of drug concentration data, i.e. drug concentration change. In clinical
settings, breath can be sampled faster over a prolonged period of time compared to drug con-
centration in the blood, and this higher sampling frequency leads to more accurate estimates
when utilized in iPBPK-R. Potential sources of inaccuracies in measuring 14CO2 production
rate via breath samples: 1) actual breath sampling times may deviate from the designed
sampling time points, 2) inconsistent analysis procedure or inaccuracies when measuring
14CO2 in breath samples, and 3) inconsistent breathing output by the individual during the
EBT. These inaccuracies need to be addressed but in experiments so far did not lead to
inaccurate indirect measurements via iPBPK-R.
2.4.3 Reduced Model
We now describe the general shape of our reduced model. This model is underlying the
modeling approach and is instantiated for EBT in section 2.5. fig. 6 shows a simple three
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PBPK model  







Figure 5: Erythromycin breath test (EBT).
compartment model and all associated quantities used in the discussion below.
Figure 6: Example graph for a 3-compartment model.
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Compartments. The reduced model underlying iPBPK-R is given by a system of non-
linear ordinary differential equations (ODEs) for time t ≥ 0, that is described as a graph
Equation 9 (Graph for a system of nonlinear ordinary differential equations (ODEs))
G = (V,E,W). (2.9)
The set of n vertices V = {V1, . . . , Vn} abstracts the compartments. Each compartment Vi
has a state variable
mi(t), t ≥ 0 with mi(0) = Mi
that is a function of time and expresses the amount of drug mass in compartment Vi at time
t. Our model is a closed system: No mass ever enters or leaves the system. This is expressed
through the system invariant
Equation 10 (System invariant for mass balance)
n∑
i=1
mi(t) = M0 for all t ≥ 0, (2.10)
where M0 is the constant drug mass in the system.
Mass flows. The set of edges E ⊆ V×V captures the channels between compartments.
The graph G is a directed graph. Edges eij = (Vi, Vj) and eji = (Vj, Vi) are together
representing the channel between compartments Vi and Vj for 1 ≤ i, j ≤ n. We require that
if edge eij is present then the eji is present as well, i.e., channels can be viewed from the
perspective of either compartment Vi or Vj.
The graph G is a weighted graph. The weight wij ∈W on edge eij is given by the mass
flow function
wij = qij(t) for eij ∈ V × V,
which expresses the flow of drug mass from compartment Vi into Vj over the edge eij as
function of time t. We define
qk`(t) ≡ 0 if ek` /∈ V × V,
i.e., for edges that do not exist. As an aside, we use the common notation m for mass, and
q = ṁ = dm
dt
for mass flow, i.e., mass flow is the first derivative of mass. Note that qij(t) and
qji(t) denote the same physical flow, but represented from the perspective of compartment
Vi and Vj as flow source, respectively. There are no self flows, i.e., qii(t) ≡ 0 for all 1 ≤ i ≤ n.
This provides another key invariant of our model,
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Equation 11 (System invariant for mass flow)
qij(t) = −qji(t) for all t ≥ 0. (2.11)
The graph G has a time-dependent anti-symmetric adjacency matrix
A(t) = [qij(t)]1≤i,j≤n ∈ Rn×n
that concisely captures the system of ODEs. The initial conditions of the system of ODEs
are given by
mi(0) = Mi.
State equations and invariants. Note that in our model some compartments Vi are
sources for which all flow qij ≥ 0 are non-negative (thus, they are out-flows), and some
compartments Vi are sinks for which all flow qji ≥ 0 are non-negative (thus, they are in-
flows). The non-linearity of the model arises through non-linearities of certain flow terms
qij(t) that are induced, for instance, through a Michaelis-Menten style saturation. This is a
special kind of monotonically increasing and differentiable non-linearity that does not pose
a fundamental issue.
The closed system assumption of eq. (2.10) provides that for each compartment Vi the
change of drug mass contents is the sum of all flows qji(t) from all other compartments
Vj, j 6= i to the compartment Vi, and since qii(t) ≡ 0 we obtain





as mass can only enter or leave a compartment Vi through a mass flow qij.
We now show that the anti-symmetry of the mass flows defined by eq. (2.11) and the
definition of compartment mass change as sum of mass flows given by eq. (2.12) are sufficient
for the ODE system invariant eq. (2.10) to hold. The proof is shown in appendix A.1.
Theorem 1 (Mass balance invariant) For a model G = (V,E,W) as defined above, and
t ≥ 0 it holds that







Finally, note that the change of drug mass contents in compartment Vi expressed in
eq. (2.12) is a sum of mass flow qji(t). Drug mass mi(t) in Vi at time t can be converted to
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drug concentration Ci(t) at time t when mi(t) is divided by the volume of compartment Vi.
Concentration based model. In Clinical Pharmacology, it is common to express








respectively (here Vi denotes the volume of the ith compartment), while mass-based equations
allow for clearer mathematical treatment of the ODEs. Thus, in pharmacological discussions
we will use C(t) and Ċ(t) while mathematical discussions will use m(t) and ṁ(t), respectively.
2.4.4 Reduced Model as a System of Non-linear ODEs
In this subsection, we define a framework that allows us to describe the system of non-
linear ODEs eq. (2.12) via the time-dependent adjacency matrix eq. (2.12) similar to how a
system of linear first order ODEs with constant coefficients is described through its constant
system matrix. Thus, we express the system of non-linear ODEs eq. (2.12) that underlies
iPBPK-R’s reduced model as a small deviation of a classical system of in-homogeneous
linear ODEs. We specifically show that the particular non-linearity of the reduced model
can be expressed with a matrix of scalar differentiable monotonically growing functions of
the current state. The formalization naturally generalizes the system matrix of linear ODEs
and the matrix-vector product capturing systems of ODEs. The formalization is derived for
mass change in molecular weight.
Definitions and conventions. Vectors x ∈ Rn are always column vectors to allow for
matrix-vector products. When necessary to understand equations, we annotate vectors as ~x.
Transposition of the vector x is denoted by xT. When the entries of the vector are needed,
we denote them as xi, 1 ≤ i ≤ n and the vector x can be written as x = (xi)1≤i≤n. Real
m× n matrices are denoted as A = [aij]1≤i≤m, 1≤j≤n ∈ Rm×n. Further, the direct sum of two
vectors ⊕ is defined as
Equation 13 (Convention for direct sum of two vectors)
(x1, . . . , xm)
T ⊕ (y1, . . . , yn)T = (x1, . . . , xm, y1, . . . , yn)T. (2.13)
We define the indicator function of the set Ω ⊂ R,
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Equation 14 (Definition of indicator function for Ω ⊂ R)
IΩ(.) : R→ R; x 7→
1, x ∈ Ω0 else, (2.14)
that is called gating function in the context of iPBPK-R as it is used to model the IV
infusion of the drug. The Michaelis-Menten function MMa,b,c is a hyperbolic function that
is parameterized by three constants a,b, and c,
Equation 15 (Michaelis-Menten function parameterized by three constants)




It is the main non-linearity used in the reduced model, and it is a monotonically increasing
differentiable function. The parameters capture the initial slope and the asymptotic value of
the function. Note that two parameters would be sufficient to uniquely define a Michaelis-
Menten function, but in our application the three-parameter formulation is more convenient.
Finally, scaling the input of a Michaelis-Menten function MMa,b,c with a real constant α
results in a new Michaelis-Menten function
Equation 16 (Michaelis-Menten function with a parameter transformation)
MMa,b,c(αx) = MMαa,b,αc(x), (2.16)
i.e., rescaling of the input is a parameter transformation.
We denote a function f(.) that depends on a parameter vector p as fp(.). In our case
the parameters pi that constitute the vector p (i.e., ~p = (pi)1≤i≤`) are to be optimized during
estimation.
Notation for non-linear operators. We unify the notation for linear and non-linear
vector-valued functions of vectors. This will allow us to analyze the system of non-linear
ODEs with its very particular type of non-linearity via its linearization, and to obtain a good
characterization of the original non-linear system with respect to parameter estimation. We
follow the notation and ideas developed in [139] [138]. Recall that all linear mappings are
given by a matrix and the respective matrix-vector product. We define the operator Ā(.)
that is induced by the matrix A,
Equation 17 (Definition of operator Ā(.))
Ā : Rn → Rm; x 7→ Ax with A ∈ Rm×n. (2.17)
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With this notation we can write Ā(x) for the matrix-vector product Ax and thus do not
have to distinguish linear and non-linear operators. When clear from the context, we may
drop the (̄.) and write Ā(.) = A(.) = A, i.e., in this case we do not distinguish the matrix
and its induced operator as they are essentially the same.
We next generalize the matrix-vector product to matrices where the entries are scalar
functions. Assume that entries at location (i, j) of a m× n matrix B are scalar functions
Equation 18 (Entries bij(.) of matrix B as scalar functions)
bij(.) : R→ R; x 7→ bij(x). (2.18)
We use B to define the non-linear operator B(.) as
Equation 19 (Nonlinear operator B(.))




The definition of B(.) is compatible with and generalizes the standard matrix-vector product.
Finally, we define operator addition U(.) + V(.) as
Equation 20 (Operator addition U(.) + V(.))(
U(.) + V(.)
)
(x) = U(x) + V(x), (2.20)
compatible with the usual addition of matrices.
Reduced model ODE as non-linear operator. With the notation introduced above
we now describe the system of non-linear ODEs concisely as a sum of operators. Our state
vector is the vector of mass in all compartments of the n-compartment model, ~m = (mi)1≤i≤n.
The forcing function
z(t) = (0, . . . , 0)T ⊕ τ I[0,t0](t)⊕ (0, . . . , 0)T (2.21)
models the IV injection of the drug as constant-rate for the time interval Ω = [0, t0]. The
linear part of the system of ODEs is given by a real n× n matrix X. All non-linearities are





where all entries yij(.) are











The matrix of functions Y is used as operator Y(.) as defined in (2.19).
With these definitions, the full system of non-linear ODEs is given by
Equation 21 (System of nonlinear ODEs using operators)
d~m
dt
= X~m+ Y(~m) + z(t). (2.23)







Dropping the ~(.) annotation from ~m we can now write the full system of non-linear ODEs
concisely as
Equation 22 (System of nonlinear ODEs with weighted graph matrix M(.))
ṁ = M(m) + z(t). (2.25)
Note that M(.) is the state-dependent adjacency matrix of the weighted graph abstraction of
the n-compartment model introduced in section 2.4.3 and captures the state-dependent mass
flows qij (depending on mi and mj). Thus, analysis of the solution of (2.25) and convergence
and uniqueness of parameter estimation via optimization is reduced to analyzing M.
By construction, the non-linear behavior of M is limited to Michaelis-Menten saturation.
Given the well-understood behavior of systems of linear ODEs and the particular type of
non-linearity, we are able to analyze solution properties of (2.25) via perturbation analysis of
the entries of M and by analyzing the linearized bounds of M. This is done in section 2.4.6.
2.4.5 Modeling the Measurements
So far, we have defined a system of ODEs with eq. (2.12) and eq. (2.25), which describes
the change in drug concentration and the change in drug mass over time for all compartments.
Next we model the pathway of the drug by-product 14CO2 from the liver to the breath and
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its ultimate concentration measurement in the breath. This is described as a measurement
operator F(.) that maps the solution vector ~C(t) of (2.25) (in drug concentration form) to
a scalar function B(t).
Measurement function. We describe the relationship between the solution of the n




1≤i≤n and the breath-time function B(t) to be measured
abstractly as given by an operator
F(.) : (R→ Rn)→ (R→ R). (2.26)
The operator F(.) maps a vector-valued time-dependent function (the solution of the ODE)
to a scalar time dependent function (the 14CO2 content in the breath). In the case of the
EBT this models the part of the drug which enters the metabolism pathway in the liver and
subsequently produces 14CO2 traveling to the lung to get released in the breath. We call the
operator F(.) the measurement function as it models how the final measurement is derived
from the solution of the ODE. The measurement function is not part of the dynamical system
as it does not feed back into the ODE.
Note that the clinical measurement in EBT is 14CO2 production rate in the breath of the
subject, B(t). Under the assumption of instantaneous metabolism of the drug in the liver
and instantaneous transfer of 14CO2 from the liver (denoted as compartment j) to the lung
we define
Equation 23 (Operator F(.) to map the solution of the ODE to breath 14CO2 rate)




Via an application of (2.27) to the solution of the system of ODEs, ~C(t), the operator
F(.) returns the breath function or the first derivative of the concentration of the liver
compartment (denoted as jth compartment), i.e.,
Equation 24 (14CO2 production rate in the breath B(t) using F(.))
B(t) = F(~C(t)) = Ċj(t). (2.28)
More realistic variants of F(.) could be defined to model the transfer of 14CO2 from the liver
to the lung more accurately. The exact equation used in this work and its underlying model
assumptions will be provided in section 2.6.
Comparing model and measurement. Next we define how to compare the modeled
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breath function B(t) as defined in (2.28) to clinical breath rate measurements. We assume
that a set of measurements consist of T samples m` = (t`, w`) measuring
14CO2 production






T×2. Our goal is to compare the simulated measurement B(t) with
the sampled clinical measurement vector ~S. We define a distance function d(., .) to denote
the distance (or disagreement) between the simulated function and the sampled data,
d(., .) : (R→ R)× RT×2 → R. (2.29)
A straight-forward example for a distance function d(., .) would be the L2 norm of the breath
function B(t) evaluated at the sample time points t` minus the measured data at the same
time points,
Equation 25 (L2 norm distance between breath function B(t) and observed data ~S)
d2(F(~C(t)), ~S) = d2(B(.), ~S) = ‖(B(t`))` − (w`)`‖2, ` = 1, . . . , T. (2.30)
The definition of (2.30) is provided as an example to make the discussion in section 2.4.6
more understandable. We will use the generic function d(., .) in the remainder of this section
as we will use a variety of such functions to handle systematic measurement problems,
misalignment, and penalty terms used to steer the parameter estimation via optimization.
We present the full definition and detailed discussion of the actually used distance functions
in section 2.6 when the detailed model and estimation procedure is presented.
2.4.6 Parameter Estimation via Optimization
The estimation of biological parameters is cast as an optimization problem that fits
a dynamical model (system of ODEs) to measurement data. The biological parameters of
interest are derived from the estimated ODE parameters that produce the best fit. Formally,
we aim to find a vector ~r that parameterizes the system of ODEs (2.25) (in concentration
form) so that the distance d(., .) in (2.29) for a given measurement vector ~S is minimized.
Further, constant parameters are captured by a parameter vector ~u. Therefore the flow
terms qij(t) in (2.12) are parameterized by ~r and ~u and need to be written as
q~r,~uij (t).
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This leads to a system of ODEs that is parameterized by ~r and ~u. We denote the solution
of this system of ODEs, parameterized by a vector ~u of constant parameters and a vector ~r
of parameters to be optimized, by
~C~r,~u(t).
The basic parameter estimation is set up as optimization problem
Equation 26 (Basic parameter estimation as optimization problem)
~r = arg min
~r′
Ψ~u(~r′) for configuration ~u. (2.31)
In (2.31), a parameter vector ~r is found that minimizes the objective function Ψ~u(.) for a
constant parameter vector ~u. A simple choice for the objective function Ψ~u(~r′) is given by
Equation 27 (Basic objective function Ψ ~u(~r))
Ψ~u(~r) = d(F(~C~r,~u(., .)), ~S). (2.32)
In this case the optimization finds the parameter vector ~r that minimizes the distance be-
tween the simulated measurement for the solution of the system of ODEs, B(t) = F(~C~r,~u(t)),
and the clinical measurement ~S. Note that in this formulation both d(., .) and F(.) are un-
specified functions that allow us to state the problem in general terms.
In iPBPK-R we estimate multiple parameters called scaling factors or adjustment factors
(see section 2.3.2) via a specialized objective function,
Equation 28 (Specialized objective function Ψ ~u(~r) with penalty term in iPBPK-R)
Ψ~u(~r) = d(F(~C~r,~u(.)), ~S) + π(~r, ~u), (2.33)
which consists of appropriately chosen distance d(., .) and penalty term π(~r, ~u). In addition
to minimizing d(., .), this ensures that the estimation returns biologically plausible values
and adjustment factors related to non-renal elimination pathways in the liver as close to 1
as possible when a PBPK model is fit to individuals’ EBT data. Accordingly, the penalty
function π(., .) needs to be chosen carefully. The penalty term is defined as
Equation 29 (Penalty term π(~r, ~u))
π(~r, ~u) = ubν(~r) + ucρ(~r) + udε(~r) + uxψ(~r). (2.34)
In (2.34), the terms ν(~r), ρ(~r), ε(~r), and ψ(~r) are constraint or penalty terms that depend
on the parameter vector ~r, and the constants ub, uc, ud, and ux are weighting factors that
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are collected in the configuration vector ~u.
These constraint and penalty terms and weighting factors need to be carefully chosen to
drive parameter estimation towards biologically plausible parameter values, i.e. values that
clinically makes sense or are accepted in the clinical pharmacology community. IVIVE values
are biologically plausible, but care needs to be taken not to distort the optimization problem
to a degree that the parameter estimation produces bad results due to strong constraints and
penalties of the objective function. The exact forms of the penalty terms will be discussed
in in section 2.6.1.
2.4.7 Analysis of iPBPK-R Estimation
In the previous subsections we have described the general form of the objective function
and optimization procedure in iPBPK-R. In this subsection, we establish the characteristics
of convergence in the optimization procedure by analyzing the ODE system and parameter
optimization. We also discuss how many parameters can be generally estimated in iPBPK-R.
We first linearize the system of non-linear ODEs and discuss the properties of the solution
to the system. We establish that in our problem setup the linear bounds are sufficient for
statements regarding parameter optimization. We then analyze perturbing the linear system
to establish convergence properties of the parameter optimization procedure. This approach
allows us to conclude that parameter estimation as it is set up in iPBPK-R is converging
as long as good starting values (in our case IVIVE estimates) are known and the number of
estimated parameters is properly bounded.
Linearization of the system of ODEs. First, we analyze linearized upper and lower
bounds for the system of nonlinear ODEs. The nonlinear ODE system eq. (2.25) can be
bounded as
Equation 30 (System of nonlinear ODEs bounded by linearized ODEs)
(X + Y−)~m(t) + ~z(t)  d~m(t)
dt
 (X + Y+)~m(t) + ~z(t) (2.35)



























Y− and Y+ are matrices representing elementwise upper and lower bounds on the matrix






holds for all matrix elements of Y for all t ≥ 0. For iPBPK-R to produce stable parameter
estimates, the distance between the boundaries |y+ij − y−ij | needs to be small enough. In
this case arguments for the linearized upper and lower bounds also hold for the system of
non-linear ODEs since all non-linearities are small and monotonically growing. The exact
bounds are problem dependent and can be checked post-hoc. In practice, this is ensured by
the low probe dose given when using the EBT clinically.
Solution of linearized ODE. Next we discuss the solution to a homogeneous system
of n linear ODEs with a real system matrix A,
Equation 31 (Homogeneous system of n linear ODEs with a real system matrix A)
d~x(t)
dt
= A~x(t), ~x(t) ∈ Rn, A ∈ Rn×n, t ≥ 0. (2.39)
We can set A− = (X + Y−) and A+ = (X + Y+), and ignore the forcing function ~z(t)
since ~z(t) ≡ 0 for t > t0. Let θi and ~ci denote eigenvalues and eigenvectors of the system
matrix A, respectively. Assume that A is a simple matrix, i.e., that it has n linearly
independent eigenvectors and thus an eigenvalue decomposition. Further, all eigenvalues
and all eigenvectors are real. For iPBPK-R this holds in practical applications due to the
characteristics of the flow terms and mass conservation. Further, the only eigenvalue with
multiplicity greater than 1 is θ0 = 0. All solution vector functions for the ODEs eq. (2.39)
are then given by





θit with ~x(t) = (xj(t))j=1,...,n (2.40)







θit with C = [~ci]i=1,...,n = [cj,i]i,j=1,...,n. (2.41)
The function xj(t) is the projection of ~x(t) into the jth dimension (i.e., jth compartment).
The matrix C is an invertible matrix collecting the eigenvectors ~ci. Further, θi, i = 1, . . . , n
are the roots of the characteristic polynomial of the system of ODEs, and the eigendecom-
position of A is given by
A = Cdiag(θi)C
−1. (2.42)
We will analyze the general solution of the linearized ODE regarding stability of parameter
estimates and map the results back to the system of non-linear ODEs of interest in iPBPK-R.
Construction of ODE solution from projection. We now consider the projection
of the solution into one compartment (i.e., dimension j) and observed data in this compart-
ment. We derive the conditions under which the entire solution ~x(t) of eq. (2.39) can be
reconstructed from the jth dimension.
A measurement consists of T samples (t`, xj(t`))`=1,...,T of the function xj(t). Under our
assumptions all eigenspaces of A are one-dimensional and thus the (normalized) eigenvectors
~ci are functions of the eigenvalues θi. This allows us to set up a system of 2n non-linear
equations in βi and θi,





θit` for ` = 1, . . . , T. (2.43)
The system of non-linear equations (2.43) has 2n independent variables to solve for. This
leads to the requirement that at least 2n observed samples are necessary to estimate the 2n
unknown values βi and θi. If more than 2n samples are available, (2.43) can be solved as
non-linear least squares problem.
A slight complication stems from the fact that the eigenvalue θ0 = 0 can have higher
multiplicity. Careful analysis reveals that this does not pose a problem as the nullspace of
A captures the source and sink of the dynamical system. In our model it is not necessary
to uniquely determine the solution in the sources and sinks, given their particular model
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characteristics. This establishes that under practical conditions the solution of the linearized
ODEs can be sufficiently reconstructed from observed data in one compartment.
Perturbation of ODE for the linearized system. Next we show that both the con-
stants βi and the eignevalues θi (and thus the eignevectors ~ci(θi)) continuously and differen-
tiably depend on the entries aij of the system matrix A as long as eigenvalue multiplicities
and the eigenspace structure of the matrix do not change. We define a small perturbation
α ≈ 1 for a matrix entry aij, i.e., replace aij with αaij and view the resulting matrix Ã as
a function of α, i.e., Ã(α). For small enough α the eigenvalues of Ã depend continuously
and differentiably on α. This can be shown by using Laplace’s formula for the determinant
and the fact that the zeroes of a polynomial depend continuously and locally differentiably
on the coefficients of the polynomial. Carmer’s formula then implies that unit eigenvectors
for eigenvalues with multiplicity 1 also continuously and differentiably depend on α. Thus,






exist at least locally. Therefore, the solution eq. (2.40) of the perturbed linear ODE changes
continuously and differentiably with α under weak assumptions that are met in practice by
iPBPK-R. The above discussion generalizes to multiple perturbations αi.
Parameter estimation for the linearized system. So far, we have shown that the
solution of the perturbed linear ODE depends continuously and differentiably on α for small
enough α. Further, we have shown that we can estimate the entire solution ~x(t) of the ODE
from enough data points in one compartment. Our goal is to estimate a set of M adjustment
factors αi for the linearized system of ODEs (2.36) and (2.37), respectively, that minimize
the difference between the measured data xj(t`) and the values for the corresponding xj(t`)
predicted by (2.39). Further, we aim to establish the number M of maximally estimable
adjustment factors αi and the minimum number of samples T required to do so.
The set of T non-linear equations (2.43) can be recast as non-linear least squares problem
for ~α = (α1, . . . , αM),
Equation 34 (Parameter solution (adjustment factors) as optimization problem of linearized ODEs)
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that has at least one solution that can be found for initial values close to the optimum. Thus,
the adjusted system matrix Ã(~α) needs to be close to the matrix A, which is derived from
IVIVE parameters. The local minimum ~α closest to 1M = (1, . . . , 1) is the most biologically
plausible estimate.
We now analyze how many perturbations (i.e., adjustment factors) can be estimated in
the linear case. As we described, the system matrix A of eq. (2.39) has eigendecomposition
eq. (2.42). Since θi are the roots of the characteristic polynomial of eq. (2.39), which has
degree n, at maximum n independent perturbations αi can be estimated, i.e., M ≤ n. The
number of estimable perturbations could be less than n, depending on the exact locations of
αi in the matrix A. For the estimation of all M adjustment factors αi to be successful, at
least 2n data points xj(t`) are needed.
Parameter estimation for nonlinearity. As last step we discuss the limits on pa-
rameter estimation for the non-linear components of (2.25). Recall that all non-linearities
are of Michaelis-Menten form and have two true parameters (initial slope at 0 and maximum
value at infinity). The nonlinear Michaelis-Menten saturation suppresses the peaks of the
exponential terms in the solution ~x(t) and thus the shapes of the solution-time curves devi-
ate from those of the corresponding pure exponential terms, in particular for high values of
‖~x(t)‖. This happen in the initial transient of the solution. To estimate such nonlinearities,
observed samples around the peaks of the exponentials are required. At least 2 samples per
nonlinear Michaelis-Menten term in a adjustment factor αi are needed to estimate its two
parameters.
Note that this discussion generalizes to the non-homogeneous system of ODEs used in
iPBPK-R as the forcing function ~z(t) is non-zero only for a short initial time period t0. In
addition, We assumed that xj(t`) are data points in a compartment while in the full iPBPK-
R setup the measurement operator F(.) will be applied. Finally, we assumed a quadratic
optimization problem. In the full iPBPK-R setup a more complex objective function Ψ~r,~u(.)
based on a general distance d(., .) is used and lead extra penalty terms in the objective
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function. These generalizations need to be carefully managed but do not pose fundamentally
new issues.
Relationship to statistical model fitting. In pharmacology, statistical model fitting
is an ubiquitous tool. Our model fitting procedure is distinctly different from statistical model
fitting, e.g., with nonlinear mixed models. This is despite the fact that both methods may
lead to similar non-linear least squares problems. The key difference is that in our case model
selection cannot be performed as dropping a variable would require dropping a compartment
and thus formal model reduction would have to be applied. This is in contrast to statistical
data fitting where a likelihood criterium would be used to select the correct model, i.e., pick
the right number of variables. Model selection in our case would be inherently a reduction
transformation on the differential equation, not a statistical transformation on the model,
and thus not considered a statistical method.
Summary and discussion on iPBPK-R estimation. In this subsection we evalu-
ated the characteristics of the convergence in the optimization procedure for the system of
non-linear ODEs used in iPBPK-R by analyzing a perturbed linearized ODE system. The
system of non-linear ODEs can be bounded by its linearized ODEs. Therefore, we considered
how small changes in adjustment factors of interest affect the solution of the linearized ODEs
and thus the solution of the non-linear ODEs with Michaelis-Menten saturation. Our anal-
ysis shows that the iPBPK-R approach allows us to obtain reasonably accurate parameter
estimates via optimization. However, one needs to keep in mind the following characteristics
for the system of non-linear ODEs with n compartments:
1. The distance between the linearized boundaries of the nonlinear term, |y+ij−y−ij |, needs
to be small enough to produce stable parameter estimates.
2. All nonlinear terms are assumed to be described with a Michaelis-Menten function
eq. (2.15).
3. At maximum n adjustment factors αi in the linearized matrix can be estimated.
4. At maximum n nonlinearities (2 parameters per nonlinear term) can be estimated.
5. Parameter estimation can be cast as an optimization problem which behaves well
locally around the solution for small perturbations αi and requires the solution of
nonlinear least squares optimization.
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6. The size of the attractor of the estimated minimum depends on the nonlinearity of
the original system of ODEs, the numerical values of eigenvalues θi, the eigenbasis,
and parameters.
7. A solution is guaranteed and can be investigated to assess its stability and plausibility.
8. Since iPBPK-R solves a nonlinear high-dimensional optimization problem, there is
no guarantees that the global optimum is found.
9. The objective function Ψ~r,~u(.) introduces penalty terms to push the optimization
towards the biologically most plausible parameter solution.
In the above list, 5. and 6. together indicate that good starting values (e.g., values chosen
based on IVIVE or biological plausibility) are absolutely essential. iPBPK-R utilizes such
values as references and constraints in a specialized objective function in the optimization
procedure.
The discussion in this section provides a worst-case estimate and bounds on how many
samples are needed and how many parameters can be estimated from data in a single com-
partment. In practice, the particular form of the system matrix/operator M(.) and objective
function Ψ~r,~u(.) has substantial impact of what can be soundly estimated. As we will see in
section 2.5, a smaller number of modes θi may be relevant and observable in the measurement
compartment j, and all scaling factors αi may be acting only on these modes. The other
modes may not have to be estimated uniquely as they may be unobservable or part of the
null space of the operator. If so, a smaller number T of samples is sufficient to resolve the
visible modes of the system in compartment j. In this case the scaling factors parameterize
a lower-dimensional manifold in the M -dimensional parameter space spanned by the αi that
captures the non-linear functional dependency that the parameters may exhibit. The par-
ticular form of the objective function Ψ~r,~u(.) serves to disambiguate parameters that have
a functional dependency as it normalizes the parameter estimates so that they are closest
to the IVIVE estimate, i.e., ~r ≈ 1M . This allows us to set up problems with more than
n scaling factors αi and let the optimization problem resolve the resulting ambiguity. The
appeal of this possibility is to cast a wider net and investigate a larger number of potential
biologically induced adjustments that have functional co-dependencies.
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2.5 The Reduced Order iPBPK-R Model
In the previous section we gave an overview of the mathematical underpinning of iPBPK-
R using EBT data. We expressed the system of non-linear ODEs matrix function representa-
tion, and introduced the general forms of the optimization method and its objective function.
In this section we provide the detailed model description of iPBPK-R as an instance of the
general framework laid out in section 2.4.
2.5.1 Developing the Reduced Model
The core of our system is a seven-compartmental PBPK model of 14C-erythromycin as
shown in eq. (2.45)–eq. (2.51). This model is an instance of the non-linear ODE system
eq. (2.12). See the corresponding fig. 7 (left panel; adapted from [105] with permission of
American Society for Pharmacology and Experimental Therapeutics (ASPET)) depicting
the ODE system of 14C-erythromycin. The model contains compartments for artery, vein,
lung, kidney, extracellular space, liver cells, and combined other organs. Further, there are
supporting source and sink compartments used for mass balance that capture IV dosing,
exponential decay in other organs, urine, bile, and metabolic by-product 14CO2.
Our ODE system is a minimum full model according to Sager et al [70]. On the other
hand, this ODE system can be also viewed as a reduced order model since the number
of compartments are limited so that parameters in the model are estimable. The seven-
compartmental PBPK model was built using the drug flow and mass balance following
section 2.4.3.
Method description. Building an iPBPK-R model (in our case of 14CO2 production
rate in healthy subjects) entails defining compartments and flow terms between the compart-
ments. The compartments were listed in fig. 7. Next, the flow terms need to be specified.
They are summarized in table 5 to table 8. In table 5, property input parameters for each
compartment, as an instance of table 4, are listed. Using the parameters in table 5, mass
flow equations of 14C-erythromycin for all compartments were set up in table 6. Then, the
set of ODE equations of 14C-erythromycin in healthy subjects were constructed as in table 7
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① Lung ⑤ Artery ② Vein 
Liver (LV) ⑥ Extracellular Space 
⑦ Liver Cell 
③ Combined  
 other organs 
④ Kidney 
⑫ Bile (B) 
⑨ Exponential  
 Decay in OT 
⑩ Urine 
⑧ IV dosing 
⑪ Metabolism 
⑬⑭ Liver Cell (= ⑦) 
Non-rate  
limiting steps 
Metabolic-by-product model  
for H14CO3
- and 14CO2 
⑮ Blood ‘Pool’ 
Figure 7: The ODE system of 14C-erythromycin (left) and metabolic by-product model
(right) in iPBPK-R.
and table 8 using these mass flows.
The Greek letters with a subscript (i.e., αk, βk, γk, γi, γj, λk, κij) are adjustment factors
that will be collected in a parameter vector ~r. They are explained in the paragraphs ti-
tled Shape of flow terms and Conventional model description in this section and in sec-
tion 2.6. Note that all Michaelis-Menten kinetic terms in these tables are described with
MMa,b = MMa,b,1 using eq. (2.15). As noted above, beyond the seven organ compartments
comprising the seven-compartmental PBPK model, five other compartments (input and
waste compartments) for 14C-erythromycin that are included in fig. 7 and table 8 in order to
retain the mass balance in the entire system. This mass balance is a instance of theorem 1
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(see section 2.4.3 and appendix A.1).
Shape of flow terms. Next we discuss the flow mass terms in our PBPK model. The
mass flows qji(t) of ODEs eq. (2.12) are expressed as a function of drug concentration Ci and
Cj in the compartments Vi and compartment Vj, respectively. First, let ~r be a parameter
vector containing adjustment factors,
Equation 35 (Vector containing adjustment factors for nonrenal elimination pathways)
~r = (αk, βk, γk, γi, γj, λk, κij), (2.59)
which can affect the shape of drug mass flows eq. (2.60). Using the Kronecker delta function
δmn =
1 if m = n0 else
the mass flow between two compartments Vi and Vj is given by three types of mass flow
explained below in (2.61), (2.62), and (2.64). The flow term qji(t) is either one of the mass
flow types Q1, Q2, and Q3, or a combination of two or three types of mass flows Q1, Q2, and
Q3 given by
Equation 36 (Flow term qji(t) as a function of mass flow types Q1, Q2, and Q3)
q~r,~uji (t) =

(−1)δki Q~r11 or (−1)δki Q~r22 or Q~r33
(−1)δki (Q~r11 +Q~r22 )
(−1)δki (Q~r11 +Q~r22 ) +Q~r33 .
(2.60)
In (2.60) ~r1 = (αk, γk), ~r2 = (αk, γk, βk, λk, h), and ~r3 = (κij, γi, γj), ~u is a configuration
vector, h, k ∈ ~u are configuration constants, where h = 0/1 implies competitive/non-
competitive mass flow inhibition and k = i or j. The details of the mass flows Q1, Q2,
and Q3 are as follows.






Ck, k = i or j, (2.61)
with IVIVE constants Kk,1 (clearance). In particular, this IVIVE value expresses a
theoretical volume of drug moved from the compartment Vk per time, which is called
clearance. αk is an adjustment factor, which is a parameter to be optimized to scale
Kk,1. Lk is a biological constant consisting of one or more factors (such as fraction
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Table 5: Property input parameters for the drug flows and ODEs of 14C-erythromycin
Parameter definition
M0 total mass of
14C-erythromycin in the system in fig. 7
t0 time of duration of the IV dosing
Q1 total blood flow
Q2 blood flow from Compartment 6 to Compartment 2
Q3 blood flow in and out of Compartment 3
Q4 blood flow in and out of Compartment 4
Q5 blood flow from Compartment 5 to Compartment 6
Q67 passive diffusion between Compartment 6 and Compartment 7
Pi partition coefficient of Compartment i to blood
Pip partition coefficient of Compartment i to plasma
fi fraction unbound in Compartment i
fib fraction unbound in blood
δGfr estimated glomerular filtration rate (GFR), Gfr, scaled with the fraction
of the drug filtered via GFR (δ)
Ja, Jb, Jc maximum velocity of transporter a, b, and c, respectively (IVIVE)
Ka, Kb, Kc Michaelis-Menten constant of transporter a, b, and c, respectively (IVIVE)
η distribution ratio of drug transporter b in Compartment 4 to 7
µ exponential decay parameter of the parent drug (initial value)
Qcyp clearance of CYP3A4 calculated via IVIVE
k1 distribution rate constant of H
14CO
−
3 from liver cell to the pool compart-
ment; assumed to be 0 based on [172]
k2 distribution rate constant of H
14CO
−
3 from the pool to liver cell; assumed
to be 0 based on [172]
k3 excretion rate constant of
14CO2 in the liver cell
φ conversion factor of 14CO2 from its molecular weight to Ci (a unit of
radioactivity) (φ = 1 in our simulations as done in molar base).
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Table 7: ODEs for concentration change of 14C-erythromycin in the organ compartments








































































































































































































Table 8: ODEs for mass change of 14C-erythromycin in the input and waste compartments
Compartment ODE for mass change
8 IV dosing dm8
dt
= −


















































Table 9: ODE for concentration change of H14CO
−

























unbound). Pk is a biological constant called partition coefficient that is optimized via
a corresponding adjustment factor γk.












, k = i or j, (2.62)
with IVIVE constants Kk,21 (maximum drug mass flow), and Kk,22 (drug concentration
where 50% of Kk,21 is achieved). βk and λk are adjustment factors to scale Kk,21 and
Kk,22, respectively, and
h =
0 if the type of reduced activity of mass flow is non− competitive,1 if the type of reduced activity of mass flow is competitive. (2.63)















where Ki,3 and Kj,3 are biological constants consisting of one or more factors including
IVIVE value of clearance. κij is an adjustment factor to optimize the whole term
eq. (2.64) as a diffusion-based flow.
Adjustment factors appeared in Q1, Q2, and Q3 (i.e., αk, βk, γk, γi, γj, λk, κij ∈ ~r) are
candidate scaling parameters for optimization either to evaluate biological activities in non-
renal drug elimination pathways or to improve the iPBPK-R model fit to the observed 14CO2
production rate data individually. Thus, these parameters may control the mass flows Q1,
Q2, and Q3 and thus, qji(t).
Conventional model description. The types of candidate parameters for optimization
in the liver were described as part of mass flowsQ1, Q2, andQ3 in the paragraph Shape of flow
terms above. They are proportional to either (1) concentration, (2) a nonlinear (Michaelis-
Menten style saturation) function of concentration, or (3) the difference in concentrations
between two compartments. The reference values for the optimization of these parameters
are IVIVE values that were calculated based on literature in pharmacology. Therefore, these
parameters, i.e., adjustment factors, were included as the parameters of interest in the ODEs
in table 7 to table 9. The definition of all adjustment factors is summarized in table 10.
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Remember that ultimately in iPBPK-R these adjustment factors are optimized to explain
how much the reference IVIVE values needed to change in the model fit optimization. While
our main goal was to estimate parameters in the liver consisting of the extracellular space and
liver cell sub-compartments, some parameters in non-liver compartments were also optimized
to improve the model fit to 14CO2 production rate data based on sensitivity analysis. The
production rate of the metabolic-by-product 14CO2 as a function of drug concentration in
the liver is given by the measurement function F(.) that was introduced in eq. (2.26).
Modeling Blood with Vein and Artery compartments. In iPBPK-R, Vein and
Artery compartments were separately modeled as eq. (2.46) and eq. (2.49) in table 7. This
is different from classical PBPK models where blood tissue is viewed as one compartment in
clinical pharmacology. In the connection from Artery, Extracellular Space, through to Vein
compartment, we assumed the two algebraic relationships (see fig. 7). First, the mass flow
from Artery to Extracellular Space q−→
5:6
is fast and thus modeled instantaneous as
C5|6 = C6. (2.65)
Second, we assumed the 2-blood compartment model (i.e., a model with Vein and Artery






Thus, eq. (2.65) and eq. (2.66) are necessary assumptions in iPBPK-R to approximate the
drug flows between the blood tissue and liver organ when the blood is modeled with two
separate compartments, Artery and Vein, while retaining the well-stirred model assumption
for the blood tissue.
Modeling 14CO2 dynamics. Beyond the drug and its metabolite,
14CO2 production
rate in the EBT needs to be modeled. Therefore we added a one-compartment metabolic-by-
product to the system which describes the non-rate limited CYP3A4-enzyme pathway within
the liver cell sub-compartment (right panel of fig. 7). This metabolic-by-product model was
originally proposed by Sugiyama et al. 2011 [172]. The one-compartment metabolic-by-
product model starts with the catalytic conversion from the parent drug, 14C-erythromycin,
to its metabolite 14C-metabolite by CYP3A4. Sugiyama et al. assumed a slow H14CO
−
3
turnover between organ and blood ’pool’ compartments with two rate constants, k1 and k2
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Table 10: List of adjustment factors in iPBPK-R of EBT in healthy subjects
Adjustment factor Definition: adjustment factor of
α3 exponential decay in Other Organs compartment
α7 CYP3A4 activity in Liver Cell compartment
β6 drug transporter a in the liver
β7,1 drug transporter b in the liver
β7,2 drug transporter c in the liver
γ3 partition coefficient of Other Organs compartment to
blood
ζ7 volume of Liver Cell compartment
κ35 arterial blood flow into Other Organs compartment
κ67 passive diffusion between Extracellular Space compart-




3 is dissolved in the blood). In this dissertation, we referred to their in vivo rat
PBPK study and set both parameters to be 0. Accordingly, we simply assumed that the
final-by-product 14CO2 gets released from H
14CO
−
3 in the liver cell with an excretion rate




15 denote the concentration of H
14CO
−
3 in the liver cell and in
the blood pool, respectively. We assume that the respired amount of H14CO
−
3 and exhaled
14CO2 have a one-to-one molar relationship (no rate-limiting step). Furthermore, let m
??
14
be the exhaled amount of 14CO2 in breath, which is assumed to instantaneously travel from
the liver cell to the lung. Then, ODEs of mass change of H14CO
−
3 and
14CO2 are shown in
table 9, respectively. Property parameters of these ODEs are listed in table 5. dm??14/dt in
eq. (2.58) is the amount of 14CO2 sampled in the breath at time t.
2.5.2 Matrix Representation of the EBT PBPK Model
In this section we present the reduced model used in iPBPK-R in the formalism described
in section 2.4.4. We here provide the full specification of all matrix elements of both the linear
and the non-linear part of the system of ODEs that constitute eq. (2.25) in section 2.4.4.
Remember that eq. (2.25) is a nonlinear set of nODEs consisting of the linear term X~m(t)
and nonlinear Michaelis-Menten function term Y(~m(t)) with a short-time intravenous drug
dosing term ~z(t) as forcing function. Setting the dosing rate τ = M/t0 and the short dosing
interval Ω = [0, t0], the 14 ODEs in table 7–table 9 can be described with the real matrix
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Equation 37 (X containing the linear part of the system of nonlinear ODEs)
X =

x1,1 x1,2 . . x1,5 . . . . . . . . .
x2,1 x2,2 x2,3 x2,4 . x2,6 . . . . . . . .
. x3,2 x3,3 . x3,5 . . . . . . . . .
. x4,2 . x4,4 x4,5 . . . . . . . . .
x5,1 . x5,3 x5,4 x5,5 x5,6 . . . . . . . .
. . . . x6,5 x6,6 x6,7 . . . . . . .
. . . . . x7,6 x7,7 . . . . . . .
. . . . . . . . . . . . . .
. . x9,3 . . . . . . . . . . .
. . . x10,4 . . . . . . . . . .
. . . . . . x11,7 . . . . . . .
. . . . . . . . . . . . . .
. . . . . . x13,7 . . . . . x13,13 .
. . . . . . . . . . . . x14,13 .

, (2.67)
that captures the linear part of the model, and the matrix of functions
Equation 38 (Ỹ containing the nonlinear part of the system of nonlinear ODEs)
Ỹ =

. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . −MMβ7,1ηJb,Kb . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . −MMβ6Ja,Ka . . . . . . . .
. . . . . MMβ6Ja,Ka −(MMβ7,1Jb,Kb +MMβ7,2Jc,Kc) . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .
. . . MMβ7,1ηJb,Kb . . . . . . . . . .
. . . . . . . . . . . . . .
. . . . . . MMβ7,1Jb,Kb +MMβ7,2Jc,Kc . . . . . . .
. . . . . . . . . . . . . .
. . . . . . . . . . . . . .

(2.68)
that captures the non-linear Michaelis-Menten style saturation. Dots . in X and Ỹ stand for















we can write the full system of non-linear ODEs used for EBT in iPBPK-R as
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Equation 39 (System of nonlinear ODEs used for EBT in iPBPK-R)
d~m(t)
dt
= X~m(t) + Ỹ(D~m(t)) + z(t). (2.70)
The diagonal elements of D pre-scale the vector elements mi(t) before Ỹ(.) is applied and
can be propagated into the parameters of yi,j(.) using the identity (2.16). This allows us to
convert (2.70) into the normal form given by (2.25) with system operator matrix
A(.) = X(.) + Y(.) with Y(.) = Ỹ(.) ◦D(.).
In eq. (2.70) and the entries of the matrices eq. (2.67) and eq. (2.68), we omit the bicarbonate
concentration in the pool compartment, C?15, since k1 = k2 = 0 was assumed (table 5). As a
result, the total number of ODEs in iPBPK-R of EBT for healthy subjects is n = 14.
Analysis. Having expressed iPBPK-R’s reduced PBPK model and all its dependencies
on parameters and adjustment factors as instance of (2.25) enables us to analyze iPBPK-R’s
estimation capabilities and stability. We want to emphasize that iPBPK-R uses standard
numerical solvers for ODE integration and optimization. The theoretical framework devel-
oped in section 2.4.7 is not used to compute the solutions but to analyze the solution quality
and soundness of the approach.
We base the discussion below on analyzing the eigendecompositions of the upper and
lower matrix approximations A+ and A− of the system operator matrix A of (2.25). The
element-wise distance |a+i,j−a−i,j| is small as required, and both A+ and A− are indeed simple
matrices.
The first observation is that while the EBT iPBPK-R model has 14 compartments for
the purpose of modeling mass balance, the underlying dynamical system has only 7 com-
partments. The 5 source/sink compartments and the 2 further helper compartments lead to
a null space of dimension 6 and can be disregarded in the discussion. Inspection of Figure 15
of chapter 3 and the simulated curves in all 7 compartments (shown in [105]) as well as
Figure 23 of chapter 4 indicate that at most four distinctive estimable mode θi are present
in the liver compartment. Thus, the T = 11 sampling points and the associated noise is
sufficient to estimate the modes to a reasonable accuracy level. The T = 11 measurements
are clustered at the early transient phase and thus allow for estimating non-linear saturation
due to Michaelis-Menten behavior. We provide the eigenanalysis of the EBT example at
concentration 0 in appendix A.2 to give a flavor of the necessary analysis. The analysis
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shows that the spectrum of the 7 compartment model has indeed three to five dominant and
distinguishable modes (32.1, 23.7; −2119.7; −434.0; −290.5, −221.4; −12.7).
Secondly, The number of adjustment parameters that can be distinguished is limited to
M = 7 functionally independent αi at max. iPBPK-R has K = 9 adjustment parameters, and
thus they must have a functional (non-linear) dependence. The dependence is actually shown
in [105] as the four main levers that shape the 14CO2 production rate curve. The condition
that the adjustment factor vector ~r needs to be as close to 1M as possible disambiguates the
functional dependency. This regularizes the estimates and pushes them towards the global
optimum analogous to the arguments presented in [151], and thus makes the estimates stable.
Further adding to stability is the nested optimization procedure employed by iPBPK-R.
In this section we described the detail of the ODE system and adjustment factor pa-
rameters used in iPBPK-R of the EBT data. Part of these parameters are to be optimized
and estimated using the objective function introduced in the previous section. In the next
section we formally define the objective function and describe the details of the optimization
procedure in iPBPK-R, presented in the next section.
2.6 Estimation Procedure for iPBPK-R Parameters
In section 2.4.6, we have discussed that the biologically plausible multiple-parameter
estimation via iPBPK-R is treated as an optimization problem for a subset of parameters
in the system of ODEs eq. (2.12). This optimization problem is to optimize a subset of
adjustment factors of all drug flow terms (2.60) by minimizing the distance d(., .) between
observed and simulated data as shown in eq. (2.29). In the previous section ~r in (2.59) denotes
a parameter vector containing adjustment factors. Some of the optimized adjustment factors
will provide parameter estimates for activities of metabolic enzyme and drug transporters
in individuals, in non-renal drug clearance. For example, optimized adjustment factor α7
(see table 7 and table 10) will explain how much the IVIVE input value of the CYP3A4
activity needs to be scaled for the particular individual in the individualized model fitting.
We developed an EBT specific objective function (an instance of eq. (2.33)) consisting of a
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Table 11: Entries of matrix X



















































































, x13,13 = −k3, x14,13 = φk3
distance measure and penalty terms that regularizes the problem. The estimation procedure
we describe here can be viewed as an indirect measurement procedure for multiple activities
in drug disposition such as enzymatic metabolism and drug transport.
2.6.1 General Setup and Distance Measure
For the high-dimensional parameter optimization procedure of iPBPK-R we developed a
tailored objective function consisting of distance measure with bias, lower bound, drift, and
x-shift penalty terms, eq. (2.33) with eq. (2.34). We now formally define each component
of the objective function. Before defining each component, let us first formally describe the
operator F(.) discussed in eq. (2.26).
Operator to model 14CO2 rate data. As in section 2.4.5, we here describe the
operator eq. (2.26) in detail as follows. Remember that B(t) denotes a 14CO2 production
rate at time t and ~C(t) denotes a solution vector of eq. (2.12) that were converted to drug
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concentrations. Furthermore, consider differentiating one element of ~C(t) that is associated
with the i? compartment and denote Ċi?(t) the differentiated form of the element Ci?(t).
Then, the operator F(.) returns Ċi?(t), i.e.,
Equation 40 (14CO2 production rate B(t) returned by F(.) in iPBPK-R)
B(t) = F(~C(t)) = Ċi?(t). (2.71)
This is an instance of eq. (2.28). When the i? compartment denotes the Liver compartment
for 14CO2 in table 9, Ċi? is approximately viewed as a modeled
14CO2 production rate at
time t in the breath sample. Thus, F(.) provides modeled 14CO2 production rate data using
the solution vector ~C of the system of ODEs.
Configuration vector. We define the configuration vector
Equation 41 (Configuration vector in iPBPK-R)
~u =
(
h,~h′,~h′′, (u`)`, ub, uc, ud, ux
)
(2.72)
where h ∈ R, ~h′ ∈ RK , and ~h′′ ∈ RK . K is the length of the parameter vector ~r. h is the
indicator defined in eq. (2.63) and influences the ODE terms. The indicator vectors ~h′ and
~h′′ are used within penalty terms to configure which adjstment factors may be penalized.
(u`)`=1,...,T, is a vector of weights for each sampling point. ub, uc, ud, and ux are weights for
bias, lower boundary, drift, and x-shift terms, respectively.
Δ 
Figure 8: 2D L2 norm and 2D distance measure
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Distance measure. Clinical measurements may be slightly shifted relative to the
planned time point. We introduce a 2D distance that was used as a distance measure
between simulated and measured 14CO2 production rate in iPBPK-R. This distance general-
izes the usual L2 norm distance eq. (2.30) by allowing for some (penalized) misalignment in
x direction in addition to value mismatch in y direction. Let us define the `th measurement
point measured at time t` as ~s` = (t`, w`). We define the point
p`′ = (t`′ , B(t`′)) such that t`′ = arg min
t′∈[t`−δ,t`+δ]
‖(t′, B(t′))− (t`, w`)‖2
for an appropriately chosen δ. We denote the distance between measurement and simulation
at sample point ` as ∆` = ‖~p`′ − ~s`‖2. See the left panel of fig. 8 for an illustration.




. Then, the 2D distance d2D(., .) between the simulated function B(t) param-
eterized by ~r and ~u and the measurement vector ~S, is defined as follows. Per time point `
and measurement ~s` the minimal Euclidean distance ∆` between the observed data point ~s`
and the modeled 14CO2 production rate-time curve B(t) is found. The 2D distance between
B~r,~u(t) and ~S is then given as the weighted sum of all squared ∆` for ` = 1, . . . , T . Formally,
the 2D distance is defined as










u`||~p`′ − ~s`||22. (2.73)
See the right panel of fig. 8 for an illustration.
2.6.2 Penalty Terms
Next we discuss the specific shapes and rationales for the penalty terms and their pa-
rameterizations. These terms are the EBT spcific instances of the general form shown in
section 2.4.6.
Bias constraint term. We introduce a bias term to disambiguate potential functional
relationships between estimation parameters and ensure that the final estimate is as close to
the initial IVIVE values as possible while matching the measurement data within its noise
bounds. The parameter vector,
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Equation 43 (Parameter vector ~r in iPBPK-R)
~r = (ri)i=1,...,K, (2.74)
which contains adjustment factors such as αk, βk, γk, γi, γj, λk, and κij, is biased towards the
IVIVE scaling estimate ~r0. Not all elements of ~r have to be used in the bias term. This
is encoded in an indicator vector ~h′ ∈ {0, 1}K. Whether or not a particular element of ~r
is included is decided based on IVIVE or on biological plausibility. Then the bias term is
formally defined as
Equation 44 (Bias constraint term ν(~r,~h′))
ν(~r,~h′) = ‖diag(~h′)(~r − ~r0)‖22 (2.75)
which is the masked squared Euclidean distance between ~r and ~r0.
Lower bound penalty term. To avoid biologically unrealistic parameter estimation,




captures the lower bounds for all scaling factors. Below these bounds, a penalty is added to
the objective function. Again, not all elements of ~r have to be used in the penalty term. This
is encoded in an indicator vector ~h′′ = (h′′i )i=1,...,K ∈ {0, 1}K. Whether or not a particular
element of ~r is included is decided based on IVIVE or on biological plausibility. The lower
bound penalty term is given by




h′′i min(ri − rLi , 0)2. (2.77)
Drift penalty term. Ensuring the correct height of the peak of the simulated curve
B(t) requires a separate penalty term called drift as the simulated function can “shoot
up” between samples if not properly constrained. Thus, we progressively penalize B(t) for
deviations in peak height from the maximum measured data point w`. The drift penalty term
is defined as the squared distance between the maximum values of modeled and observed
14CO2 production rate data,











X-shift penalty term. The 2D distance d2D(., .) allows for slight x shifts of the mea-
surements relative to their nominal sampling time points t`. To minimize the per-timepoint
shift we penalize differences between t` and t`′ linearly. We define the x shift penalty term
as




|t`′ − t`|. (2.79)
In practice, using a linear penalty term for x shift but bound the maximum shift worked
best for our purpose.
2.6.3 Objective Function and Optimization Problem
We now combine the distance function and all penalty terms into the overall objective
function Ψ(.) and formally state the exact iPBPK-R EBT parameter estimation problem.
The problem is an instance of the general form discussed in section 2.4.6.
Objective function in iPBPK-R. Our tailored objective function is expressed as a
weighted combination of the 2D norm distance, and constraint and penalty terms. Using the
previously defined weights in the configuration vector eq. (2.72) and 2D distance, constraint
and penalty terms in eq. (2.73), eq. (2.75), eq. (2.77), eq. (2.78), and eq. (2.79), the objective
function is expressed as
Equation 48 (Objective function Ψ~r,~u2D (., .) in iPBPK-R)
Ψ~r,~u2D (., .) : (B
~r,~u(t), ~S) 7→ d2D(B~r,~u(t)), ~S) +ubν(~r,~h′) +ucρ(~r,~h′′) +udε(~r) +uxψ(~r). (2.80)
Note that different variants of Ψ~r,~u2D (., .) can be configured via indicator vectors and weights.
Such configurations are collected in the configuration vector ~u defined in eq. (2.72).
Estimation as optimization problem. Recall that the biologically plausible multiple-
parameter estimation via iPBPK-R is treated as an optimization problem where a subset
of parameters of all drug flow terms are optimized to best fit the system of ODEs to the
measured data ~S. The result is the parameter/adjustment factor vector ~r defined in (2.74).
Given the configuration vector ~u defined in (2.72), optimization of the parameter vector is
performed by minimizing the objective function eq. (2.80). Formally, iPBPK-R solves the
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optimization problem
Equation 49 (Optimization problem in iPBPK-R)








for configuration ~u (2.81)
to estimate the most likely configuration ~r. The full optimization space allows for 7 indepen-
dent parameters, but in practice not all of them are strongly influencing the fit. Depending
on the goodness-of-fit of modeling, some less influential parameters in ~r can be fixed as con-
stants and not necessarily be optimized. This is achieved through appropriate setting of the
indicator vectors ~h′ and ~h′′.
2.6.4 Handling Combined Pre/Post Treatment Estimates
The impact of a treatment on biological parameters is often the focus in clinical pharma-
cology studies. An intervention is performed on an individuals, and the goal is to evaluate
the effect of the intervention by comparing the same type of data obtained before and after
the intervention.
Treatment effect on estimates. In our case of chapter 4, the intervention of interest
is dialysis. In a kidney disease study where EBT is used before and after the patients
receive dialysis, our goal is to apply iPBPK-R to these two data series to estimate the effect
of dialysis on biological parameters of individual patients. We assume that independent
parameters remain unchanged while co-optimization parameters change from pre-dialysis to
post-dialysis. To estimate both co-optimization parameters and independent parameters,
we developed a co-optimization method by introducing additional parameters and extending
the optimization discussed in eq. (2.81), discussed next.
Suppose that the same data sampling procedure using configuration ~u is performed pre
and post dialysis, leading to data sets ~S1 and ~S2. From the corresponding parameter es-
timates ~r1 and ~r2 we derive the simulated breath curves B1(t) and B2(t). The parameters
vectors ~r1 and ~r2 are not independent: we set
~r1 = ~rc ⊕ ~ri,1 and ~r2 = ~rc ⊕ ~ri,2
where ⊕ denotes the vector direct sum,
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Equation 50 (Co-optimized parameter vector ~rc in iPBPK-R)
~rc = (βk, γk, γi, γj, λk, κij), (2.82)
denoting the co-optimized parameter vector, and
Equation 51 (Independent parameter vectors ~ri,1 and ~ri,2 in iPBPK-R)
~ri,1 = (ξ1, αk,1), and ~ri,2 = (ξ2, αk,2), (2.83)
denoting the independent parameter vectors, respectively (the subscript i stands for indepen-
dent). ξ1 and ξ2 are inhibition parameters as elements of ~ri,1 and ~ri,2, respectively. Further
αk,j, j = 1, 2 are independent adjustment factors in mass flow Q1 (see eq. (2.61)).
Co-optimization setup. Now we discuss how the three parameter vectors are used
to co-optimize pre- and post-dialysis parameters. In the pre-dialysis modeling of the EBT
data, ~ri,1 and ~rc are optimized while ξ1 is used to replace βk and λk with ξ1βk and ξ1λk in
nonlinear mass flow Q2 of ODEs (see eq. (2.62)). Similarly, in the post-dialysis modeling of
the EBT data, ~ri,2 and ~rc are optimized while ξ2 is used to replace βk and λk with ξ2βk and
ξ2λk in Q2 of ODEs. Thus, ξ1 and ξ2 act as additional inhibition (as stated above). The
parameter vector ~ri,1 and ~rc are optimized for pre-dialysis while ~ri,2 and ~rc are optimized post-
dialysis. Thus, ~rc encodes the pre/post constraint while ~ri,1 and ~ri,2 encode the independent
adjustment factors.
As example let Q2,1 and Q2,2 be nonlinear mass flows in pre- and post-dialysis, respec-
tively. These are pre/post dialysis inbstances of eq. (2.62). Compared to the original mass
flow Q2 defined in eq. (2.62) where biological inhibition is not accounted for, Q2,1 and Q2,2



























, k = i or j. (2.85)
The mass flows Q2,1 and Q2,2 show that we used inhibition parameters to scale adjustment
factors of interest and to indicate altered or reduced biological activity from the adjusted
IVIVE values in iPBPK-R (Note: An adjusted IVIVE value means an IVIVE value multiplied
by a corresponding adjustment factor). Usually the values of inhibition parameters range
from 0 to 1 but they can take a value greater than 1 if the parameters should describe
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increased biological activity from the adjusted IVIVE values.
Combined optimization problem. With the above setup we can formally express co-
optimization across treatment in an EBT study using patients with kidney disease. Again,
we have two data sets ~S1 and ~S2 obtained pre- and post-dialysis, respectively, and two
solutions of the respective pre- and post-dialysis systems of ODEs, B1(t) and B2(t). The
same configuration ~u is used for both pre- and post-dialysis. Estimating parameter vectors
~r1 and ~r2 (or ~ri,1, ~ri,2, and ~rc) is expressed as a single optimization problem,
Equation 52 (Combined optimization problem for multiple data series in iPBPK-R)


















As a note, inhibition parameters like ξ1 and ξ2 can be introduced dependent on the
addressed research question. In our application of EBT using patients with kidney disease
pre- and post-dialysis in chapter 4, we introduce inhibition parameters to multiply to the
adjustment factors related to the non-renal elimination pathways (β6, β7,1, and β7,2 in table 7
– table 8) and to evaluate the effect of dialysis on the non-renal elimination pathways. In a
general application of co-optimization in iPBPK-R, parameters beyond ~r defined in (2.59)
may need to be included in ~r1 and ~r2, and ~u needs to be chosen carefully to model pre/post
dependencies and address particular research.
2.6.5 Numerical optimization methods and implementation
We implemented optimization discussed in section 2.6.3 and section 2.6.4 in the R system.
We used the R function ode in the deSolve package that implements a suite of ODE solvers,
including explicit and implicit solvers, adaptive solvers, and Runge Kutta solvers [165] [166].
Optimization was performed using the L-BFGS-B and BFGS algorithms provided by the R
function optim that implements quasi-Newton method with or without a limited-memory
modification, respectively [167]. The nested optimization used for co-optimizing estimates
is implemented via a generalized Hill Climbing approach. Optimization of the independent
parameter vectors ~ri,1 and ~ri,2 were performed first independently in a inner loop. Optimiza-
tion of the co-optimization parameter vector ~rc was implemented in an outer loop. This
iteration was performed iteratively until sufficient convergence.
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2.7 Examples and Results
This section provides a brief summary of two applications of iPBPK-R in terms of method
perspectives. The detailed results and pharmacological interpretations of the first application
in healthy subjects are described in chapter 3. The second application of iPBPK-R in patients
with kidney disease is detailed in chapter 4, of which preliminary results were presented as
a poster at the American Society of Nephrology 2019 (Kidney Week 2019) [106].
2.7.1 Estimating Parameters in Healthy People
The first application of iPBPK-R is to model 14CO2 production rate data obtained from
12 healthy subjects in an EBT study to estimate biological parameters. The study design
of the EBT study is described in section 2.4.2 and chapter 3 [105]. Briefly, 12 healthy
subjects received a single IV dose of 14C-erythromycin and breath samples were collected
immediately at 11 time points within two hours including the baseline time point of EBT.
14CO2 production rates in the collected breath samples were calculated.
The model structure of iPBPK-R and the system of ODEs were shown earlier in fig. 7 and
table 7–table 9, respectively. For all nonlinear mass flow terms in the ODEs we assumed the
type of reduced activity of mass flow to be non-competitive, and thus set h = 0 in eq. (2.63).
The initial values of the input parameters in table 5 including IVIVE values can be found in
table 12 of chapter 3. Note that fraction of the drug filtered via GFR (δ) and distribution
ratio of drug transporter b in Compartment 4 to Compartment 7 (η) in table 5 were not
available in the literature. We pre-estimated these two parameters by applying iPBPK-R to
the mean value of 14CO2 production rate at 20 minutes obtained from a published clinical
EBT study [169], and used them as fixed values in the iPBPK-R modeling of EBT data of
12 healthy subjects.
Through an initial manual investigation we first identified that nine parameters were
either impacting the shape of the simulated rate-time curve B(t) or biologically relevant.
Using the notation in table 7, these nine parameters were
Ja, Jb, Jc, Qcyp, V7, P3, µ3, Q3, and Q67,
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(see table 10), and their respective adjustment factors
β6, β7,1, β7,2, α7, ζ7, γ3, α3, κ35, and κ67. (2.87)
were optimized.
The results are summarized in Figure 15 of Chapter 3. The iPBPK-R model fit well
for individual 14CO2 production rate-time curves as result of high-dimensional parameter
optimization. Among the optimized adjustment factors summarized in eq. (2.87), factors
β6, β7,1, β7,2, α7, ζ7, and κ67 were associated with the Liver compartment, where activities
in non-renal elimination pathways are target of the research. The estimated values of these
parameters are shown in Figure 9, which is identical with Figure 17 (A) in chapter 3. While
adjustment factors β7,1 and β7,2 did not have impact on the model fit in the figure, we
forced them into the iPBPK-R model to satisfy mechanistic considerations. Among the
parameter estimates of interest, α7 was stratified and evaluated by gender. This led to our
finding of gender difference in enzyme-mediated drug elimination in the liver as described in
Chapter 3 [105]. This finding also aligned with literature where the gender-related difference
was seen in the same enzyme expression in human liver bank samples [173]. The 3D plot in
fig. 10 is an instance of change in the 14CO2 production rate-time curve from one subject
during the high-dimensional parameter optimization. Section 2.4.7 provides the theoretical
foundation for accuracy of our estimates, given the number of parameters in the optimization
and initial IVIVE values. In addition, we run numerical experiments during the development
of iPBPK-R that indicated the practical stability of the method.
In this application we were able to estimate parameters on both rate-limiting step and
non-rate-limiting steps in the non-renal elimination pathways of erythromycin in individual
healthy subjects via iPBPK-R taking advantage of the reduced order model as well as high
information contents of the rate data. A production simulation run on average required
about 10 CPU hours per subject on the Bridges supercomputer at PSC [126].
2.7.2 Co-Estimation Pre- and Post Dialysis
The second example is the application of iPBPK-R to the 14CO2 production rate data
obtained from 12 patients with kidney disease in an EBT study. The study design of the
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Figure 9: Box plot of estimated adjustment factors of the Liver in 12 healthy subjects.
Figure 10: 3D plot of 14CO2 production rate-time curve during the optimization in one
subject.
EBT study is illustrated in fig. 11 and described in Chapter 4 [128] [106]. Briefly, 12 patients
with end-stage renal disease received a single IV dose of 14C-erythromycin before taking
a 4-hour dialysis. Two hours post-dialysis these patients received another single IV dose
of 14C-erythromycin. In each EBT breath samples were collected immediately at 11 time
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points within two hours of IV, including the baseline time point of EBT. Subsequently 14CO2
production rates in the collected breath samples were calculated for the pre- and post-dialysis
EBTs.
Figure 11: iPBPK-R application to the 14CO2 production rate data in patients with kidney
disease who underwent dialysis.
The model structure of iPBPK-R and the system of ODEs were similar to those in the
first example with healthy subjects, and we assumed that the type of reduced activity of
mass flow is non-competitive. The mass flow from the Kidney compartment to the Urine
compartment (see fig. 7) was removed assuming no kidney function in the patients and drug
removal by dialysis was assumed negligible. Note that it is generally possible to account for
the effect of dialysis on the drug clearance of the pre-dialysis dosing and simulate its carryover
drug concentrations for the subsequent drug dosing in iPBPK-R. Since we assumed that the
percentage of drug removal was 0, we simply simulated the drug concentrations at nine hours
of the first EBT without the effect of dialysis and superimposed them on the baseline drug
concentrations of the second EBT. Nine hours was assumed to be the time interval between
the start of the first EBT and the start of the second EBT. Although the timing of dialysis
and time interval between two EBTs were assumed to be the same for all patients in this
example, different timings of dialysis can be also incorporated in iPBPK-R.
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We selected the same set of parameters for optimization as the in first example with
healthy subjects. In the optimization procedure with the two EBT datasets pre- and post-
dialysis, we implemented a nested co-optimization for each patient as described in sec-
tion 2.6.4. One difference from the previous example is that the adjustment factor α7 in
eq. (2.87) was optimized in the inner loop rather than the outer loop of the nested co-
optimization so that the linear mass flow associated with CYP3A4 activity can be evaluated
pre- and post-dialysis independently. Thus, the adjustment factors pre- and post-dialysis
for CYP3A4 activity were independently estimated. Inhibition parameters associated with
drug transporters were also estimated independently pre- and post-dialysis in the inner loop
so that the change in the activity of each drug transporter could be evaluated by comparing
the inhibition parameters pre- and post-dialysis.
We show the resulting iPBPK-R model fit for all patients pre- and post dialysis in
Figure 23 of chapter 4. The iPBPK-R model fit the individual 14CO2 production rate-time

















were independently estimated in the inner loop. Using these estimates, activities of CYP3A4
enzyme and drug transporters could be compared between pre- and post-dialysis in each
patient so that the effect of dialysis on the non-renal elimination pathways could be evaluated.
iPBPK-R enabled us to individually estimate both rate-limiting and non-rate-limiting steps
of non-renal elimination pathways and their changes in drug disposition. The changes in
parameter estimates could be also used to evaluate correlations between the activities in the
non-renal elimination pathways and candidate biomarkers such as plasma concentrations of
uremic toxins across patients. A production simulation run on average required 24 CPU
hours per patient on the Bridges supercomputer at PSC. The comprehensive results are
described in chapter 4.
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2.8 Discussion
In this section we discuss the iPBPK-R method and its comparisons with other tradi-
tional pharmacokinetics modeling. As briefly reviewed in Section 2.7, we demonstrate that
experimental findings in literature are captured by our method in Chapter 3. Our estimated
adjustment factor on CYP3A4 activity show gender-related difference similarly to a study
where the CYP3A4 in human liver bank samples was analyzed, and we detail this biological
significance in Chapter 3. In this chapter, several techniques of iPBPK-R that enabled us
to simultaneously estimate multiple physiological parameters in individuals were described.
2.8.1 iPBPK-R Characteristics
Use of rate data. Production rate data as the first derivative of drug concentration
data was used in the iPBPK-R model fitting. The simulated 14CO2 production rate data
was used in nested (co-)optimization to inversely estimate multiple parameters of interest.
Through the dynamic changes in the early phase of a 14CO2 production rate-time curve,
parameters of both rate-limiting and non-rate-limiting steps could be estimated. Even with
one dosage, small but detectable variation in the data allowed us to infer parameters govern-
ing nonlinearity through the coupled system of ODEs. We also benefited from the frequently
sampled 14CO2 production rate data within the first 2 hours of the breath test since it pro-
vided the sensitive signals of physiological changes that we were interested in. While we used
a rate measurement in the examples with EBT, multiple drug concentration datasets per
individual can be also used in iPBPK-R if available. Such datasets can be coupled through
rate relationships within a system of ODEs. Using multiple drug concentration datasets is
explored in chapter 5 as the next step of iPBPK-R development.
Use of reduced order model. We used a reduced order model in iPBPK-R. As
explained in section 2.5, the number of compartments was limited so that parameters in the
model could be estimable. At the same time the model structure we used in the examples
with EBT was a full PBPK model according to Sager et al. [70]. It is essential to use a
reduced order model in iPBPK-R since the main purpose of this method is not to predict
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drug concentration behaviors but to back estimate multiple physiological parameters of a
system of nonlinear ODEs in individuals. In section 2.4.7, we showed that the parameter
estimation in iPBPK-R can be cast as an optimization problem and that the optimization
behaves well locally around the solution given a carefully designed objective function. Given
the number of compartments we provided the theoretical foundation regarding the number of
parameters (or adjustment factors) that we can generally estimate with iPBPK-R. iPBPK-R
differs from conventional PBPK modeling where a limitless number of parameters is used
to capture all foreseen variabilities in various clinical scenarios or populations. iPBPK-R is
complemental to the conventional PBPK approaches.
Objective function in iPBPK-R. We developed a specialized objective function for
parameter optimization of iPBPK-R. In the objective function a 2D distance measure be-
tween simulated and observed rate data was combined with constraint and penalty terms
such as bias, lower bound, drift, and x-shift (see section 2.6.1). Furthermore, these terms
can be weighted depending on optimization problem characteristics. When the underlying
system of ODEs includes instable nonlinear terms a considerable effort is generally required
for stable parameter estimation. Our objective function aids convergence without skewing
the results of high-dimensional optimization as discussed in section 2.4.7. Optimization
with the objective function is implemented using a quasi-Newton method with or without a
limited-memory modification as described in section 2.6.5.
Use of biological knowledge as reference. A priori knowledge in related literature,
for example, clinically anticipated physiological parameters derived from in-vitro in-vivo
extrapolation (IVIVE), were used as reference values in parameter optimization as well as in
the aforementioned objective function. This is part of aiding convergence around the solution
and it is useful in selecting sensitive parameters as optimization parameters. In the system of
nonlinear ODEs we introduced and estimated adjustment factors which measure the size of
deviation from reference values such as IVIVE values in individuals. This technique allows
us to obtain biologically plausible estimates for parameters of interest. As established in
section 2.4.7 parameter estimates via iPBPK-R are close to IVIVE values since the starting
values of the optimization are derived from IVIVEs. This is a major strength of iPBPK-R
even though the global minimum in parameter optimization is not guaranteed.
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Co-optimization for estimating altered physiological parameters. In order to
estimate some physiological parameters independently while co-estimating other physiologi-
cal parameters as unchanged before and after intervention in each individual, we developed
a nested co-optimization approach. Independent parameters are optimized in the inner opti-
mization loop while common parameters are optimized in the outer optimization loop. The
nested co-optimization is based on a generalized Hill Climbing algorithm as described in
section 2.6.4. We provided a brief summary of the application example using EBT data
in patients with kidney disease who received EBTs pre- and post-dialysis. The nested co-
optimization was conducted to estimate altered parameters by dialysis in section 2.7.2. The
results of this example showe consistent and plausible parameter estimates in each patient
and across patients in chapter 4. The timing of dialysis were assumed to be the same for all
patients but different timings of dialysis across patients can be also modeled in iPBPK-R.
The biological details of the parameter estimates and clinical interpretations are described
in chapter 4. Co-optimization to estimate altered physiological parameters can be applied to
evaluation on the impact of not only intervention but also disease progression or some status
change due to co-medication in individuals. iPBPK-R is a powerful tool to identify particular
changes in modeled physiological activities in particular individuals and thus differentiate
the individuals based on the physiological activities that cannot be measured directly.
Computational cost and time. Lastly, iPBPK-R simulation and parameter optimiza-
tion was implemented using R, which demanded high computational resources and resulted
in long run times. We conducted the large-scale simulations needed for production runs,
method development, and design space exploration at the Bridges supercomputer at PSC.
iPBPK-R model fitting took four hours to eight days per individual. A total of 150,000 CPU
hours was approximately spent in the development and applications of iPBPK-R. The exe-
cution time depends on the difficulty of the optimization problem. By switching to a more
efficient programming language like C++ it would be possible to shorten the simulation time
enormously and improve the efficiency of iPBPK-R. This would come at substantial devel-
opment cost and should only be done when the method development has fully concluded.
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2.8.2 Comparison to Other Procedures
As mentioned above, iPBPK-R was developed for estimating multiple physiological pa-
rameters. This is distinctly different from classical approaches for estimation and prediction.
A cocktail approach where a subject takes multiple activity-specific probe drugs is the stan-
dard method to indirectly estimate different biological activities [122] [123]. The group-wide
activities associated with the respective drugs are statistically estimated, in contrast to in-
dividual estimates in iPBPK-R. In conventional population PBPK modeling, IVIVE values
are generally used as fixed input for simulations and prediction. It is assumed that the ex-
trapolated physiological values from preclinical literature are population means in humans
and corresponding assumed variance may be given. Thus, population PBPK modeling is a
statistics-based modeling approach. Population PBPK modeling for prediction are generally
conducted before observed data from clinical studies are available. Such PBPK models are
later validated when observed clinical data become available.
Mechanistically dependent parameters are estimated in iPBPK-R. Unlike pop-
ulation PBPK modeling for prediction, iPBPK-R does not use distributional assumptions
for physiological parameters but uses them as reference values. It then numerically fits to
individual observed data to perform parameter estimation (i.e., estimation of adjustment fac-
tors). The iPBPK-R approach makes sense when we are interested in estimating individual
parameters for precision medicine and when these physiological parameters are mechanisti-
cally dependent in the system. If we instead use a population PBPK model and inversely
solve for multiple parameters of the underlying system of ODEs, it is likely to produce bi-
ased estimates since many physiological parameters in the population model are treated as
independent in their distributional assumptions. iPBPK-R overcomes this potential bias by
utilizing a reduced order model and numerically optimizing multiple parameters simultane-
ously via individual model fitting.
Adjustment factors explain interindividual variability. IVIVE values which are
used in both population PBPK and iPBPK-R modeling, are not guaranteed to be a clinically
relevant population mean values. The mathematical equations used to extrapolate in vitro
experimental values to obtain IVIVE values are based on relatively simple mathematical
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models. In vitro data may not necessarily represent the average value of response in a
particular type of cells when the sample size is small or experimental conditions for cell
culture vary. While a log-log plot is commonly used to show a good linear correlation in
IVIVE research, it does not mathematically indicate a linear relationship if the plot deviates
from the diagonal line. In iPBPK-R, we estimate adjustment factors to measure the exact
size of deviation from the IVIVE references individually. iPBPK-R overcomes the limitations
of the typical use of IVIVE.
Real-time and parallel validation with observed data. In population PBPK mod-
eling, a model validation step is required to confirm its predictive ability when observed data
become available. Sufficient predictive ability of a population PBPK model is essential if,
for example, the model is subsequently used to predict lower and upper bounds of the drug
concentration-time behavior for another population. On the other hand, iPBPK-R uses a
pre-determined model structure and the model fits to individual observed data to inversely
estimate parameters given the model structure. In this sense iPBPK-R does not require a
separate model validation step with observed data. Instead, visual inspection of a goodness-
of-fit plot with every individual dataset serves as independent and parallel validation steps.
Successful high-dimensional parameter optimization also serves as model validation.
Use of nonlinear ODE system for estimation but not for covariate selection.
The core of the methodological procedure to estimate multiple physiological parameters of
iPBPK-R is a high-dimensional parameter optimization procedure. iPBPK-R does not rely
on model selection in the same sense as population PK modeling. Unlike PBPK modeling,
classical PK modeling is a non-mechanistic modeling approach and it is frequently imple-
mented with specialized PK software such as NONMEM. Population PK modeling is useful
to identify important covariates (e.g., ethnicity, gender, age, clinical laboratory data among
others) that impact on inter-individual variability in drug exposure. Covariate selection
or model selection is an important part of the modeling procedure. While population PK
modeling itself is typically based on a nonlinear model structure, covariate selection is done
within a linear term of the model structure. Apparently mechanistically-unrelated covariates
are selected to explain systematic differences in a clearance term, for example. The selection
criteria are based on some statistical method such as a likelihood ratio test. iPBPK-R, on
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the other hand, is based on a pre-defined system of nonlinear ODEs as a model structure
which needs to sufficiently describe mechanistically dependent relationships in the system of
interest. Multiple physiological parameters in both linear and nonlinear terms across ODEs
are optimized rather than being dropped or added. These parameters may be functionally
dependent unlike in population PK modeling where covariates are assumed to be independent
variables.
In iPBPK-R, the dependent parameters comprise a complex optimization problem in-
stead of a model selection problem. Unlike population PK modeling where two sets of linear
covariate combinations between nested models are compared, multiple potentially dependent
mechanistical parameters of a system of nonlinear ODEs are simultaneously estimated in
iPBPK-R. There is no formal statistical test to compare two sets of multiple dependent
parameters with respect to model fitting in iPBPK-R. However, it is generally understood
that such two sets of parameters for the same system of nonlinear ODEs result in quite
different sets of solutions. Consequently, high-dimensional parameter (co-)optimization of
iPBPK-R is expected to produce accurate parameter estimates as we have established via
the theoretical foundation in section 2.4.7.
Conditions to avoid overfitting and stability issues. In absence of covariate selec-
tion in iPBPK-R, one might be concerned with potential model overfitting and parameter
stability issues. In particular, these issues might be raised when two application examples
in section 2.7 have shown that iPBPK-R model fitting was consistently good as in Fig-
ure 15 of chapter 3 and Figure 23 of chapter 4. As we have established the theoretical
foundation in section 2.4.7, the numbers of optimized parameters in these examples were
within the maximum number of estimable parameters in the system of nonlinear ODEs for
14C-erythromycin. This supports that the application examples of iPBPK-R were free from
overfitting and parameter stability issues. In addition, the computational cost and time for
high-dimensional parameter (co-)optimization were substantial on the supercomputer at the
PSC, making numerical stability experiments and Monte Carlo style evaluation beyond a
few samples impractical. We established good numerical behavior within the practical limits
posed by our fully exploited grant of 150,000 CPU hours at PSC.
Novel, indirect measurement approach. In summary, iPBPK-R is a novel indirect
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measurement approach which is useful to estimate multiple physiological parameters in indi-
viduals using clinical observed data. Breath biopsy data [124,125] is particularly well-suited
as it can be modeled as first derivative of drug concentration data. Using a reduced order
model and a specialized objective function with IVIVE references, adjustment factors are
optimized via nested optimization that can be used for investigating inter-individual vari-
ability. By implementing nested co-optimization, altered physiological parameters by an
intervention can be also estimated per individual. Unlike population PK modeling and pop-
ulation PBPK modeling, covariate selection or model validation is irrelevant in our approach.
The core part of the iPBPK-R procedure is high-dimensional optimization in a system of
nonlinear ODEs across all data of an individual. In iPBPK-R other types of clinical datasets
including multiple drug concentration datasets per individual can be used, which we address
in Chapter 5 and future work.
2.9 Conclusions
In this chapter we presented a novel PBPK approach we call iPBPK-R that allows us
to estimate multiple parameters on physiological activities that cannot be directly measured
in individuals. This indirect measurement approach integrates several features: rate data,
use of a reduced order model as a PBPK model structure, specialized objective functions
utilizing a prior knowledge obtained from in vitro experiments (i.e., use of IVIVE), and
nested (co-)optimization. Thus, iPBPK-R can be applied to clinical rate data sampled from
a breath test. We provide the theoretical foundation of the parameter estimation and provide
evidence that multiple parameter estimates in iPBPK-R are stable and accurate.
In an application of iPBPK-R to 14CO2 production rate data from an EBT it has been
demonstrated that biological findings derived from parameter estimates were compatible with
biological experiments. Furthermore, physiological activities pre- and post-dialysis were in-
dependently estimated in individual patients via the nested co-optimization. iPBPK-R uses
high-dimensional parameter estimation. It is an approach complementary to population PK
and PBPK modeling. Based on the success with the applications to EBT, we anticipate
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various opportunities to apply iPBPK-R and assist future precision drug dosing and person-
alized medicine. At this point the iPBPK-R approach is computationally costly but it can be
made fast and cheap enough for deployment through proper performance-oriented software
engineering. We also anticipate that iPBPK-R can be applied to multiple datasets of drug
concentrations per individual. The first application to such data is shown in Chapter 5 and
discussed as our next research direction for iPBPK-R in Chapter 6.
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3.0 Simultaneous Assessment of Hepatic Transport and Metabolism Pathways
with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production
Rate Data (iPBPK-R)
This chapter has been published in the Journal of Pharmacology and Experimental Ther-
apeutic (2019) 371:151–161; DOI: https://doi.org/10.1124/jpet.119.257212. The entire chap-
ter was adapted from the publication with permission of American Society for Pharmacology




Erythromycin is a substrate of cytochrome P4503A4 (CYP3A4) and multiple drug trans-
porters. Although clinical evidence suggests that uptake transport is likely to play a domi-
nant role in erythromycin’s disposition, the relative contributions of individual pathways are
unclear. Phenotypic evaluation of multiple pathways generally requires a probe drug cocktail.
This approach can result in ambiguous conclusions due to imprecision stemming from over-
lapping specificity of multiple drugs. We hypothesized that an individualized physiologically-
based pharmacokinetic modeling approach incorporating 14CO2 production rates (iPBPK-R)
of the erythromycin breath test (EBT) would enable us to differentiate the contribution of
metabolic and transporter pathways to erythromycin disposition. A seven-compartmental
PBPK model was built for 14C-erythromycin administered intravenously. Transporter and
CYP3A4 clearance were embedded in hepatic compartments. 14CO2 production rates were
simulated taking the first derivative of by-product 14CO2 concentrations. Parameters related
non-renal elimination pathways were estimated by model fitting the EBT data of 12 healthy
subjects individually. Optimized iPBPK-R models fit the individual rate data well. Using
one probe, nine PBPK parameters were simultaneously estimated per individual. Maximum
velocity of uptake transport, CYP3A4 clearance, total passive diffusion and others were
found to collectively control 14CO2 production rates. The median CYP3A4 clearance was
12.2% of the input clearance. Females had higher CYP3A4 activity than males by 11.3%.
We applied iPBPK-R to EBT data to distinguish and simultaneously estimate the activity
of multiple non-renal elimination pathways in healthy subjects. The iPBPK-R framework is
a novel tool for delineating rate-limiting and non-rate-limiting elimination pathways using a
single probe.
3.2 Introduction
The macrolide antibiotic erythromycin is a nonrenally cleared drug that undergoes hep-
atic elimination via multiple pathways [110] [174] [171] [175] [87]. In the past, erythromycin
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was commonly used as a metabolic probe drug. It was administered intravenously and
employed in the erythromycin breath test (EBT) to noninvasively measure in vivo hepatic
cytochrome P450 (CYP) 3A4 (CYP3A4) activity [176] [177] [128] [178]. Use of the EBT in
this manner relied on the premise that intravenously administered radiolabeled erythromycin
undergoes N-demethylation by CYP3A4 in the liver and that 14CO2, a final by-product of
the CYP3A4-mediated elimination pathway, is rapidly detected in breath [176] [128]. How-
ever, it is now known that erythromycin also undergoes hepatic drug transport, i.e., hepatic
clearance by organic anion transporting polypeptides (OATPs), P-glycoprotein (P-gp), and
multidrug resistance-associated protein 2 (MRP2)-mediated elimination pathways [174] [171]
[169] [170] [175] [179] [180].
After hepatic uptake transport by OATPs into the cells, 14C-erythromycin partly under-
goes N-demethylation by CYP3A4 and gets converted to N-demethylated metabolites and
14C-formaldehyde. 14C-formaldehyde gets mostly converted to 14C-formate. Subsequently,
14CO2 is released and exhaled in breath in this CYP3A4-mediated pathway. Meanwhile, un-
metabolized drug and N-demethylated metabolites are excreted by the transporter P-gp [169]
[170]. Accordingly, interpretations of EBT data were misleading under the assumption the
erythromycin clearance was dependent solely on CYP3A4-mediated metabolism [133] [132].
While some studies with EBT concluded that there was a positive or inverse relationship
between an EBT measure and a change in CYP3A4 activity [177] [128] [178], a pilot pediatric
study show neither a consistent peak of 13CO2 flux across preterm infants nor a potential use
of EBT for measuring CYP3A activity in these patients [176]. The EBT has been reported
to correlate poorly with the clearance of other drugs [129] [130]. Furthermore, clinical stud-
ies with OATP and/or P-gp inhibitors [169] [170] or a MRP2 variant [171] indicated that
the effects of uptake and efflux transporters on erythromycin disposition would need to be
accounted for in the interpretation of EBT results. Consequently, research using the EBT
became less attractive and less common. In fact, it was determined that more research on
the EBT itself was necessary in order to establish its reliability [169] [132] [181] [168].
The 14CO2 production rate measurement of EBT results may provide a unique oppor-
tunity to differentiate contributions of metabolic versus transporter-mediated pathways to
erythromycin disposition since 14CO2 concentration in breath is proportional to the
14CO2
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production rate in the hepatocyte. Moreover, contributions of specific pathways may be esti-
mated within individuals or per person when physiologically-based pharmacokinetic (PBPK)
modeling is applied to 14CO2 production rate data. By measuring the breath concentration
as proxy for 14CO2 production rate, a hidden behavioral signal can be captured, which
is usually unrecognized and treated as noise in modeling mean drug concentrations [134].
Thus, the advantage of incorporating measured 14CO2 production rate into PBPK modeling
is that the concentration change, or rate, contains greater information and is more sensitive
to physiological changes compared to concentration itself as described in Highly sensitive
indirect measurement of Section 2.4.1 (Chapter 2) and also described in the Method Section
(Section 3.3.4) along with Figure 12 in this chapter. Therefore, multiple elimination path-
ways of a single drug can be differentially estimated using the rate data. The mechanism
and validity of differentially dissecting the multiple parameter estimates are provided via
the detailed analysis of estimation and use of regularization in Chapter 2 (see Sections 2.6
and 2.4.7).
The aim of this work was to estimate the activity and corresponding contribution of
mutliple nonrenal clearance pathways to the elimination of a single probe (erythromycin)
with our novel individualized PBPK modeling approach using rate data (iPBPK-R). The
present study establishes proof of concept that rate data may be used as a method for
estimating the activities and differentiating the contribution of multiple clearance pathways
to the elimination of a single probe drug that exhibits overlapping substrate specificity.
We anticipate that the iPBPK-R framework will be applicable to breath rate data of other
compounds such as volatile organic compounds [118] [182] to evaluate drug-drug interactions,
disease effects on drug disposition, and the relationship between potential biomarkers and
intervention, among others.
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Subject A Subject B 
Subject C Subject D 
1 
↓CYP3A4 activity 
↑Uptake transport  
       maximum velocity  
↓Partition coefficient  
in other organs 
Figure 12: Examples of impact of PBPK parameters on the shape of the 14CO2 production
rate – time curves compared to the shape of the 14CO2 concentration – time curves in the
hepatocyte.
When drug concentration-time curves (inset panel figures) and corresponding rate-time
curves (larger panel figures) are simulated, the number of parameters for which informa-
tion can be extracted via modeling differs between the drug concentration data versus rate
data. The rationale is provided in Highly sensitive indirect measurement in Section 2.4.1
(Chapter 2) and in Section 3.3.4 (Chapter 3). We here illustrate three parameter examples1
visually affecting the rate-time curves (while the concentration-time curves are generally
described with two parameters) using four hypothetical subjects A-D. In each of the four
panels (A – D), the main plot shows the 14CO2 production rate – time curve and the inset
smaller panel shows the corresponding 14CO2 concentration – time curve. Both curves were
simulated using PBPK modeling. The upper left panel: this panel illustrates 14CO2 pro-
1As a result of the application of iPBPK-R, we found that more than three parameters affect the rate-time
curves as described in the Result Section (Section 3.4).
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duction rate – time curve and 14CO2 concentration – time curve for a hypothetical healthy
subject denoted Subject A. The upper right panel for Subject B: Compared to the 14CO2
production rate – time curve of Subject A, Subject B has a lower CYP3A4 clearance and
the 14CO2 production rate – time curve of Subject B is flatter without presenting a sharp
peak accordingly. The lower left panel for Subject C: Compared to Subject A, Subject C
has a higher peak of the 14CO2 production rate – time curve due to the increased maximum
velocity of the uptake drug transport. The lower right panel for Subject D: Compared to
Subject A, Subject D shows the greater AUC of the 14CO2 production rate – time curve due
to the decreased volume of the hepatocyte. Subject D has less steep slopes in the first and
second elimination phases of the 14CO2 production rate – time curve due to the decreased
partition coefficient of the combined other organs compared to those of Subject A. Note
that the curves of Subject B – D were simulated by changing particular parameter(s) based
on the curves of Subject A, and these subjects are hypothetical examples. Figure 12 was
adapted from [105] with a modification to clarify the AUC of the 14CO2 production rate –
time curve increases with a decreased partition coefficient of the combined other organs.
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3.3 Materials and Methods
3.3.1 Clinical Data Sources
The 14CO2 production rate data were obtained from a prospective cohort study in which
the EBT was administered to 12 healthy Caucasian subjects (7 male) [127]. Briefly, a single
0.074 mmol (0.04 mg, 3 µCi) dose of [14C-N-methyl] erythromycin (Metabolic Solutions Inc.,
Nashua, NH) was intravenously administered and breath samples were collected immediately
before receiving the dose and at 5, 10, 15, 20, 30, 40, 50, 60, 90, and 120 min post dosing
as previously described [128]. The study adhered to the Declaration of Helsinki and was
approved by the Maine Medical Center Institutional Review Board and the Radiation Safety
Committee. Parameters for which no in vitro values were available in the published literature
and that could not be calculated using the in vitro–in vivo extrapolation (IVIVE) approach
were estimated by applying the PBPK-R model (described in the next subsections) to the
previously published 14CO2 production rate at 20 minutes [169].
3.3.2 PBPK Model Structure
As shown in Figure 13, a PBPK model comprising six organ compartments was built with
pharmacokinetic parameters for 14C-erythromycin. These compartments were artery (Art),
Vein, lung (LG), liver (LV), kidney (KD), and combined other organs (OT). The liver com-
partment consisted of two sub-compartments, extracellular space (ES) and liver cell (LC).
A non-linear meta-uptake transporter (OATPs are combined; see ‘Model Assumptions’) and
total passive diffusion modeled the drug transfer between the ES and LC sub-compartments.
Non-linear efflux transporters (P-gp and MRP2) and CYP3A4 clearance were modeled in the
LC compartment. CYP3A4 clearance was observed to be linear, which is not surprising since
a low dose of 14C-erythromycin was administered and it was expected that its concentration
was well below the maximum velocity of nonlinear kinetics.
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Figure 13: Schematic representation of a PBPK model for describing the time profiles of
14C-erythromycin after intravenous 14C-erythromycin administration in a healthy subject.
The PBPK model consisting of six organ compartments was built with pharmacokinetic
parameters for 14C-erythromycin. The upper right shows the liver comprised of two sub-
compartments (extracellular space (ES) and liver cell or hepatocyte (LC)) where non-linear
uptake and efflux transporters and linear enzymatic clearance were embedded. In the lower
right, the metabolic by-product model is illustrated where the metabolite 14C-formate is con-
verted to radiolabeled bicarbonate H14CO−3 in the CYP3A4-mediated pathway and dissolved
in the LC sub-compartment. The series of conversion from 14C-formaldehyde to H14CO−3 is
assumed to be a rapid process and non-rate-limiting. Then, 14CO2 is produced and exhaled
in breath as a result of the first-order elimination of bicarbonate (with a constant kresp)
from the LC sub-compartment.
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3.3.3 Ordinary Differential Equations, Kinetic Parameters, and Data Input
Changes in drug concentrations of all compartments and sub-compartments contained
within the PBPK model were mathematically described with a set of ordinary differential
equations (ODEs) (see B). We used permeability-limited liver models in the ODEs associated
with the ES and LC sub-compartments [101]. In addition, we referred to Kanamitsu et
al. [183] for the metabolic by-product model in order to describe the series of non-rate-
limiting steps from 14C-formaldehyde to bicarbonate and subsequent 14CO2 generation within
the LC sub-compartment This allowed us to approximate the CO2 concentration in the
breath through the first derivative of the cumulative CO2 concentration generated in the LC
sub-compartment (CO2 concentration rate of the LC sub-compartment) (see Figure 13 and
‘Model Assumptions’). Table 12 provides physiological and kinetic parameters that were
calculated based on IVIVE. These parameter values were used as initial input values in the
iPBPK-R model fitting.
Table 12: Parameters used for the erythromycin breath test simulations
Description (units) Notation Value Reference/Comments
Dose (mmol) 0.074
Volume of kidney (L) VKD (= V4) 0.270 [184]
Volume of lung (L) VLG (= V1) 0.775 [184]
Volume of vein (L) Vvein (= V2) 2.700 [184]
Volume of the combined other or-
gans (L)
VOT (= V3) 52.337 Calculated based
on [184]
Volume of artery (L) Vart (= V5) 2.700 [184]
Volume of extracellular space in the
liver (L)
VES (= V6) 0.340 Calculated based
on [184] [101] [185]
Effective volume of Extracellular
space in the liver (L)
VES,eff (= V
′
6) 0.543 Based on modification
of equation 2 of [101]
Volume of hepatocyte (L) VLC (= V7) 1.139 Calculated based
on [184] [101] [185]
Blood flow of kidney (L/hr) QKD (= Q4) 66 [5]
Estimated glomerular filtration rate
(L/hr)
eGFR (= δGfr) 5.964 Average value of this co-
hort of the 12 healthy
subjects
Total body blood flow (L/hr) QTotal (= Q1) 300 [5]
Blood flow of the combined other or-
gans (L/hr)
QOT (= Q3) 136 Calculated based on [5]
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Table 12: Parameters used for the erythromycin breath test simulations
Description (units) Notation Value Reference/Comments
Blood flow of hepatic artery (L/hr) QLV,Art (= Q5) 98 Calculated based
on [186]; Portal blood
hepatic artery blood
flow were combined to
simplify the model
Blood flow of hepatic vein (L/hr) QLV,Vein (= Q2) 98 [186]
Total passive diffusion between ex-
tracellular space and hepatocyte
(L/hr)
QES−LC (= Q67) 227 [187]
Clearance via hepatic uptake trans-
port (L/hr)
CLUP1 212.29 [187]
Clearance via Pgp (L/hr) CLOUT1 0.347 Assumed based on an
initial simulation using
[169]
Clearance via MRP2 (L/hr) CLOUT2 1.735 ×
10−4
Calculated by Jmax and
Km
Clearance via CYP3A4 (L/hr) CLCYP (= Qcyp) 176.4 [183]
Fraction unbound in blood fu,BL (= fb) 0.27 Assumed based on [188]
Fraction unbound in extracellular
space
fu,ES (= f6) 0.425 Calculated based on
[189] [190] [191] [192]2
Fraction unbound in hepatocyte fu,LC (= f7) 0.05 [187]
Partition coefficient of lung to
plasma
PLG:P 0.33 Assumed based on [194]
Partition coefficient of the combined
other organs to plasma
POT:P 0.801 Calculated based
on [195] [196] [188]
Partition coefficient of blood to
plasma
PBL:P (= Pb) 0.854 [186]
Partition coefficient of kidney to
plasma
PKD:P 2.23 [186]
Partition coefficient of hepatocyte
to plasma
PLC:P (= P7p) 2.71 [186]
Partition coefficient of extracellular
space to plasma
PES:P (= P6p) 1.10 Assumed based on par-
tition coefficient of ep-
ithelial lining fluid to
plasma in [194]
2fu,ES was calculated applying the assumption proposed for general physiological PK modeling by Khor
et al. to our modeling. This assumption was ’the blood protein to which the drug binds is also present
in interstitial fluid and that the association binding constant is the same in both blood and interstitial
fluid’ [189]. Extracellular space matrix (ECM) is known to have many proteins such as fibrillar collagens,
proteoglycans, growth factors, cytokines, chemokines, enzymes, among others [193]. We treat these proteins
in ECM in the liver as a general protein that can bind to erythromycin in the modeling.
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Table 12: Parameters used for the erythromycin breath test simulations
Description (units) Notation Value Reference/Comments
Maximum velocity of hepatic uptake
transport (mmol/hr)
Jmax,UP1 (= Ja) 9.6833 ×
10−3
[187] [67] [184] [197]
Michaelis constant of MRP2 (mM) Km,OUT2 (= Kc) 64.4 × 10−3 [171]
Maximum velocity of transport by
MRP2 (mmol/hr)
Jmax,OUT2 (= Jc) 11.17314 ×
10−6
[171]
Elimination constant of bicarbonate
(hr−1)
kresp (= k3) 12.72 [172]
3.3.4 Rate Data and Reduced Order Model
Frequently sampled rate data has more information compared to equivalently sampled
concentration data3. However, it requires more effort to extract the information. Non-linear
model fitting of measured first derivative data is often performed to estimate sensitive param-
eters in established methodologies utilized in digital signal processing and other engineering
disciplines [134]. We modeled the 14CO2 production rates from the EBT study using the
same concept, which is illustrated in Figure 12. Accordingly, the iPBPK-R method was
applied to the 14CO2 production rate data, and multiple hepatic elimination pathways, i.e.,
uptake and efflux transport and passive diffusion parameters, were estimated using the sin-
gle probe drug 14C-erythromycin. In order to achieve high precision in model fitting to the
high resolution 14CO2 rate data, we used a reduced order model as detailed in Section 2.5 in
Chapter 2 [198]. Reduced order models are generally complex enough to capture the behav-
ior of interest but simple enough so that the mathematical models are well-posed providing
estimable parameters. Based on this rationale, the seven-compartmental PBPK model was
built as described in Subsections 3.3.2 and 3.3.3.
3In other words, we here specifically contrast the mathematical properties between drug concentration
data and rate data both of which are observed or calculated data at the same sampling points and accuracy
as described in Highly sensitive indirect measurement of Section 2.4.1. The difference between the data is
the measurement unit, and the observed rate data as treated as the first derivative of drug concentration
data leads to higher accuracy and thus good separation of estimated model parameters.
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3.3.5 Model Assumptions
The number of compartments was limited to seven including sub-compartments to fa-
cilitate fitting of PBPK models to EBT data while enabling estimation of the activity and
corresponding of effect of CYP3A4 and drug transporters on erythromycin disposition. The
modeling was carried out under the following assumptions:
• 14C-erythromycin is intravenously administered for 30 seconds. Except for the liver
and kidney compartments, all compartments were assumed to be perfusion-limited
where the distribution of a drug rapidly reaches equilibrium via passive diffusion and
the unbound concentration in the compartment is the same as those in the diffused
space at equilibrium. Perfusion-limited compartments were described with a well-
stirred model [183] [199].
• Pathways from the ES compartment to the LC compartment for erythromycin are
comprised of total passive diffusion + summation of uptake transporters only. Ery-
thromycin mainly undergoes hepatic uptake transport by OATP isoforms OATP1B1
and OATP1B3. These uptake transport processes were modeled as a single meta-
uptake process.
• CO2 is present in the systemic circulation under steady state conditions. Accordingly,
14CO2 is instantaneously released in breath via the lung without being stored in
or released from any other compartments after it gets generated in the LC sub-
compartment.
• We assume that a metabolite 14C-formate is converted to radiolabeled bicarbonate
H14CO−3 as a by-product in the CYP3A4-mediated pathway and dissolved in the
LC sub-compartment. The series of conversion from 14C-formaldehyde, 14C-formate
through to H14CO−3 is rapid and not rate-limiting as assumed by Sugiyama et al. [172].
The final by-product 14CO2 in this elimination pathway is produced and exhaled in
breath as a result of a first-order elimination of bicarbonate (with a constant kresp)
from the LC sub-compartment [172].
• The liver (composed of ES and LC sub-compartments) and the kidneys (KD com-
partment) are elimination organs. In addition, a parameter µ was included in the
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OT compartment to explain the exponential decay that was seen in the observed
14CO2 production rate data. We anticipated that this parameter µ would improve
the model fitting. Thus, the exponential decay was assumed to explain any loss or
decomposition of the drug before the drug reaches the liver in the system.
• The unbound drug, but not the bound drug, is subject to uptake and efflux transport,
enzymatic metabolism, and elimination in the liver.
• For the intrinsic clearance of CYP3A, linearity was assumed after investigating the
model fitting in comparison to non-linear intrinsic clearance.
3.3.6 Simulations, Optimizations, and Sensitivity Analysis
We developed the iPBPK-R framework shown in Figure 14. Specifically, concentration-
time curves of 14C-erythromycin and enzymatic by-products H14CO−3 and
14CO2 were sim-
ulated for individual subjects based on the ODEs (Figure 13 and appendix B). 14CO2
production rates were simultaneously simulated by taking the first derivative of cumulative
14CO2 data generated.
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Pre-estimation on P-gp parameters in a healthy population 
Outer loop –  IVIVE adjustment 
• Maximum velocity of uptake transporter (Vmax, UP1) 
• CYP3A4 clearance (CLCYP) 
• Partition coefficient in the OT compartment (POT:P) 
• Exponential decay in the OT compartment (μ) 
Inner loop –  model fitting 
• Fraction of the drug filtered via the glomerulus (δ) 
• Distribution ratio of P-gp in the HC and KD compartments 
1st and 2nd steps: PBPK modeling of ERMBT  
(literature data of mean 14CO2 production rate at 20 minutes) 
Nested 9-parameter estimation in healthy subjects 
Outer loop –  IVIVE adjustment 




• Maximum velocity of MRP2 (Vmax, OUT1) 
• Maximum velocity of P-gp (Vmax, OUT2) 
• Volume of hepatocyte (VLC)  
• Blood flow into the OT compartment (QOT)  
• Total passive diffusion between ES and LC compartments (QES-LC) 
Inner loop –  model fitting 
• Scaling coefficient for Vmax, UP1 
• Scaling coefficient for Vmax, OUT1 
• Scaling coefficient for Vmax, OUT2 
3rd step: Individualized PBPK modeling of ERMBT (iPBPK-R)  
(14CO2 production rate data from 12 healthy subjects) 
Fixed-point iteration 
Figure 14: Framework of the application of iPBPK-R to the EBT study in 12 healthy
subjects.
The optimization setup in the application of iPBPK-R to the EBT data per subject was
mathematically described using objective function with regularization in Section 2.6.3. The
bottom box of the framework diagram depicts which parameters are estimated in the co-
optimization setting in the actual application to the 14CO2 production rate data set of
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healthy subjects, and a co-optimization of multiple parameters with outer and inner loops
was conducted in each subject accordingly. The top box of the diagram illustrates the
parameter estimation using clinical EBT literature that was conducted prior as described in
Section 3.3.6.
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Parameters were optimized via a 3-step iPBPK-R framework (Figure 14). In each step, a
nested optimization was used. In the first and second steps, the fraction of the drug filtered
via the glomerulus (δ) and expression ratio of P-gp transporters between liver and kidney
compartments were pre-estimated in the inner optimization loop of the iPBPK-R model
fitting to the previously published mean 14CO2 production rate at 20 minutes post EBT
[169]. In the same two steps, four PBPK parameters (maximum velocity of the meta uptake
transport process, CYP3A4 clearance, partition coefficient in the combined other organs, and
exponential decay parameter µ) were pre-estimated via the outer loop optimization. The pre-
estimated parameter values in the first two steps were used as initial input values in the third
step. In the third step (main step), the nested optimization process consisting of the inner
loop and outer loop was used to optimize and estimated IVIVE adjustment factors for five
PBPK parameters (maximum velocity of two efflux transporters: P-gp and MRP2, volume
of total hepatocyte, blood flow into the combined other organs, and total passive diffusion
between extracellular space and hepatocyte). This was done so that we could implement
iPBPK-R model fitting to the observed 14CO2 production rates between 0-120 minutes in
12 healthy subjects. In this step, the model fit was evaluated using goodness-of-fit plots,
normalized residuals between predicted and observed rates, visual inspection, and plausibility
of the resulting parameter estimates. Among the PBPK parameters in Table 12, nine outer
loop parameters (see Figure 14, 3rd Step) were selected4 to optimize and estimate since
they were essential parameters for model fitting based on visual investigation and sensitivity
analysis. In fact, adjustment factors for maximum velocity of efflux transporters did not
have a critical effect of controlling the shape of the 14CO2 production rate – time curves.
However, these parameters were kept for optimization since they were part of nonrenal
elimination pathways. The three scaling parameters in the inner optimization loop in the
third step (Figure 14) were used to calculate final adjustment factors for IVIVE values of
transporter kinetics. One cycle of fixed-point iteration was conducted and the results of the
third step outer loop were used in subsequent simulations to refine the parameter estimates.
4The number of observed samples per individual in this simultaneous PBPK model fit is 11 time points.
The number of functionally dependent parameters to optimize here (i.e., nine outer loop parameters) is
valid as as shown in the analysis of iPBPK-R estimation using regularization in Section 2.4.7. Also see
Section 2.5.2 where the analysis of matrix in the iPBPK-R model identified three to five dominant and
distinguishable modes (Appendix A.2).
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All the simulations and parameter estimations were implemented with the programming
language and free software environment R 3.4.4. The R package deSolve was utilized for
solving the set of ODEs, and large-scale simulations were conducted via the Bridges super-
computer at the Pittsburgh Computing Center [126]. Methodological details of the iPBPK-R
approach were described in Chapter 2.
3.3.7 Statistical Analysis
Our primary aim was to simultaneously estimate PK parameters associated with metabolic
versus transporter-mediated pathways within individual study subjects using iPBPK-R. De-
scriptive statistics were presented with mean ± SD and/or median (range). Twenty-fifth and
75th percentiles were also obtained for creating box plots. This study explored feasibility and
estimability on model parameters, and no statistical test was powered in advance. Assuming
that all measurements were non-normally distributed, one-sided Wilcoxon-Mann-Whitney
tests were conducted for comparing two independent groups. Spearman’s ρ correlation co-
efficients were calculated in correlation analysis for studying the relationships between es-
timated adjustment factors for non-renal elimination parameters and baseline demographic
or uremic solute concentrations (BUN, SCr, and TNF-α). An adjustment factor of 1 means
that there was no need to adjust the initial parameter input value in the optimization. A
P-value < 0.05 was considered statistically significant for all comparisons. All statistical
analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
3.4 Results
The iPBPK-R model was applied to fit the observed 14CO2 production rate data for
the 12 healthy subjects (Figure 15). The nested optimization procedure yielded parameter
estimates for all subjects, and the excellent model fit was confirmed with the goodness-of-fit
plots across subjects, normalized residuals (mean 10−4, standard deviation 10−4) (Figure 16,
Table 13, and Table 14).
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Figure 15: iPBPK-R model fit to the individual EBT data from the 12 healthy subjects.
The black lines are modeled 14CO2 production rate-time curves and the black dots indicate
the observed 14CO2 production rates. The goodness-of-fit of these curves are discussed in
Section 3.5 along with Figure 16.
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Figure 16: Goodness-of-fit plots for the 12 healthy subjects.
Observed versus modeled (simulated) 14CO2 production rates are shown
5, which correspond
to the iPBPK-R model fit to the EBT data (See Figure 15). While there are data points
slightly off from the diagonal line in the patients of ID = 12, ID = 17, and ID = 22, these
may be potentially caused by protocol deviations on sample collection times. These data
points do not appear critically off the diagonal line and the iPBPK-R model fitting excelled
in the overall performance as discussed in Section 3.5.
5Rather than the normalized residual-time plots in our published article [105], goodness-of-fit plots are
being presented here. The normalized residuals were calculated as the difference between modeled and
simulated 14CO2 production rates divided by the observed
14CO2 production rate at each sampling time.
Such normalized residuals may lead to misinterpretation of the actual model fit at the earlier sampling times
since the absolute size of the observed 14CO2 production rate is quite small, which makes the normalized
residual % quite large even though the simulated data are well performed results and very close to the
observed data points.
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The estimated adjustment factors for parameters in the liver and combined other organ
compartments are shown in Figures 17 (A) and 18, respectively. The estimated median
CYP3A4 clearance was 87.8% lower than the original IVIVE value (adjustment factor =
0.122 in Figure 17 (A)) and the median adjustment factor for total passive diffusion was
33.5% lower than the original IVIVE value (adjustment factor = 0.665 in Figure 17 (A)).
The adjustment factor for maximum velocity (Vmax) of the meta-uptake transporter varied
by individuals (25th quantile adjustment factor 0.74; 75th quantile adjustment factor 0.99).
When stratified by gender (Figure 17 (B)), the adjustment factor for Jmax of the meta-
uptake transporter did not differ by gender; a few female healthy subjects had reduced
uptake transport activity (the median adjustment factor in male: female = 0.99: 0.67; the
one-sided exact p-value P = 0.10). Jmax of efflux transporters (P-gp and MRP2) did not
require an adjustment from the original IVIVE values since the estimated median and mean
adjustment factors were 1.00. The median adjustment factors for total hepatocyte volume,
CYP3A4 clearance, and total passive diffusion varied among individuals (Figure 17 (A)).
In the combined other organs compartment (Figure 18), arterial blood flow barely required
IVIVE adjustment (median adjustment factor 0.87 or 13% decrease from the IVIVE value)
while IVIVE values of exponential decay µ and partition coefficient needed to be adjusted
as high as 4.0 and 18.8 times (by median), respectively. The latter two parameters did
not vary by individuals but the adjustment factor for arterial blood flow relatively varied
by individuals (25th quantile adjustment factor 0.52; 75th quantile adjustment factor 0.99).
Since the meta-uptake transporter, CYP3A4 clearance, volume of total hepatocyte, and total
passive diffusion varied in their adjustment factor, we stratified these adjustment factors by
gender in the box-and-whisker plots (Figure 17 (B)). When compared by gender using one-
sided Wilcoxon-Mann-Whitney tests, the CYP3A4 clearance was significantly lower in male
than in female (the median reduction from the IVIVE value in male: female = 89.3%:78.0%;
the one-sided exact P = 0.04). The total hepatocyte volume and total passive diffusion did
not differ by gender (the one-sided exact p-values = 0.27 and 0.17, respectively).
The observed 14CO2 production rate – time curves of 12 healthy subjects had three
phases: (i) increasing absorption/distribution phase, (ii) the first elimination phase, and (ii)
the second elimination phase (depicted by the black dots in Figure 15). Through the sensitiv-
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ity analysis in the iPBPK-R model fitting, we found that multiple physiological parameters
interact and control the shape of the 14CO2 production rate – time curve (Figure 19). When
CYP3A4 clearance increases, the peak height and the area under the curve (AUC) increase
with a steeper absorption phase. Jmax of uptake drug transport and total passive diffusion
together control the peak height, the first elimination phase, and the second elimination
phase of the curve. As part of the sensitivity analysis, we simulated 14CO2 production rate –
time curves with one additional varying parameter (see 3-dimensional plots in Figure 20). In
Figure 20 (A), CYP3A4 clearance varied from 1% to 100% of the IVIVE value. In Figure 20
(B), Jmax of the meta-uptake transporter varied from 1% to 200% while keeping the total
passive diffusion at 50% of its optimal value. Modeled 14CO2 production rates were sensitive
to changes in CYP3A4 clearance (see Figure 20 (A)). Changes in total passive diffusion and
uptake drug transport together have an effect on the shape of 14CO2 production rate – time








Figure 17: Box plots of estimated IVIVE adjustment factors for PBPK parameters in the
liver compartments (ES and LC sub-compartments).
The PBPK parameters are maximum velocity of the meta-uptake transporter, maximum
velocity of P-gp, maximum velocity of MRP2, CYP3A4 clearance, the volume of the hepato-
cyte, and total passive diffusion between ES and LC sub-compartments (from the left to the
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right on the x-axis). These PBPK parameters were estimated in the main step (3rd step)
of the iPBPK-R framework as shown in Figure 14. N = 12 in all box plots. (B) Estimated
IVIVE adjustment factors in the liver compartments stratified by gender. N = 7 for males
and N = 5 for females. These selected estimates adjust CYP3A4 clearance, the volume of
the hepatocyte, and total passive diffusion between ES and LC sub-compartments. When
the IVIVE adjustment factor is estimated to be 1, it is interpreted that the parameter input
was not adjusted from the original IVIVE input value through the iPBPK-R model fitting.
Exact p-values are shown based on Wilcoxon-Mann-Whitney tests for comparing between
male and female (one-sided test). ? indicates a statistically significant difference at a signif-
icance level of 0.05.
As described in Statistical Analysis Section (Section 3.3.7) statistical tests to compare two
groups are not powered. Thus, these statistical tests are treated as exploratory analyses.
Note that a clinical threshold for comparing adjustment factors is not 2-fold and has not
been established as this is the first study to simultaneously estimate multiple functionally
dependent parameters in an automated fashion as discussed in Section 3.5.
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Figure 18: Estimated IVIVE adjustment values for PBPK parameters in the combined other
organs (OT) compartment.
The PBPK parameters are arterial blood flow, exponential decay, and partition coefficient
between OT and plasma, respectively (from the left to the right on the x-axis). These PBPK
parameters were estimated in the main step (3rd step) of the iPBPK-R framework as shown
in Figure 14. When the IVIVE adjustment value is estimated to be 1, it is interpreted
that the parameter input was not adjusted from the original IVIVE input value through the
iPBPK-R model fitting. N = 12 in all box plots.
123
Figure 19: EBT data interpretation as a result of the application of iPBPK-R.
The modeled 14CO2 concentration – time curve represents three phases: the increasing
absorption phase, the first elimination phase after the peak of the curve, and the second
elimination phase. Red line and texts: the increased absorption phase gets less steep as
CYP3A4 clearance decreases. Blue line and texts: The peak of the curve increases as (1)
CYP3A4 clearance increases, (2) maximum velocity of the meta-uptake transporter increases,
(3) arterial blood flow in the combined other organ (OT) compartment (QOT,Art) decreases,
(4) the partition coefficient of OT to plasma decreases, and/or (5) total passive diffusion
between ES and LC sub-compartments increases. Green line and texts: the first elimination
phase of the curve gets less steep as (1) the partition coefficient of OT to plasma decreases, (2)
maximum velocity of the meta-uptake transporter increases, and/or (3) QOT,Art increases.
Yellow line and texts: the second elimination phase of the curve gets less steep or shifts
upwards as (1) the partition coefficient of OT to plasma decreases, (2) exponential decay in
the OT compartment decreases, and/or (3) total passive diffusion between ES and LC sub-
compartments decreases. Purple texts: the AUC of the curve increases as (1) the volume of
the hepatocyte decreases, (2) CYP3A4 clearance increases, and/or (3) QOT,Art decreases. It
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is not feasible to show all the sensitivity analysis results on multiple functionally dependent
parameters, which were conducted along with the model development using more than 50,000
CPU hours (= 5.7 CPU years) on the Bridges supercomputer. As discussed in Section 3.4,
two examples of sensitivity analyses are shown in Figures 20(A) and 20(B) of which findings
contributed to developing this interpretation figure. It is important to remember that general
interpretations for plasma concentration-time curves do not apply to 14CO2 concentration –










Figure 20: Example of sensitivity analysis. Simulated 3D 14CO2 production rate – time
curves.
(A) CYP3A4 clearance was varied from 1% to 100% of the IVIVE value and (B) maximum
velocity of the meta-uptake transporter was varied from 1% to 200% while keeping the total
passive diffusion at 50% of its optimal value.
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As an exploratory analysis, Spearman correlation analysis between the estimated ad-
justment factors for non-renal elimination parameters (Jmax of meta-uptake transporters,
CYP3A4 clearance, and total passive diffusion) and baseline parameters was conducted (see
Table 15 and Table 16). These baseline parameters were demographic and physical factors
(height, weights, age, and estimated GFR) and uremic solute concentrations including SCr,
BUN (a low molecular weight solute), and TNF-α (a middle molecular weight solute). In
all 12 subjects, the correlation coefficient between BUN and the adjustment factor for Jmax
of meta-uptake transporters was estimated to be negative and strong, and this correlation
was statistically significant (ρ = -0.608; P=0.04) (Table 15). In the male subjects, BUN
was negatively correlated with the adjustment factors for Jmax of meta-uptake transporters,
CYP3A4 clearance, and passive diffusion (ρ = -0.857; P=0.01, ρ = -0.857; P=0.01, and
ρ = -0.821; P=0.02, respectively), which were very strong according to Evans’ correlation
criteria [200] (Table 16).
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Table 13: Parameter estimates through the nested optimization and normalized residuals in the iPBPK-R modeling of the EBT
study in 12 healthy subjects
Estimated parameter Mean ± SD Median (Range)
IVIVE adjustment (adjustment factor)
Meta-uptake transporter 0.84 ± 0.26 0.98 (0.23, 1.00)
P-gp 1.00 ± 0.00 1.00 (1.00,1.00)
MRP2 1.00 ± 0.00 1.00 (1.00, 1.00)
CYP3A4 clearance 0.14 ± 0.06 0.12 (0.07, 0.24)
Hepatocyte volume 0.78 ± 0.19 0.73 (0.50, 1.01)
Partition coefficient in the combined other organs 18.77 ± 0.03 18.78 (18.72, 18.84)
Blood flow in the combined other organs 0.80 ± 0.27 0.87 (0.45, 1.22)
Exponential decay parameter in the combined other organs 3.99 ± 0.01 3.99 (3.97, 4.03)
Total passive diffusion between ES and LC 0.60 ± 0.21 0.67 (0.13, 0.87)
Model fit: normalized residual 10−4 ± 10−4 0.0001 (0, 4×10−4)
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Estimated parameter Mean ± SD Median (Range) Mean ± SD Median (Range) p-valuea
IVIVE adjustment (ad-
justment factor)
Meta-uptake transporter 0.96 ± 0.07 0.99 (0.81, 1.00) 0.66 ± 0.33 0.67 (0.23, 1.00) 0.101
P-gp 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.265
MRP2 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.254
CYP3A4 clearance 0.10 ± 0.03 0.11 (0.07, 0.14) 0.19 ± 0.07 0.22 (0.07, 0.24) 0.037b
Hepatocyte volume 0.74 ± 0.16 0.68 (0.58, 1.00) 0.83 ± 0.23 0.98 (0.50, 1.01) 0.265
Partition coefficient in
the combined other or-
gans
18.78 ± 0.03 18.78 (18.74, 18.84) 18.77 ± 0.03 18.78 (18.72, 18.80) 0.319
Blood flow in the com-
bined other organs
0.83 ± 0.28 0.90 (0.45, 1.22) 0.75 ± 0.28 0.83 (0.45, 1.01) 0.378
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Estimated parameter Mean ± SD Median (Range) Mean ± SD Median (Range) p-valuea
Exponential decay pa-
rameter in the combined
other organs
3.99 ± 0.01 3.99 (3.99, 4.00) 3.99 ± 0.01 4.00 (3.98, 4.00) 0.378
Total passive diffusion
between ES and LC
0.68 ± 0.15 0.68 (0.44, 0.87) 0.50 ± 0.25 0.65 (0.13, 0.71) 0.172
Model fit: normalized
residual
1× 10−4 ± 10−4 1×10−4 (0.00,
4×10−4)
2×10−4 ± 10−4 1×10−4 (10−4,
3×10−4)
aExact p-value of a Wilcoxon-Mann-Whitney test to compare between male and female (one-sided test)
bp-value < 0.05 indicating a statistically significant difference between male and female
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Table 15: Spearman correlation coefficients among the estimated PBPK parameters, demographic and physiological data, and
uremic solute concentrations in 12 healthy subjects.
HT WT BMI Age eGFR SCr BUN TNF-α
IVIVE adjustment (ad-
justment factor)
Meta-uptake transporter ρa 0.371 0.147 -0.259 -0.372 0.007 0.351 -0.608 -0.161
p-value 0.235 0.648 0.417 0.234 0.983 0.263 0.036b 0.618
CYP3A4 clearance ρa -0.529 -0.378 0.154 0.319 -0.571 0.092 -0.504 -0.399
p-value 0.077 0.225 0.633 0.312 0.053 0.775 0.095 0.199
Total passive diffusion be-
tween ES and LC
ρa 0.476 0.308 -0.175 -0.204 -0.175 0.414 -0.196 0.112
p-value 0.117 0.330 0.589 0.526 0.586 0.181 0.542 0.729
WT, weight (kg); HT, height (cm); BMI, body mass index (kg/m2); eGFR, estimated Glomerular Filtration Rate (L/hr); SCr,
serum creatinine (mg/dL); BUN, blood urea nitrogen (mg/dL); TNF-α, tumor necrosis factor-α (pg/mL)
aSpearman correlation coefficient; bp-value < 0.05 indicating a statistically significant correlation
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Table 16: Spearman correlation coefficients among the estimated PBPK parameters, demographic and physiological data, and
uremic solute concentrations by gender
Male Female
7 5







ρa 0.321 0.429 0.250 -0.321 -0.286 0.309 -0.857 -0.250 -0.308 -0.300 -0.300 0.300 -0.200 0.289 -0.200 -0.500
p-value 0.482 0.337 0.589 0.482 0.535 0.500 0.014b 0.589 0.614 0.624 0.624 0.624 0.747 0.638 0.747 0.391
CYP3A4 clear-
ance
ρa -0.071 0.214 0.357 -0.250 -0.250 0.273 -0.857 -0.143 -0.667 -0.400 0.100 0.100 -0.600 0.866 -0.600 -0.500





ρa 0.393 0.571 0.464 -0.286 -0.357 0.309 -0.821 -0.179 0.462 -0.600 -0.900 0.500 -0.600 0.289 0.400 0.300
p-value 0.383 0.180 0.294 0.535 0.432 0.500 0.023b 0.702 0.434 0.285 0.037b 0.391 0.285 0.638 0.505 0.624
WT, weight (kg); HT, height (cm); BMI, body mass index (kg/m2); eGFR, estimated Glomerular Filtration Rate (L/hr); SCr,
serum creatinine (mg/dL); BUN, blood urea nitrogen (mg/dL); TNF-α, tumor necrosis factor-α (pg/mL)
aSpearman correlation coefficient; bp-value < 0.05 indicating a statistically significant correlation
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3.5 Discussion
This is the first study to show that the activity of multiple non-renal elimination pathways
can be estimated within individual study subjects with a single probe drug, erythromycin,
via PBPK modeling and optimization-based model fitting of rate data (iPBPK-R). The
iPBPK-R method is distinctly different from and advantageous over other approaches that
use multiple pathway-specific probes (i.e., the ‘cocktail’ approach). The cocktail approach
may lead to higher imprecision due to (1) uncertainty in parameter estimates pertinent to
different probes’ characteristics, (2) varying interactions with physiological properties, and
(3) inter-cohort variabilities [122] [123]. The iPBPK-R method overcomes these by utilizing
the distinct and dynamic information contained in rate data solely obtained with a single
probe.
Non-linear model fitting of measured rate data [134] was adopted in our individualized
PBPK modeling, which enabled multiple-parameter optimization to achieve high accuracy
as shown in the goodness-of-fit plots in Figure 16. In these individual goodness-of-fit plots,
the simulated and observed 14CO2 production rates are on or close to the diagonal line
including the data points in the lower range of 14CO2 production rate. There are data
points slightly off from the diagonal line in the patients of ID = 12, ID = 17 and ID =
22. These may be caused by the actual sample collection times that deviated from the
planned sample collection times as the breath samples were intensively collected within the
two hours. Since the general decision criterion for acceptable PBPK model simulation is
within 2-fold of the observed Cmax and AUC
6 [76,90,93,101,102], which suggests that PBPK
model fitting is generally considered to be difficult, the iPBPK-R model fitting excelled in
the overall performance. Figure 12 illustrates that the 14CO2 production rate data contains
more information than the cumulative 14CO2 concentration data when they are observed.
First, as shown in the inset panels for hypothetical subjects A, B, C, and D, the simulated
curves of the cumulative amount of 14CO2 generated during the study period are not sensitive
to any underlying parameter changes since all four subjects’ cumulative curves look similar.
6This criterion is just for population mean values of Cmax and AUC but not individually simulated values
of Cmax and AUC since individual PBPK modeling is rarely conducted.
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On the other hand, simulated curves of 14CO2 production rates show a dynamic change
depending on the parameter change since the shape of the rate-time curves visibly differ
across the subjects. This illustrates that, for a given measurement accuracy, measuring the
first derivative data allows us to estimate parameter differences while these differences cannot
be estimated from the original data. The iPBPK-R method utilized here leverages this for
the purposes of characterizing multiple non-renal clearance pathways simultaneously.
Historically, erythromycin was commonly used as a metabolic probe drug. It was ad-
ministered intravenously and employed in the EBT to noninvasively measure in vivo activity
of hepatic CYP3A4 [176] [177] [128] [178]. However, it is now known that erythromycin
undergoes hepatic clearance by OATPs, P-gp, and MRP2-mediated elimination pathways
as well [174] [171] [169] [170] [175] [179] [180]. Accordingly, interpretations of EBT data
were misleading under the assumption that erythromycin clearance was dependent solely on
CYP3A4-mediated metabolism [133] [132]. We were interested in accounting for the mul-
tiple nonrenal elimination pathways of erythromycin and estimating corresponding kinetic
parameters within individual healthy subjects through modeling observed rate data. Rate
data is commonly utilized in engineering disciplines, typically in digital signal processing.
We anticipated that by applying mechanistic iPBPK-R to the EBT data we could simulta-
neously estimate the activity of multiple non-renal elimination pathways. Although this is a
pilot study, we found that CYP3A4 activity was consistently estimated to be lower than the
IVIVE-based CYP3A4 activity in all subjects. This lower estimated value of CYP3A4 clear-
ance can be explained by our consideration of the functional dependency among parameters
for not only CYP3A4 activity but also for transporter activities and other properties in the
modeling. Accordingly, parts of the estimate value, which would have been solely allocated
to CYP3A4 activity in a simple population model, were allocated to other dependent param-
eter effects. Thus the size of CYP3A4 activity may have decreased because iPBPK-R models
the detailed physiological processes in an integral manner. In addition to the explanation
based on the functional dependency, the lower estimated value of CYP3A4 activity may be
also explained by the Biopharmaceutics Drug Disposition Classification System (BDDCS)-
based prediction for erythromycin [201]. In BDDCS, erythromycin is classified into class
3, and class 3 drugs are highly soluble and poorly metabolized. Thus, the low estimated
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value of CYP3A4 activity aligns with this predicted poor metabolism. Regarding OATP, its
estimated activity showed a large interindividual variability. If the abundance of tranporters
in hepatocytes is assumed to be correlated with the OATP activities in hepatocytes, the
estimated variability of OATP activity aligned with the large variabilities of the abundance
in OATP1B1 and OATP1B3 estimated in a meta-analysis of Caucasians abundance data
in the literature [68]. These transporters showed the highest coefficient of variation (CV)%
values (66 and 70, respectively) in the abundance analysis among the evaluated transporters
(OCT1, NTCP, MATE1, P-gp, BSEP, MRP2, MRP3, and BCRP). The 20-minute 14CO2
flux of the observed data showed a CV value of 22% [127], which is viewed as a result of
projection of a trajectory in a high dimensional space (as a solution of a system of nonlinear
ODEs) to one plane in iPBPK-R as detailed in Chapter 2. iPBPK-R allowed us to differenti-
ate the multiple functionally dependent adjustment factors and to estimate them, including
the adjustment factor for OATP activity that showed a large variability. This estimated
large variability aligns with or is supported by the meta-analysis literature [68] as discussed
above, and thus it presents the soundness of the iPBPK-R method.
Simultaneous estimation of the activity of multiple non-renal elimination pathways facili-
tates studying the interaction between enzymatic metabolism and drug transport or enzyme-
transporter interplay [110]. As discussed previously, the EBT was actively used to probe in
vivo CYP3A catalytic activity in the past. However, across clinical studies using the EBT,
there were conflicting results in predicting total body clearance from the 14CO2 production
rate analysis. Rivory et al. discussed possible causes for the inconsistent results among
the EBT studies [132]. The reasons included high inter-individual variability of the 14CO2
production rate data, potential overestimation of 14CO2 production in females, and use of
different type of measurements among studies (i.e., inverse time to the peak, 14CO2 produc-
tion rate at 20 minutes, and AUC from 0 to 2 hours). As erythromycin was found to be a
substrate of not only CYP3A but also P-gp, Mrp2, and Oatp2 in in vitro studies [180] [171],
studying the effect of enzyme-transporter interplay on non-renal drug elimination became
essential [174]. To study the enzyme-transporter interplay, mechanistic PBPK modeling is
a useful tool as it allows us to explicitly describe the activity of each elimination pathway in
the whole body system. iPBPK-R showed that OATP activity controls the peak of 14CO2
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production rate-time curve while P-gp did not have a significant role. These findings aligned
with the results of a EBT DDI study by Frasseto et al [169]. They compared the 20-min
14CO2 fluxes between EBT alone versus EBT with a single dose rifampin (as an OATP in-
hibitor) as well as between EBT alone versus EBT with a P-gp inhibitor lansoprazole in 16
healthy subjects. The 20-min 14CO2 flux increased by the OATP inhibitor but did not signif-
icantly increase by the P-gp inhibitor. Paine et al. evaluated the interplay between CYP3A4
activity and P-gp activity using two types of EBT tests [202]. One was to intravenously ad-
minister a small amount of 14C-erythromycin (0.07 µmol EBTIV, similar to our EBT data)
and the other was to orally administer 500mg of 13C-erythromycin (EBTPO). The 20-min
14CO2 fluxes were compared for both EBTIV and EBTPO between EBT alone versus EBT
with troleandomycin (CYP3A4 inhibitor) as well as EBT alone versus EBT with repeatedly
administered rifampin (CYP3A4 inducer as well as P-gp inducer) in 14 young healthy sub-
jects (21-43 years old). It was found that erythromycin undergoes CYP3A4 metabolism in
the liver and in the intestine. In addition, no change was observed in the 20-min 14CO2 flux
of EBTPO in the presence of rifampin, which led to a conclusion that erythromycin under-
goes the P-gp-mediated absorption in the intestine. Thus, these results did not contradict
our findings since we evaluated nonrenal elimination pathways of erythromycin. Hepatic P-
gp might not have a significant role for erythromycin because more erythromycin undergoes
CYP3A4 metabolism first in the liver and has a less likelihood to undergo the P-gp-mediated
pathway (i.e., the order of being exposed to these nonrenal pathways may matter). On the
other hand, the authors did not exclude the possibility of the significant role of hepatic P-gp
activity on erythromycin. However, this study design could not allow the authors to differ-
entially evaluate P-gp activities in the liver and in the intestine. Other limitations of this
study to compare to our results were a small sample size, a young cohort, different doses
of erythromycin between EBTIV and EBTPO, which may have led to linear and nonlinear
CYP3A4 metabolism of erythromycin, respectively. In iPBPK-R, by combining the set of
mathematical equations with multi-parameter optimization, one can indirectly estimate the
activity of different elimination pathways in the target organ [174]. The iPBPK-R approach
overcomes infeasible direct sampling of drug concentrations from the target organ where the
in vivo enzyme-transporter interplay may be occurring.
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In studies using the EBT, 14CO2 production may have been overestimated in females
and the difference between genders was around 20-25% [132]. We observed higher CYP3A4
activity in females than in males and the difference between genders was about 11%. In fact,
the result for females aligned with the study of human liver bank samples where expression
levels of CYP3A4 in female samples were found to be higher than in male samples [173]. No
correlation was observed between CYP3A4 activity or drug transport activity and physio-
logical factors, weight, height, or BMI in all subjects or in each gender. Accordingly, our
study indicated that there is a sex-related difference in CYP3A4 activity.
It is important to emphasize that the main purpose of the iPBPK-R research is to suc-
cessfully back-estimate multiple functional dependent parameters, adjustment factors, and
interrogate the activities of nonrenal elimination pathways as presented in Figures 17(A) and
17(B). In other words, we do not compare AUC or Cmax of plasma concentrations
7 as such
comparison is not aligned with the purpose. The clinical threshold for an adjustment factor
is not a 2-fold difference that is typically used for AUC and Cmax of plasma concentrations
in PBPK modeling. Establishing a clinical threshold for changes in adjustment factors for
activity of CYP3A4 (as well as other nonrenal clearance pathways) will require extensive
research accounting for pharmacologic and pharmacotherapeutic considerations such as a
drug’s therapeutic window. However, it is clear that a change in CYP3A4 activity estimated
by iPBPK-R is impactful enough to dramatically alter the shape of the 14CO2 production
rate-time curves in breath samples (and not plasma concentration-time curves) after con-
trolling for other dependent parameters as shown in Figure 20(A) as a part of sensitivity
analysis. This is also discussed in the application of iPBPK-R to the EBT data in patients
with kidney disease in Section 4.5.
We further conducted correlation analysis on the adjustment factors for non-renal elim-
ination clearance with plasma concentrations of uremic solutes. There was a significant
inverse correlation between the uremic solute BUN and the adjustment factor for Jmax of
the meta-uptake transporter (OATPs) in 12 subjects (ρ = -0.608). In males, significant in-
verse correlations were observed between BUN and maximum velocity of OATPs, CYP3A4
clearance, and passive diffusion, respectively. Despite the small sample size, we showed
7Plasma concentrations were not measured in the study [127].
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that correlation analysis can be used to explore relationships between the activity of non-
renal elimination pathways and potential surrogate biomarkers (such as uremic solutes) after
iPBPK-R modeling.
There are several limitations in this study. First, the detailed structures in the kidney
compartment were omitted and were not modeled so that multiple parameters could be es-
timated using a reduced order model. Second, in the reduced order PBPK model it is not
possible to distinguish the value of maximum velocity and the number of individual trans-
porters. Third, we did not distinguish in vitro parameter values between 14C-erythromycin
and erythromycin for IVIVE calculations. The two compounds are not the same but they
are used interchangeably in clinical research. Therefore, the literature values are the best
parameters that we could use. Fourth, no genetic variant data of OATPs was available, so we
could not conclude whether low CYP3A4 activity was truly caused by the gender difference
or the interplay with OATP variants. Fifth, OATP1B1 and OATP1B3 uptake transporters
in the liver were modeled as a meta-transporter. The reasons are (1) we used a reduced
order model to limit the number of parameters, (2) the literature used for IVIVE calculation
did not provide separate intrinsic clearances for the two uptake transporters, and (3) it is
unknown whether two transporters having the same role of drug transport in the system of
nonlinear ODEs can be separately estimated. It may be possible to differentially estimate
parameters for such two transporters but as the feasibility would depend on the initial input
values, which leads to requiring further mathematical research like Chapter 2. For the same
reason without mathematical investigation, P-gp and MRP2 efflux transporters could not
be differentiated in the iPBPK-based estimation. Via sensitivity analysis, we found that
P-gp and MRP2 did not have impact on the 14CO2 production rate-time curves (because
CYP3A4-mediated elimination seems to be dominant when the functional dependencies of
multiple parameters are simultaneously accounted in the system of nonlinear ODEs) so we
could take them out from the model. However, we forced them into the model to satisfy
mechanistic considerations and as such, we prefer to retain them. Sixth, IVIVE values were
calculated based on an average 70 kg male data. Although both males and females were
enrolled in the clinical study with EBT, the average body weight was close to 70 kg (68 kg).
Therefore, use of the average 70 kg male data is not expected to cause a large bias. The
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variability in weight is reflected in the estimated adjustment factors for the total hepatic
volume. Finally, the CYP3A4 and transporter activity estimates derived from iPBPK-R
modeling were not compared to or validated using specific pharmacologic probe substrates
as controls. The fitted model cannot be validated against the measurements beyond the
breath data. However, the model is a reduced order model, and we could establish that the
model was not overfitted. Furthermore, the goodness-of-fit plots, visual inspection, and nor-
malized residuals calculated from predicted and observed curves indicated excellent model fit
across all individual subjects. By conducting simultaneous optimizations of parameters and
sensitivity analysis, we showed the robustness of parameter estimates and consistency in the
estimated CYP3A4 activity across 12 subjects. Similarly, the estimated uptake transporter
activity was robust and consistent across males while a wider variability was seen in females.
iPBPK-R can be applied to any rate-derived data beyond EBT. Ideal characteristics of
measurements are: (1) rate measurement with long elimination half-life and frequent sam-
pling, (2) in vitro data sufficient for IVIVE, (3) intravenous dosing, and (4) individual data.
The underlying idea for (1) is that rate information can be utilized to capture both non-
rate-limiting and rate-limiting steps in elimination pathways of interest. As another example,
breath rate data of volatile organic compounds can be used to study the role of potential
biomarkers on hemodialysis efficiency [118]. Other potential areas of application include
drug-drug interaction, pathophysiological effects, and the effect of intervention, polyphar-
macy, or any other extrinsic factors on drug disposition by estimating adjustment factors and
conducting correlation analysis. In the future, we plan to apply the iPBPK-R framework to
rate data of other compounds that are known to be cleared by multiple nonrenal elimination
pathways.
3.6 Conclusions
The iPBPK-R approach was applied to evaluate 14CO2 production rate data of the EBT
in healthy subjects. Optimized iPBPK-R models fit the individual data well and it allowed
us to distinguish and simultaneously estimate the activity of multiple non-renal elimination
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pathways of the single probe 14C-erythromycin. The median in vivo CYP3A4 activity was es-
timated as low as 12.2% of the IVIVE-based CYP3A4 clearance. 14CO2 production rate data
has rich information allowing estimation of per-person rate-limiting and non-rate limiting
PK parameters. Accordingly, we found that the multiple PK and physiological parameters
collectively control the 14CO2 production rate – time curve of the EBT. Adjustment factors
for the activity of drug transporters were also estimated in all subjects. Lastly, correlation
analysis can be used to explore relationships between the activity of non-renal elimination
pathways and potential surrogate biomarkers (such as uremic solutes) via iPBPK-R mod-
eling. In summary, we applied iPBPK-R to EBT data to distinguish and simultaneously
estimate the activity of multiple non-renal elimination pathways in healthy subjects. This
serves as proof of principle that the iPBPK-R framework is a novel tool for delineating
rate-limiting and non-rate limiting elimination pathways using a single probe.
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4.0 Application of iPBPK-R to Evaluate the Effect of Hemodialysis on
Nonrenal Clearance Pathways
4.1 Abstract
The aim of this study was to apply iPBPK-R modeling of 14CO2 production rates mea-
sured by the EBT to characterize the effect of hemodialysis on the function of nonrenal
clearance pathways in patients with end-stage renal disease (ESRD). Twelve patients pre-
viously received 14C-erythromycin intravenously pre- and post-hemodialysis. Serial breath
samples were collected after each dose over two hours. Eight PBPK parameters were co-
estimated across periods, while activity of CYP3A4 was independently estimated for each
period. Inhibition coefficients for OATP, P-gp, and MRP2 activities were also estimated.
Nonrenal clearance parameter estimates were explored regarding sex differences, correlations
with uremic toxins, and used in hierarchical cluster analysis (HCA). Relationships between
the function of nonrenal clearance pathways and uremic toxin concentrations were explored.
Mean CYP3A4 clearance increased by 2.2% post-hemodialysis. Uptake transporter activity
was highly variable between subjects across hemodialysis. Five females had 22.2% and 29.8%
higher median CYP3A4 activity than seven males pre- and post-hemodialysis, respectively.
Exploratory HCA identified two patients had an increased CYP3A4 activity (measured by
the adjustment factors pre and post-hemodialysis which were used as features in HCA; me-
dian increase 8.6% versus 0.7% in others) with decreased plasma concentration of intact
parathyroid hormone post-hemodialysis1. This is the first study to utilize the iPBPK-R
approach to simultaneously estimate multiple in vivo nonrenal elimination pathways in in-
dividual patients with kidney disease and to assess the effect of hemodialysis.
1HCA analysis used the iPBPK-R based estimated values of adjustment factors for CYP3A4 activity pre-
and post-hemodialysis, and the two patients found in the same cluster as a result of HCA had a decreased
concentration of intact parathyroid hormone (iPTH) from pre- to post-hemodialysis. This is an exploratory
analysis and does not make a mechanistic inference by itself beyond the temporal relationship between the
two types of measurements, adjustment factors and concentrations of iPTH. See the discussion on HCA
analysis in Section 4.5.
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4.2 Introduction
iPBPK-R is a novel PBPK approach to indirectly and simultaneously measure the ac-
tivity of multiple nonrenal elimination pathways within individual subjects via parameter
estimation [105]. Recently, we used iPBPK-R and 14CO2 production rate data generated
from the EBT to demonstrate proof of principle that erythromycin may serve as a sin-
gle phenotypic probe to simultaneously assess and differentiate contributions of nonrenal
metabolic and transport pathways to its disposition in healthy subjects [105]2. This strategy
may be leveraged to study the interplay between metabolic enzymes and transporters and
to overcome the limitations of using a single probe drug that exhibits overlapping substrate
specificity or using a cocktail approach (see the statistical rationale of the limitations de-
scribed in Section 2.2.1). As such, it has particular appeal for use in assessing the effects
of complex disease states, drugs or other interventions on multiple nonrenal elimination
pathways.
Chronic kidney disease (CKD) afflicts millions of people worldwide [203,204]. The disease
is notorious for impacting the disposition of both renally and nonrenally cleared substances
[17], and for complicating the selection and dosing of drugs, particularly as kidney disease
progresses. This is further complicated by initiation of renal replacement therapies such
as intermittent hemodialysis (HD) because it clears dialyzable substances [87, 205, 206]. In
addition, hemodialysis may improve the function of nonrenal clearance pathways, though
the precise mechanism and pathways impacted are unclear [17, 87, 205, 206]. For example,
hemodialysis was shown to improve hepatic CYP3A4 activity in a population PK analysis of
EBT data pre- and post-hemodialysis [128]. It may be possible that this improvement was
caused by some uremic toxins (e.g., iPTH [207,208]) removed by hemodialysis. On the other
hand, Thomson et al. showed that AUC of midazolam (nonrenally cleared specific probe
for CYP3A4) was higher in ten patients who were on hemodialysis than eight patients with
CKD who were not dependent on hemodialysis [209]. In another study, patients with ESRD
2As described in the previous chapter (Section 3.2), the mechanism and validity of differentially dissecting
the multiple parameter estimates are provided via the detailed analysis of estimation and use of regularization
in Chapter 2 (see Sections 2.6 and 2.4.7). This principle can be applied to the application of iPBPK-R to
the patient data in this chapter as well.
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receiving hemodialysis was shown to have reduced nonrenal transporter activity compared
to healthy subjects using PO fexofenadine while CYP3A4 activity was not affected in those
ESRD patients compared to healthy subjects using PO midazolam [210]. Novel strategies to
ascertain the impact of kidney disease and hemodialysis on drug disposition and individual
nonrenal clearance pathways are needed. We hypothesized that the iPBPK-R approach may
be applied to EBT data in patients with stage 5 CKD [i.e., end-stage renal disease (ESRD)]
to evaluate the effect of chronic intermittent HD on nonrenal clearance pathways.
The aims of this chapter were to apply iPBPK-R (1) to differentially estimate contri-
butions of nonrenal clearance pathways to erythromycin in individual patients with ESRD
pre- and post-HD, (2) to investigate the effect of hemodialysis on these pathways, and (3)
to explore the relationships between parameter estimates and uremic toxin concentrations.
4.3 Methods
4.3.1 Clinical Data Sources
The 14CO2 production rate data was collected from a prospective cohort study where
12 ESRD patients (7 male; 11 white, 1 black) receiving chronic intermittent hemodialysis
treatment received the EBT. A single 0.074 mmol (0.04 mg, 3 µCi) dose of [14C-N-methyl]
erythromycin (Metabolic Solutions Inc., Nashua, NH) was given intravenously. Breath sam-
ples were collected directly before receiving the dose and at 5, 10, 15, 20, 30, 40, 50, 60,
90, and 120 min post dosing as previously described [128]. The study was approved by the
Maine Medical Center Institutional Review Board and the Radiation Safety Committee and
it adhered to the Declaration of Helsinki. Published clinical EBT data [169] was used to
pre-estimate parameters that could not be obtained via the in vitro–in vivo extrapolation
(IVIVE) by applying the PBPK-R model, which follows our previous study [105].
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4.3.2 PBPK Model Structure
A PBPK model consisting of seven organ/tissue compartments and sub-compartments
( 1©- 7© in Figure 21) was built with physiological and kinetic parameters (i.e., PBPK pa-
rameters) for 14C-erythromycin. The compartments included were artery (Art), vein, lung
(LG), liver (LV), kidney (KD), and combined other organs (OT). The liver compartment
consisted of extracellular space (ES) and liver cell (LC) sub-compartments. The model
structure is similar to the model for healthy subjects as published previously [105]. A non-
linear meta-uptake transporter (combining OATPs; see Model Assumptions in Section 4.3.5)
and total passive diffusion were included to model the drug transfer between ES and LC.
Non-linear efflux transporters (P-gp and MRP2) were modeled using maximum velocity and
Michaelis-Menten constant or intrinsic clearance in LC. CYP3A4 clearance was modeled to
be linear since the drug concentration with a low dose of 14C-erythromycin was well below
the maximum velocity of nonlinear kinetics [105].
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Figure 21: A schematic representation of a seven-compartmental PBPK model ( 1©- 7©) for
describing the time profiles of 14C-erythromycin after intravenous 14C-erythromycin admin-
istration in a patient with ESRD.
Adapted from [105] with permission. m, q, and C denote drug mass, drug mass flow,
and drug concentration. The liver comprised of two sub-compartments (extracellular space
(ES) and liver cell or hepatocyte (LC)) where non-linear uptake and efflux transporters






as detailed in Table 6
and Supplemental materials of [105]. In the right figure, the metabolic by-product model
is illustrated where the metabolite 14C-formate is converted to radiolabeled bicarbonate
H14CO−3 in the CYP3A4-mediated pathway and dissolved in the LC sub-compartment. The
series of conversion from H14C-formaldehyde to H14CO−3 is assumed to be a non-rate-limiting.
14CO2 is produced in breath as a result of the first-order elimination of bicarbonate (with a
constant kresp) from the LC. Based on this iPBPK-R model, a system of nonlinear ordinary
differential equations (ODEs) was set up for simulations to maintain the mass balance of
14C-erythromycin in the body system [105].
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4.3.3 Ordinary Differential Equations, Kinetic Parameters, and Data Input
Drug concentration dynamics of all compartments and sub-compartments were math-
ematically described with a set of ODEs. The ODEs were the same as those for healthy
subjects in Chapter 3 [105] except for the ODE modeling the KD compartment, which did
not include the clearance terms of P-gp (assuming negligible tubular secretion in the pa-
tients [211]) nor glomerular filtration rate for the patients with ESRD. The ODE of the vein
compartment was identical to that for healthy subjects since the percentage of drug removal
via hemodialysis was set to 0 (See 10. of Table 17 in Model Assumptions). Permeability-
limited liver models were used in the ODEs associated with ES and LC [101] (See 2. of
Table 17 in Model Assumptions). We referred to Kanamitsu et al. [183] for the metabolic
by-product model to describe the series of non-rate limiting steps from 14C-formaldehyde
to bicarbonate H14CO−3 and subsequent
14CO2 generation within the LC sub-compartment.
This enabled us to approximate the 14CO2 production rate in the breath by the first deriva-
tive of the cumulative 14CO2 concentration generated in LC (see Model Assumptions in
Section 4.3.5). Parameters in Table 12 for healthy subjects were also used for ESRD pa-
tients except for the parameters listed in Table 18. Thus, Table 18 provides parameters
which were uniquely obtained for ESRD patients. These parameters were used as input
values in the estimation of scaling factors, which is described later.
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Table 17: List of assumptions used in iPBPK-R of EBT data from patients with ESRD
Number Assumption
1 The duration of intravenous dosing of 14C-erythromycin was 30 seconds.
2a Our model is well-stirred [183] [199]. Thus, the distribution of a drug rapidly
reaches equilibrium via passive diffusion and the unbound concentration in
the compartment is the same as those in the diffused space at equilibrium.
All compartments except for the liver compartment are perfusion-limited3.
For the liver, permeability-limited model4 was used as detailed in 3.
3 Pathways from the extracellular space to the liver cells (ES → LC sub-
compartment) for erythromycin consist of total passive diffusion and sum-
mation of uptake transporters. The hepatic uptake transport processes of
14C-erythromycin by OATP isoforms OATP1B1 and OATP1B3 were mod-
eled as a single meta-uptake process.
4 After being generated in the LC sub-compartment, 14CO2 is instantaneously
released in breath via the lung without being stored in or released from any
other compartments. CO2 in the systemic circulation is at steady state.
5 In the CYP3A4-mediated pathway, the series of conversion from 14C-
erythromycin, 14C-formaldehyde, 14C-formate through to a by-product ra-
diolabeled bicarbonate (H14CO−3 ) is rapid and not rate-limiting as assumed
by Sugiyama et al. [172] H14CO−3 is dissolved in the LC sub-compartment
and the final by-product 14CO2 in this pathway is produced and exhaled in
breath as a result of a first-order elimination of H14CO−3 (with a constant
kresp) from the LC sub-compartment [172].
3A perfusion-limited kinetic model describes the limiting process that is defined by the blood flow to the
tissue [212].
4A permeability-limited kinetic model describes the limiting process that is defined by the permeability
of drug across the cell membrane. Rather than depending on the blood flow, the time to reach equilibrium
of the drug concentrations across the membrane is highly dependent on the drug-specific permeability such
as active transport processes [212].
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Table 17: List of assumptions used in iPBPK-R of EBT data from patients with ESRD
Number Assumption
6a The liver consisting of ES and LC sub-compartments is an elimination or-
gan. In addition, a parameter µ was incorporated in the OT compartment
to explain the exponential decay that was seen in the observed 14CO2 pro-
duction rate data. We expected that this µ would improve the model fitting.
Thus, the exponential decay was assumed to account for any loss or decom-
position of the drug before the drug reaches the liver within the system.
7 The unbound drug was subject to uptake and efflux transport, enzymatic
metabolism, and elimination in the liver.
8 We assumed linearity for the intrinsic clearance of CYP3A after investigat-
ing the model fitting in the iPBPK-R development.
9b All patients received the second EBT at nine hours post dosing of the first
EBT.
10b Patients underwent a 4-hour hemodialysis after the two-hour sample col-
lection of the first EBT, the drug removal by hemodialysis in the carryover
concentration of the first EBT to the second EBT was negligible [213,214]5.
aThe assumption was modified for the ESRD patient population from the corresponding
assumption used in our previous model application for healthy subjects since the kidney
compartment is not an elimination organ in ESRD. bThe assumption was newly added in
this model application because of the study design with 2 study b periods (pre- and post-HD).
5Based on the references [213,214], %dialyzed of erythromycin is low (0-7%) and supplemental dosing is
not required for erythromycin during hemodialysis (HD). Accordingly, we assumed that erythromycin does
not get removed by HD. The only difference from the case to account for a minor removal of erythromycin
is whether we will have a carryover 14CO2 production rate from pre-HD EBT at the beginning of EBT
post-HD. As seen Figure 23 the assumption of no removal of the drug leads to accounting for the maximum
possible carryover 14CO2 production rate, which showed great model fit to the observed data at the baseline
of the 14CO2 production rate-time curves post-HD. Accordingly, this assumption was considered to be
appropriate and sufficient, and sensitivity analysis on %dialyzed would not have any impact but rather make
the simulated curves fit less to the observed data at the baseline of post-HD EBT.
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Table 18: Parameters used for the erythromycin breath test simulations for patients with
ESRD
Description (units)6 Notation Value Reference/Comments
Glomerular filtration rate (L/hr) eGFR (= δGfr) 0 Assumed
Clearance via Pgp (L/hr) CLOUT1 0.1735 Pre-estimated for the
liver based on an initial
simulation using [169]
Fraction unbound in blood fu,BL (= fb) 0.30 Assumed for ESRD
based on [188]
Fraction unbound in extracellular
space
fu,ES (= f6) 0.462 Calculated for ESRD
based on [189] [190],
[191], and [192]7
Partition coefficient of the combined
other organs to plasma
POT:P 0.775 Calculated based
on [195] [196] [188]
6This table lists the input parameters which were uniquely obtained for patients with ESRD and different
from those for healthy subjects in Table 12 of Chapter 3.
7fu,ES was calculated applying the assumption proposed for general physiological PK modeling by Khor
et al. to our modeling. This assumption was ’the blood protein to which the drug binds is also present
in interstitial fluid and that the association binding constant is the same in both blood and interstitial
fluid’ [189]. Extracellular space matrix (ECM) is known to have many proteins such as fibrillar collagens,
proteoglycans, growth factors, cytokines, chemokines, enzymes, among others [193]. We treat these proteins
in ECM in the liver as a general protein that can bind to erythromycin in the modeling.
149
4.3.4 Rate Data and Reduced Order Model
Frequently sampled production rate data has mathematically higher information content
(i.e., it enables higher accuracy of estimated model parameters) compared to equivalently
sampled concentration data (see the details in Highly sensitive indirect measurement of
Section 2.4.1 or in Section 3.3.4). However, more effort is required to extract this information
[105]. In digital signal processing and other engineering disciplines, non-linear model fitting
of observed first derivative data is often conducted to estimate sensitive parameters [134].
We borrowed this concept in our previous application of iPBPK-R [105]. In this chapter,
the 14CO2 production rate data from the EBT study in patients with ESRD was modeled
in a similar fashion. The iPBPK-R model was fit to the 14CO2 production rate data via a
nested co-optimization procedure. Multiple nonrenal elimination pathways, i.e., uptake and
efflux transport and total passive diffusion parameters, were estimated via scaling factors
relative to IVIVE using the single probe drug 14C-erythromycin. The types of scaling factors
used were: (1) co-optimized adjustment factors, (2) independent adjustment factors, (3)
inhibition coefficients, and (4) total adjustment factors (see Simulations and Optimizations
in Section 4.3.6). In order to obtain high precision in the model fitting, we used a reduced
order model [198]. Reduced order models are sufficiently complex to capture the behavior of
interest but simple enough to be well-posed, providing estimable parameters. Based on this
rationale, the total number of compartments and sub-compartments was limited to seven,
as described in the preceding subsections.
4.3.5 Model Assumptions
Adopting the concept of reduced order model enabled us to achieve superior goodness-
of-fit in iPBPK-R modeling of EBT data and to implement high-dimensional parameter
estimation. We performed the iPBPK-R modeling under similar assumptions that were
previously used for healthy subjects [105]. A part of these assumptions were adapted for
patients with ESRD due to the disease stage and study design. The list of assumptions for
the present study is shown in Table 17.
150
4.3.6 Simulations and Optimizations
Concentration-time curves of 14C-erythromycin and by-products H14CO−3 and
14CO2 were
simulated for individual patients using the system of ODEs as in Chapter 3 [105] with minor
modifications described in Section 4.3.3. By taking the first derivative of cumulative 14CO2
concentrations in LC, 14CO2 production rates were simulated.
Prior to conducting the high-dimensional parameter optimization for patients with ESRD,
the following PBPK parameters were pre-estimated as in Chapter 3 using literature data [105]
[169]: maximum velocity of the meta uptake transporter, maximum velocity of the hepatic
P-gp, CYP3A4 clearance, partition coefficient in the combined other organs, and exponential
decay parameter. These pre-estimated parameter values were used in the high-dimensional
parameter optimization as starting values for patients with ESRD.
iPBPK-R uses a nested co-optimization procedure, which consists of the inner loop and
outer loop to optimize PBPK parameters (Figure 22) (See Section 2.6.4 of Chapter 2). In
the outer loop, eight scaling factors for the following PBPK parameters were optimized8:
maximum velocity of OATPs, P-gp, and MRP2 (Jmax,UP1, Jmax,OUT1, and Jmax,OUT2), volume
of total hepatocyte (VLC), total passive diffusion between extracellular space and hepatocyte
(QES−LC), arterial blood flow into the combined other organs (QOT) , exponential decay pa-
rameter (µ), and partition coefficient of the combined other organs to plasma (POT:P). These
parameters were assumed to be shared between pre- and post-HD and thus co-optimized
within individuals. We called these scaling factors co-optimized adjustment factors. In
model fitting, the co-optimized adjustment factors result in patient-specific baseline adjust-
ment of population IVIVE (or input values) regardless of the study periods. In the inner
loop, four scaling factors in each study period (pre- and post-HD, for a total of eight scaling
factors) were independently optimized9: scaling parameters for the nonlinear OATPs, P-
8The number of observed samples per individual in this simultaneous PBPK model fit is 11 time points ×
2 datasets (pre- and post-hemodialysis) = 22 data points. The number of functionally dependent parameters
to optimize here (i.e., 8 outer loop parameters) is sound as shown in the analysis of iPBPK-R estimation
using regularization in Section 2.4.7.
9The number of observed samples per individual in this simultaneous PBPK model fit is 11 time points
for each EBT test (pre- and post-hemodialysis, respectively). The number of independent parameters to
optimize here (i.e., 2 inner loop parameters pre- and post-hemodialysis, respectively) is valid as these inner
loop optimization steps are independent of the outer-loop optimization in the nested co-optimization process
as described in 2.7.2.
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gp, and MRP2 clearance, and an adjustment factor for linear CYP3A4 clearance (CLCYP).
The scaling parameters for drug transporters are interpreted as non-competitive inhibition
coefficients in the pathophysiological state (i.e., ESRD). Inhibition coefficients are used to
evaluate the reduction in the co-optimized adjustment factor for Jmax,UP1, Jmax,OUT1, and
Jmax,OUT2 pre- and post-HD. Scaling factors were estimated via nested co-optimization that
minimizes the errors of the fitted model of 14CO2 production rates.
The model fit was evaluated using goodness-of-fit plots, normalized residuals between
predicted and observed rates, visual inspection, and plausibility of the parameter estimates.
Among the PBPK parameters in Table 18, aforementioned outer loop and inner loop pa-
rameters were selected for optimization. Using sensitivity analysis in healthy subjects, these
selected parameters were found to be essential for fitting the model to the EBT data [105].
Adjustment factors for maximum velocity of efflux transporters were not sensitive enough
to contribute to controlling the shape of the 14CO2 production rate-time curves. However,
these parameters were kept in the optimization since they were part of nonrenal elimination
pathways. The inhibition coefficients in the inner optimization loop were used to calculate
total adjustment factors for IVIVE values of transporter kinetics pre- and post-HD, where
total adjustment factor = co-optimized adjustment factor × inhibition coefficient.
Simulations and parameter co-optimization were implemented with R 3.4.4. The R
package deSolve was used for solving the set of ODEs, and large-scale simulations were
performed via the Bridges supercomputer at PSC [126]. Methodological details of iPBPK-R
were described in Chapter 2.
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Figure 22: Framework of the application of iPBPK-R to the EBT study in 12 patients with
ESRD.
The optimization setup in the application of iPBPK-R to two EBT datasets per patient
was mathematically described in Section 2.6.4. The framework diagram illustrates which
parameters are estimated in the nested co-optimization setting in the actual application to
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the 14CO2 production rate data set pre- and post-hemodialysis, and a nested co-optimization
of multiple parameters with outer and inner loops was conducted in each patient accordingly.
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4.3.7 Statistical Analysis
Mean ± SD and/or median (range) were used as descriptive statistics. Box plots were
created for visualization of estimation results. No statistical test was powered in advance
since the study explored feasibility and estimability. For comparing parameters pre- and
post-HD, paired t-tests were conducted in case of normally distributed measurements. Oth-
erwise, Wilcoxon signed-rank tests were conducted. One-sided tests were used to test an
increase in activity of metabolic enzyme and drug transporters by the effect of hemodialysis.
Two-sided Wilcoxon-Mann-Whitney tests were conducted for comparing two independent
subgroups. One-sided tests were used to evaluate a higher enzyme activity in females than
in males that was found in our previous study [105]. Spearman’s ρ correlation coefficients
were obtained in correlation analysis to explore the relationships between estimated param-
eters and baseline demographic or uremic solute concentrations pre-HD, post-HD, and in
the change from pre- to post-HD. Finally, hierarchical clustering analysis (HCA) [215] was
applied to parameter estimates to explore potential cluster sub-groups and interindividual
differences. In all comparisons a P-value < 0.05 was considered statistically significant. Scal-
ing factors were interpreted as follows. An adjustment factor 1 indicates that the estimated
parameter did not require any adjustment from the initial input parameter value as a result of
parameter optimization. Inhibition coefficient of 0 indicates complete non-competitive inhi-
bition while inhibition coefficient of 1 indicates no non-competitive inhibition. All statistical
analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
4.4 Results
The iPBPK-R model was fit to the observed 14CO2 production rate data pre- and post-
HD for the 12 patients with ESRD (Figure 23). The nested co-optimization procedure yielded
parameter estimates for all patients, and goodness-of-fit plots across subjects showed an
excellent model fit for all patients (Figure 24). Figure 25 provides an example of 3D 14CO2
production rate-time curve simulations in one patient where the nested co-optimization leads
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to the final model fit pre- and post-HD simultaneously. This procedure provides eight outer
loop and four inner loop parameters per study period (Figure 22 and Table 19).
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1.09 ± 0.18 1.04 (0.98, 1.65)
P-gp (baseline deviation
from IVIVE)
1.00 ± 0.01 1.00 (1.00,1.02)
MRP2 (baseline deviation
from IVIVE)
1.01 ± 0.03 1.00 (1.00, 1.09)
Hepatocyte volume 1.06 ± 0.19 1.06 (0.81, 1.39)
Total passive diffusion be-
tween ES and LC
0.41 ± 0.24 0.37 (0.13, 0.92)
Arterial blood flow in the
combined other organs
0.64 ± 0.41 0.46 (0.45, 1.86)
Exponential decay param-
eter in the combined other
organs
4.33 ± 0.86 4.07 (4.03, 7.06)
Partition coefficient in the
combined other organs
18.77 ± 0.06 18.79 (18.60, 18.82)
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0.66 ± 0.28 0.62 (0.25, 1.00) 0.46 ± 0.26 0.38 (0.09, 0.97) 0.957
P-gpb 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.125
MRP2b 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.125
IVIVE adjustment : total
adjustment factor
CYP3A4 clearancea 0.17 ± 0.13 0.13 (0.05, 0.40) 0.20 ± 0.14 0.12 (0.07, 0.44) 0.033?
Meta-uptake transporter
OATPsa
0.71 ± 0.29 0.72 (0.27, 1.10) 0.49 ± 0.26 0.49 (0.10, 0.99) 0.964
P-gpb 1.00 ± 0.01 1.00 (1.00, 1.02) 1.00 ± 0.01 1.00 (1.00, 1.02) 0.125
MRP2b 1.01 ± 0.03 1.00 (1.00, 1.09) 1.01 ± 0.03 1.00 (1.00, 1.09) 0.125
ESRD, end-stage renal disease; IVIVE, in-vitro in-vivo extrapolation; OATPs, organic anion transporting polypeptides; P-gp,
P-glycoprotein; MRP2, multidrug resistance-associated protein 2; CYP3A4, cytochrome P450 3A4
aOne-sided paired t-test was conducted.; bOne-sided paired Wilcoxon signed rank test was conducted. ? indicates a statistically
significant increase from pre- to post-hemodialysis at a significance level of 0.05.
Note that a clinical threshold for evaluating adjustment factors has not been established as this is the first study in ESRD
patients to simultaneously estimate multiple dependent parameters in an automated fashion as discussed in Section 4.5.
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Figure 23: iPBPK-R per-individual simultaneous model fit to the EBT data pre- and post-
hemodialysis (HD) from the 12 patients with ESRD.
The red lines and blue lines are modeled 14CO2 production rate-time curves pre- and post-
HD, respectively. The dark red and dark blue dots indicate the observed 14CO2 production
rates pre- and post-HD, respectively. The goodness-of-fit of these curves are discussed in
Section 4.5 along with Figure 24. The orange lines indicate the subjects (ID = 3, 16)
identified as a cluster group in the hierarchical clustering analysis as described in Figure 29.
159
ESRD patient (ID=1)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=2)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=3)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=4)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=5)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=6)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=7)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=8)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=9)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=10)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=15)



























0 0.02 0.04 0.06 0.08 0.1
ESRD patient (ID=16)



























0 0.02 0.04 0.06 0.08 0.1
Figure 24: Goodness-of-fit plots pre- and post-hemodialysis (HD) for the 12 patients with
ESRD.
Observed versus modeled (simulated) 14CO2 production rates are shown
10, which correspond
to the iPBPK-R model fit to the EBT data in Figure 23. The dark red and dark blue dots
indicate the results pre- and post-HD, respectively. The simulated and observed 14CO2
production rates are on or close to the diagonal line across the 12 patients pre- and post-
dialysis. There are data points slightly off from the diagonal line in the patients of ID =
5, ID = 6, and ID = 15. These may be caused by the actual sample collection times that
deviated from the planned sample collection times as the breath samples in the early phase
were intensively collected within the two hours. This is discussed in Section 4.5.
10Rather than the normalized residual-time plots, goodness-of-fit plots are being presented here for the
same reason described in Figure 16.
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Figure 25: An example of 3D 14CO2 production rate-time curve simulations in one patient.
The nested co-optimization simultaneously leads to the final model fit pre- and post-hemodialysis
(HD). The curves in the blue – green – blue color transition show the simulated curves pre-
HD and the curves in the red – yellow – red color transition show the simulated curves
post-HD during the nested parameter co-optimization (high-dimensional parameter estima-
tion). Both curves were simultaneously fit to the patient’s observed data pre- and post-HD
at the end of the optimization process. In other words, this figure presents one individual’s
iPBPK-R example that iPBPK-R is searching multiple parameter values simultaneously and
consistently, which are visualized via the 14CO2 production rate-time curve simulations at
earlier optimization numbers (z-axis). This search finds a solution of multiple functionally
dependent parameters (adjustment factors) and simulates the final curves pre- and post-
HD at the last optimization number due to the successful nested co-optimization with the
well-crafted regularization described in Sections 2.4.7, 2.6, and 2.6.4.
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Table 19 shows eight co-optimized adjustment factors for Jmax,UP1, Jmax,OUT1, Jmax,OUT2,
VLC, QES−LC, QOT, µ, and POT:P in the outer loop (Figure 22). Most mean co-optimized
adjustment factors in the liver were close to 1 (indicating no adjustment of IVIVE or popu-
lation input value) except for QES−LC (0.41 ± 0.24, mean ± SD). Co-optimized adjustment
factors were relatively variable for QES−LC and VLC (1.06 ± 0.19) (Figure 26(A)). In the OT
compartment, all co-optimized adjustment factors differed from 1 (0.64 ± 0.41 for QOT, 4.33
± 0.86 for µ, and 18.77 ± 0.06 for POT:P) (Figure 27). Though the co-optimized adjustment
factors in the OT compartment do not provide biological implication, they were included
in the optimization for the purpose of model fitting, similarly to our previous study [105].
In the inner loop, adjustment factors for CLCYP3A4 and inhibition coefficients for OATPs,
P-gp, MRP2 were estimated independently pre- and post-HD, respectively (Figure 26(B)).
In Figure 26(C), the total adjustment factor (co-optimized adjustment factor × inhibition
coefficient) for Jmax,UP1 had relatively large interindividual variability, which did not improve
from pre- to post-HD (0.71 ± 0.29 pre-HD; 0.49 ± 0.26 post-HD, p=0.96). The total adjust-
ment factors for Jmax,OUT1 and Jmax,OUT2 were close to 1 and they did not show interindividual
variability both pre- and post-HD. The adjustment factor for CLCYP3A4 increased slightly
from pre- to post-HD (0.17 ± 0.13 pre-HD; 0.20 ± 0.14 post-HD, p=0.03); mean CLCYP3A4
at the beginning of the study was 17% of the IVIVE value and was increased by 2.2% (mean
paired difference, not tabulated) after hemodialysis.
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Figure 26: Box plots of estimated scaling factors (co-estimated adjustment factors, inhibition
coefficients, and total or independently optimized adjustment factors) in the liver.
(A) Co-optimized adjustment factors for maximum velocity of OATPs, P-gp, and MRP2
(Jmax,UP1, Jmax,OUT1, Jmax,OUT2), hepatocyte volume (VLC), and passive diffusion between
extracellular space and liver cell (QES−LC) in the outer loop. (B) Inhibition coefficients for
OATPs, P-gp, and MRP2 pre- and post-hemodialysis (HD) in the inner loop. (C) Total
adjustment factors for OATPs, P-gp, MRP2, and CYP3A4 pre- and post-HD, respectively.
The total adjustment factors for CYP3A4 pre- and post-HD were independently estimated in
the inner loop. The total adjustment factors for transporters were calculated by co-optimized
adjustment factor × inhibition coefficient. One sided exact or t-test p-values are shown and
? indicates a statistically significant difference at a significance level of 0.05. N = 12 in all
box plots.
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Figure 27: Box plots of co-optimized adjustment factors associated with the combined other
organs (OT).
Co-adjustment factors for arterial blood flow, exponential decay, and partition coefficient of
OT to plasma are shown. N = 12 in all box plots.
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Next, parameters were compared by sex (Table 20(B) and (C)). The total adjustment
factor for Jmax,UP1 did not differ by sex pre- and post-HD (p=0.76 and p=0.15, respectively).
The adjustment factor for CLCYP3A4 was significantly greater in females than in males pre-
HD (the median reduction from the IVIVE value in males: females = 92%:70%, p=0.005).
The adjustment factor for CLCYP3A4 post-HD showed a similar sex difference (the median
reduction from the IVIVE value in males: females = 92%:62%, p=0.003) (Figure 28). The
co-optimized adjustment factor which indicates patient-specific baseline adjustment differed
for OATPs by sex (Table 20(A)). The co-optimized adjustment factor for VLC also differed
by sex (p=0.003) but it did not differ for QES−LC (p=0.64).
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Estimated parameter Mean ± SD Median (Range) Mean ± SD Median (Range) p-valuea
(A) IVIVE adjustment:
co-adjustment factor
Meta-uptake transporter 1.02 ± 0.03 1.02 (0.98, 1.07) 1.20 ± 0.25 1.10 (1.05, 1.65) 0.005??
P-gp 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.01 1.00 (1.00, 1.02) 0.88
MRP2 1.00 ± 0.01 1.00 (1.00, 1.02) 1.02 ± 0.04 1.00 (1.00, 1.09) 0.27
Hepatocyte volume 0.93 ± 0.10 0.92 (0.81, 1.08) 1.25 ± 0.08 1.22 (1.17, 1.39) 0.003??
Total passive diffusion be-
tween ES and LC
0.43 ± 0.19 0.37 (0.13, 0.69) 0.39 ± 0.32 0.33 (0.14, 0.92) 0.64
Arterial blood flow in the
combined other organs
0.54 ± 0.17 0.47 (0.45, 0.91) 0.78 ± 0.61 0.45 (0.45, 1.86) 0.53
Exponential decay param-
eter in the combined other
organs
4.08 ± 0.05 4.06 (4.03, 4.18) 4.68 ± 1.33 4.10 (4.05, 7.06) 0.20
Partition coefficient in the
combined other organs
18.79 ± 0.01 18.79 (18.78, 18.82) 18.75 ± 0.08 18.79 (18.60, 18.79) 0.76
a Exact p-value of a Wilcoxon-Mann-Whitney test to compare between male and female (two-sided test).
?? indicates a statistically significant difference between male and female at a significance level of 0.01.
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Table 20: Parameter estimates via nested co-optimization in the iPBPK-R modeling of the EBT study in 12 patients with
ESRD by sex (continued)
Male Female
N 7 5







0.67 ± 0.34 0.71 (0.25, 1.00) 0.64 ± 0.22 0.57 (0.43, 1.00) 0.44
P-gp 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.92
MRP2 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.31
IVIVE adjustment : Total
adjustment factorb
CYP3A4 linear clearancec 0.10 ± 0.05 0.08 (0.05, 0.19) 0.29 ± 0.12 0.30 (0.15, 0.40) 0.005??
Meta-uptake transporter
OATPs
0.68 ± 0.35 0.73 (0.27, 1.03) 0.74 ± 0.21 0.71 (0.57, 1.10) 0.76
P-gp 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.01 1.00 (1.00, 1.02) 0.88
MRP2 1.00 ± 0.01 1.00 (1.00, 1.02) 1.02 ± 0.04 1.00 (1.00, 1.09) 0.27
a Exact p-value of a Wilcoxon-Mann-Whitney test to compare between male and female (two-sided test).
b Total adjustment factors for nonlinear clearance by drug transporters were calculated by co-adjustment factor times inhibition
coefficient.
c One-sided tests were applied due to the prior knowledge in literature.
??indicates a statistically greater median value in female compared to male at a significance level of 0.01.
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Table 20: Parameter estimates via nested co-optimization in the iPBPK-R modeling of the EBT study in 12 patients with
ESRD by sex (continued)
Male Female
N 7 5







0.59 ± 0.27 0.68 (0.22, 0.97) 0.28 ± 0.12 0.30 (0.09, 0.42) 0.11
P-gp 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.12
MRP2 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.00 1.00 (1.00, 1.00) 0.15
IVIVE adjustment : Total
adjustment factorb
CYP3A4 linear clearancec 0.10 ± 0.06 0.08 (0.07, 0.23) 0.33 ± 0.13 0.38 (0.13, 0.44) 0.003??
Meta-uptake transporter
OATPs
0.60 ± 0.27 0.69 (0.23, 0.99) 0.34 ± 0.18 0.31 (0.10, 0.55) 0.15
P-gp 1.00 ± 0.00 1.00 (1.00, 1.00) 1.00 ± 0.01 1.00 (1.00, 1.02) 0.88
MRP2 1.00 ± 0.01 1.00 (1.00, 1.02) 1.02 ± 0.04 1.00 (1.00, 1.09) 0.27
a Exact p-value of a Wilcoxon-Mann-Whitney test to compare between male and female (two-sided test).
b Total adjustment factors for nonlinear clearance by drug transporters were calculated by co-adjustment factor times inhibition
coefficient. c One-sided tests were applied due to the prior knowledge in literature.
??indicates a statistically greater median value in female compared to male at a significance level of 0.01.
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As described in Statistical Analysis Section (Section 4.3.7) statistical tests to compare two groups are not powered. Thus, these
statistical tests are treated as exploratory analyses. Note that a clinical threshold for comparing adjustment factors has not
been established as this is the first research to simultaneously estimate multiple functionally dependent parameters in ESRD
patients in an automated fashion as discussed in Section 4.5.
169
Figure 28: Box plots of selected total adjustment factors associated with nonrenal elimination
pathways (OATPs, P-gp, and MRP2 and CYP3A4) pre- and post-hemodialysis are compared
by sex.
Exact p-values are shown and ?? indicates a statistically significant difference at a significance
level of 0.01. N = 7 for males and N = 5 for females.
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As an exploratory analysis in the 12 patients (see Table 21), Spearman correlations be-
tween inhibition coefficients, total adjustment factors, and adjustment factors for non-renal
elimination parameters (Jmax,UP1, CLCYP3A4, and QES−LC) versus BMI, age, and uremic solute
concentrations were estimated. Uremic solutes included SCr, BUN (low molecular weight
solutes), and TNF-α, β2-M, and iPTH (middle molecular weight solutes)
11. The inhibi-
tion coefficient and total adjustment factor for Jmax,UP1 were strongly correlated with β2-M
(ρ=0.692, p=0.01 and ρ=0.643, p=0.02, respectively) pre-HD, based on Evans’ correlation
criteria [200], but they did not correlate post-HD nor in the change from pre- to post-HD.
The adjustment factor for CLCYP3A4 was strongly correlated with age both pre- and post-HD
(ρ=0.657, p=0.02 and ρ=0.755, p=0.005), but its change between pre-and post-HD was not.
The co-optimized adjustment factor for QES−LC was negatively and strongly correlated with
TNF-α pre-HD, but it was positively correlated with its change from pre- to post-HD. There
was no correlation with TNF-α post-HD.
Figure 29 shows the result of the exploratory HCA. Clustering was performed using the
estimated changes in inhibition coefficient for Jmax,UP1 and adjustment factor for CLCYP3A4
from pre- to post-HD (average silhouette width = 0.45 for three clusters). The HCA identified
two patients (ID = 3 and 16 marked in Figure 23) who showed more increased CYP3A4
activity by hemodialysis compared to the other patients (median increase 8.6% versus 0.7%,
p=0.03; Figure 30(A)). The average change in the concentration of iPTH in these two patients
was numerically much lower (without overlapping ranges) than that for the other patients
(Figure 30(C)). However, with just two patients identified in the cluster analysis, it did not
provide a statistically significant difference.
11This iPBPK-R study used the published clinical data [128] and these uremic toxins were designed to
serve as model uremic toxins for different weight classes in the published clinical study.
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Table 21: Correlation coefficients among estimated PBPK parameters, demographic data, and uremic solute concentrations in
12 patients with ESRD
Period Estimated PBPK pa-
rameter on







ρa 0.407 -0.077 0.049 -0.088 0.692 0.091 -0.329




ρa 0.365 -0.028 0.112 0.052 0.643 0.035 -0.441




ρa -0.305 0.657 -0.315 -0.518 -0.476 -0.021 0.105
p-value 0.335 0.020? 0.319 0.084 0.118 0.948 0.746
Total passive diffusion
between ES and LC
ρa -0.119 -0.077 0.504 0.361 0.203 -0.636 0.000
(IVIVE co-adjustment
factor)
p-value 0.712 0.812 0.095 0.249 0.527 0.026? 1.000
BMI, body mass index (kg/m2); SCr, serum creatinine (mg/dL); BUN, blood urea nitrogen (mg/dL); TNF-α, tumor necrosis factor-α
(pg/mL); ES, extracellular space; LC, liver cell; IVIVE, in-vitro in-vivo extrapolation; β2-M , β2-microglobulin; iPTH, intact parathyroid
hormone; NA, not applicable since the PBPK parameter was co-estimated between pre- and post-hemodialysis. aSpearman correlation
coefficient. ? and ?? indicate a statistically significant correlation at a significance level of 0.05 and 0.01, respectively.
12This iPBPK-R study used the published clinical data [128] and these uremic toxins were designed to serve as model uremic toxins for different
weight classes in the published clinical study.
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Table 21: Correlation coefficients among estimated PBPK parameters, demographic data, and uremic solute concentrations in
12 patients with ESRD (continued)
Period Estimated PBPK pa-
rameter on






ρa 0.291 -0.322 0.322 0.558 -0.196 0.259 0.014




ρa 0.126 -0.280 0.350 0.505 -0.126 0.091 0.084




ρa -0.225 0.755 -0.392 -0.414 0.007 -0.098 0.371
p-value 0.483 0.005?? 0.207 0.181 0.983 0.762 0.236
Total passive diffusion
between ES and LC
ρa NA NA 0.333 0.126 -0.119 -0.399 0.070
(IVIVE co-adjustment
factor)
p-value NA NA 0.291 0.696 0.713 0.199 0.829
BMI, body mass index (kg/m2); SCr, serum creatinine (mg/dL); BUN, blood urea nitrogen (mg/dL); TNF-α, tumor necro-
sis factor-α (pg/mL); ES, extracellular space; LC, liver cell; IVIVE, in-vitro in-vivo extrapolation; β2-M , β2-microglobulin;
iPTH, intact parathyroid hormone; NA, not applicable since the PBPK parameter was co-estimated between pre- and post-
hemodialysis. aSpearman correlation coefficient. ? and ?? indicate a statistically significant correlation at a significance level of
0.05 and 0.01, respectively.
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Table 21: Correlation coefficients among estimated PBPK parameters, demographic data, and uremic solute concentrations in
12 patients with ESRD (continued)
Period Estimated PBPK pa-
rameter on






ρa -0.123 -0.168 0.084 -0.225 0.490 0.098 -0.028
post-
hemodialysis




ρa -0.123 -0.168 0.084 -0.225 0.490 0.098 -0.028




ρa -0.421 0.350 -0.196 0.134 0.042 0.301 -0.084
p-value 0.173 0.265 0.542 0.679 0.897 0.342 0.795
Total passive diffusion
between ES and LC
ρa NA NA -0.329 -0.548 -0.154 0.797 0.014
(IVIVE co-adjustment
factor)
p-value NA NA 0.297 0.065 0.633 0.002?? 0.966
BMI, body mass index (kg/m2); SCr, serum creatinine (mg/dL); BUN, blood urea nitrogen (mg/dL); TNF-α, tumor necro-
sis factor-α (pg/mL); ES, extracellular space; LC, liver cell; IVIVE, in-vitro in-vivo extrapolation; β2-M , β2-microglobulin;
iPTH, intact parathyroid hormone; NA, not applicable since the PBPK parameter was co-estimated between pre- and post-
hemodialysis. aSpearman correlation coefficient. ? and ?? indicate a statistically significant correlation at a significance level of
0.05 and 0.01, respectively.
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Figure 29: Dendrogram of hierarchical cluster analysis when change in adjustment factor for
CYP3A4 clearance and change in inhibition coefficient for OATPs were used as features.
Hierarchical cluster analysis (HCA), a data mining technique in statistics (also one of the
techniques used in machine learning), was conducted using the estimated adjustment factors
for CYP3A4 activity pre- and post-HD and the estimated adjustment factors for OATP
activity pre- and post-HD as features13 (features are essentially used in HCA). The numbers
shown at the bottom of the dendrogram are patient IDs that correspond to the patient IDs in
Figure 23. ID = 3 and 16 in the orange square make a distinct cluster group that are marked
in Figure 23. As discussed in Section 4.5 the purpose of this HCA analysis is to just suggest
a new approach and its feasibility, and this HCA should be treated as exploratory analysis.
In Figure 23, it does not look to be feasible to visually identify which patients may differ
from the others within the same ESRD cohort. However, this HCA showed the potential to
identify unique patients since the above two patients in a cluster showed a greater decrease
in adjustment factor for CYP3A4 activity from the rest of patients as shown in Figure 30.
13Various combinations of estimated adjustment factors were explored as features in HCA analyses. Fig-
ure 29 provided the best average silhouette width value [215], which indicates that using adjustment factors
for CYP3A4 activity pre- and post-HD and adjustment factors for OATP activity pre- and post-HD makes
best clustering of the samples.
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Figure 30: Box plots of change in scaling factors are compared by between a sub-group of
ID = 3 and 16 versus others based on the hierarchical clustering analysis (Figure 29)).
The changes scaling factors are for CYP3A4 and OATPs. Exact p-values are shown and ?
indicates a statistically significant difference at a significance level of 0.05.
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4.5 Discussion
We present an application of iPBPK-R to EBT data in patients with ESRD to evaluate
the effect of chronic intermittent hemodialysis on nonrenal clearance pathways. Alterations
in erythromycin disposition were mechanistically evaluated within individual patients. Two
sets of 14CO2 production rate data (pre- and post-HD) were simultaneously modeled and a
total of 16 scaling factors (adjustment factors and inhibition coefficients) were estimated per
patient via the nested co-optimization.
Similar to the study in healthy subjects, the 14CO2 production rate-time curves of 12
patients had three phases. However, the slopes of the curves differed pre- and post-HD and
the curves varied among patients (Figure 23). In the goodness-of-fit plots (Figure 24), the
simulated and observed 14CO2 production rates are on or close to the diagonal line across
the 12 patients pre- and post-dialysis. There are data points slightly off from the diagonal
line in the patients of ID = 5, ID = 6, and ID = 15. These may be caused by the actual
sample collection times that deviated from the planned sample collection times since the
breath samples were intensively collected within the two hours. However, considering that
the general decision criterion for acceptable PBPK model simulation as high as 2-fold of
the observed Cmax and AUC [76, 90, 93, 101, 102] as discussed in Section 3.5, the iPBPK-R
model fitting performed well pre- and post-HD. The parameter estimates of hepatic CYP3A4
and uptake transport activities were consistent with those in healthy subjects [105]. Thus,
CYP3A4 activity was estimated to be lower than the IVIVE-based CYP3A4 activity in all
patients. An increase in CYP3A4 activity from pre- to post-HD of just 2.2% on average was
observed. Although the 2.2% increase in post-HD CYP3A4 activity is numerically small, it
represents a change in rate and quite possibly could have enough of an effect to increase the
20-minute 14CO2 flux of EBT after hemodialysis because the value affects an exponential
term of the solution of the model. Whether or not a 2.2% increase in post-HD CYP3A4
activity is clinically significant is unclear. The effect of hemodialysis on in vivo CYP3A4
activity has not been estimated in individual patients while accounting for system- and drug-
specific parameters and their dependency using the phenotypic probe erythromycin to date.
Establishing a threshold for changes in activity of CYP3A4 (as well as other nonrenal clear-
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ance pathways) for clinical applications will require extensive research within the context of
individual drugs, i.e., accounting for pharmacologic and pharmacotherapeutic considerations
such as a drug’s therapeutic window. However, it is clear that a small change in CYP3A4
activity estimated by iPBPK-R is impactful enough to alter the shape of the 14CO2 pro-
duction rate-time curves after controlling for other dependent parameters. This was shown
in the part of our previous sensitivity analysis in healthy subjects [105], in Figure 20(A)
where a small %change in adjustment factor14 alters the 14CO2 production rate-time curve
dramatically, and was reproduced in the present study. Note that depending on observed
data, it is possible to see a case where a dynamic change in 14CO2 production rate-time
curve is observed while zero %change is estimated for the adjustment factor for CYP3A4
activity from pre- to post-hemodialysis because the effects of other dependent adjustment
factors affect the 14CO2 production rate-time curve. To understand the clinical meaning of
specific adjustment factors in the system built in iPBPK-R, more observed data is necessary
to evaluate their relationships with clinical outcome, biomarkers, ideally in different patient
cohorts (e.g., if it’s kidney disease, patients in different stages including the end-stage on- and
off-hemodialysis). Because of this reason, again, establishing a clinical meaningful thresh-
old for adjustment factors requires formally designed clinical research/program as discussed
above, potentially in a collaborative manner.
The results of our iPBPK-R analysis suggest that OATP activity (meta-uptake trans-
porter) did not increase from pre- to post-HD (Figure 26 (C)). Uptake transporter activity
pre- and post-HD was variable ranging from 10% to 110% of the IVIVE value. We and
others have previously shown that transporter function, likely hepatic OATP uptake, is de-
creased in patients with kidney disease, including patients with ESRD receiving hemodial-
ysis [30, 92, 93, 209, 210, 216]. While OATP activity recovers after kidney transplantation
and restoration of kidney function [216], the effect of intermittent hemodialysis on OATP
function has not been assessed previously. Although the originally published data that we
employed in the present work showed an increase in 20-minute 14CO2 flux post-HD, the effect
of hemodialysis on OATP activity was not interpreted and unclear as erythromycin was as-
14The adjustment factor for CYP3A4 activity in Figure 20(A) is treated as an independent parameter, so
its clinical role in multiple functionally dependent adjustment factors need to be evaluated in a well-designed
prospective clinical study.
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sumed to be a phenotypic probe for CYP3A4 [128]. Tan et al. reported that OATP activity
decreases with declining kidney function [92,93]. However, OATP activity between patients
with ESRD during off-dialysis periods versus patients on-dialysis periods was inconclusive.
Even if a small improvement in OATP activity is elicited by hemodialysis it is likely to be
difficult to detect due to the high interindividual variability in uptake transport observed in
the patients with ESRD across hemodialysis. This estimated variability may also explain
visually observed heterogeneity in the 14CO2 production rate-time curve among 12 patients
pre- and post-HD (Figure 23). The 20-minute 14CO2 flux of the observed data showed CV
values of 34% and 35% pre- and post-HD, respectively [127], which is viewed as a result of
projection of a trajectory in a high dimensional space (as a solution of a system of nonlinear
ODEs) to one plane in iPBPK-R as detailed in Chapter 2. iPBPK-R allowed us to differenti-
ate the multiple functionally dependent adjustment factors and to estimate them, including
the adjustment factor for OATP activity that showed a large variability. This estimated
large variability aligns with the meta-analysis literature [68] as discussed in Section 3.5, and
thus it presents the soundness of the iPBPK-R method. Our findings regarding the effect
of hemodialysis on OATP activity are exploratory and they should be confirmed in future
well-planned, independent clinical studies.
We observed sex-differences in CYP3A4 activity pre- and post-HD (Figure 28). Higher
CYP3A4 activity in females was also observed in the EBT study of healthy subjects in
Chapter 3 [105]. This is also supported by a study of human liver bank samples where
expression levels of CYP3A4 were higher in females than in males [173]. On the other hand,
a correlation between CYP3A4 activity and age was observed in all patients pre- and post-
HD. An age-dependent change in CYP3A4 activity cannot be excluded as a confounder even
though it was excluded in our previous study [105].
The co-optimized adjustment factor for hepatocyte volume was largely variable across
patients and it was higher in females than males on average (Table 20). This result is
intuitively contrary from what we expected relative to sex. A possible explanation for this
sex-difference is that iPBPK-R uses a reduced order model and thus simulates for total
hepatocyte volume. Accordingly, instead of modeling the detailed sex-difference in total
hepatocyte volume, the adjustment factor for hepatocyte volume may have reflected the
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sex-difference in the composition of hepatocyte such as proteasomes and lipids [217, 218].
However, the exact reason is unclear.
Generally, if patients experience an improved uremic state and an increased activity of
OATPs or CYP3A4, a negative correlation will be observed between uremic solutes and clear-
ance activities. BUN was not statistically correlated with any of the nonrenal elimination
pathways in our patient cohort. This result differed from the study in healthy subjects in
Chapter 3 [105] where BUN was inversely correlated with nonrenal elimination parameters.
Since BUN was well dialyzed in all patients (Figure 30(D)), it may not have an ability to
differentiate changes in nonrenal elimination pathways that were highly inter-variable in the
patient cohort. Thus, BUN may not serve as a candidate biomarker for evaluating the nonre-
nal drug disposition in the patient population of ESRD. The observed relationships between
TNF-α and total passive diffusion of 14C-erythromycin between the extracellular space and
hepatocyte varied pre-HD, post-HD, and from pre- to post-HD, showing inverse correlation,
no correlation, and positive correlation, respectively (Table 21). Whether TNF-α has an
impact on 14C-erythromycin passive diffusion has not been reported previously.
The exploratory HCA identified two patients who showed improved CYP3A4 activity.
The observed decrease of iPTH in two patients was well separated from the other patients
(with no statistical power). PTH is known to decrease CYP3A activity in rats [219, 220].
While a direct relationship between PTH and CYP3A4 has not been evaluated clinically,
Michaud et al. showed that uremic pre-HD serum obtained from patients with ESRD de-
creased CYP3A4 activity compared to serum obtained from healthy subjects in a rat liver
microsome stability assay [205]. Post-HD serum of the same patients improved the CYP3A4
activity compared to the pre-HD serum (but not to the level of CYP3A4 activity shown with
the serum from the healthy subjects) . Separately, it is known that elevated PTH can occur
as hyperparathyroidism in patients with renal insufficiency [221], and it has also been shown
that dialysis removes serum iPTH in patients with ESRD [207, 208]. These together might
indicate that it is important to explore the patient population in ESRD in greater depth,
which may solicit unique biomarker-based responders within the heterogeneous population.
The purpose of this HCA analysis is to just suggest a new approach and its feasibility, i.e.,
using iPBPK-R-based parameter estimates in a subsequent exploratory analysis of uremic
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toxins (as an example) in the context of hypothesis-generating research. When combined
with HCA analysis, iPBPK-R may have the potential to become a tool that can inform
which uremic toxin(s) to explore as well as which patients may respond to an intervention.
Our approach can be viewed as an illustration of a first step of biomarker reserach and this
could eventually support biomarker-based precision medicine approaches in patients with
kidney disease in a well-designed large clinical study.
This study has several limitations: (1) Due to the nature of the reduced order model, mul-
tiple uptake OATP transporters were modeled as a meta-transporter. (2) 14C-erythromycin
and erythromycin were not differentiated in IVIVE calculations. The two compounds are
often used indistinguishably in clinical research. (3) Genetic variant data of OATPs was not
available, which did not allow us to investigate the cause of the observed variability in the
OATPs activity. (4) We used population IVIVE values calculated for a 70 kg male. The
variability in body size may be partly reflected in the adjustment factor for the total hep-
atic volume. (5) The fitted iPBPK-R models cannot be validated against the measurements
other than the 14CO2 production rate data. We showed the excellent model fit via visual
inspection and goodness-of-fit plots across all individual patients. Our analysis establishes
that the model was not overfit.
4.6 Conclusions
In this chapter, nested co-optimized iPBPK-R models allowed us to simultaneously es-
timate the effect of hemodialysis on the multiple non-renal elimination pathways of 14C-
erythromycin in individual patients with ESRD. iPBPK-R results indicate that CYP3A4
activity increased by 2.2% post-HD. Although OATP activity did not increase post-HD, it
exhibited high interindividuality, which likely contributes to the heterogeneity in the14CO2
production rate-time curves among patients. To our knowledge, this is the first study to
apply iPBPK-R to quantify and simultaneously characterize the effect of hemodialysis on
nonrenal elimination pathways in patients with ESRD while accounting for system- and
drug-specific parameters and their dependency using a single phenotypic probe. Although it
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is exploratory, other findings included that females had higher CYP3A activity than males
pre- and post-HD. Hierarchical cluster analysis with iPBPK-R may provide mechanistic in-
sights as two patients were identified to show a greater decrease in iPTH and a greater
increase in CYP3A4 activity compared to the other patients after hemodialysis. iPBPK-R
can be applied to multiple sets of rate data from repeated administrations of a single probe
in order to evaluate alteration in drug disposition in individual patients.
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5.0 Simultaneous Assessment of the Effect of Rifampin on Hepatic Transport
and Metabolism Pathways using iPBPK-R Modeling of Temsirolimus and its
Metabolite Sirolimus
5.1 Abstract
Temsirolimus, used to treat renal cell carcinoma by intravenous dosing, is a nonrenally
cleared drug with overlapping substrate specificity for enzymes and transporter. We evalu-
ated the ability of our iPBPK-R to distinguish and simultaneously estimate the contributions
of nonrenal elimination pathways mediated by CYP3A4 and P-gp to the disposition of tem-
sirolimus and its metabolite sirolimus within healthy individuals. We also estimated the
effect of co-administered rifampin on the elimination pathways. A reduced order PBPK
model was built for temsirolimus and sirolimus. Linear CYP3A4 clearance and nonlinear
P-gp clearance with a Michaelis-Menten term were included in hepatocyte-related equations.
Thirteen PBPK parameters were selected for nested co-optimization on the Bridges super-
computer based on sensitivity analysis using four time series of blood concentrations of a
DDI study with rifampin. Scaling factors (induction/inhibition coefficients) for CYP3A4 and
P-gp activity were estimated to evaluate the effect of rifampin. iPBPK-R simultaneously
captured the time-dependent behavior of concentrations of temsirolimus and sirolimus in 15
healthy subjects. The estimated scaling factors1 indicated that rifampin did not affect the
CYP3A4-mediated pathway of temsirolimus but increased CYP3A4 clearance of sirolimus
by 73%2. P-gp transport of temsirolimus and sirolimus was not altered by rifampin. The ap-
plication of iPBPK-R to the four sets of drug concentration data enables us to differentially
quantify the extent and changes of P-gp versus CYP3A4-mediated elimination pathways of
temsirolimus and sirolimus in a DDI study with rifampin in healthy individuals.
1These iPBPK-R’s scaling factors were included to measure the effect of rifampin on CYP3A4 and P-gp
clearances in the system of nonlinear ODEs for temsirolimus and sirolimus. In our model, esterase activity
was assumed to be constant during the study (see Section 5.3.5).
2The scaling factors were designed to indicate a decrease if its estimated value is less than 1; an increase
if the estimated value is greater than 1. See Section 5.3.6.
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5.2 Introduction
Temsirolimus formulated for intravenous infusion was approved by the FDA in 2007,
and it is a first-in-class mammalian target of rapamycin (mTOR) inhibitor for treating
advanced renal cell carcinoma [222, 223]. Inhibiting mTOR, a kinase enzyme which plays
a central role to control cell growth, proliferation, metabolism and angiogenesis, confers
an anti-cancer effect [224, 225]. Temsirolimus undergoes hepatic elimination via multiple
pathways [226], mainly CYP3A4 and efflux drug transporter P-gp [227]. Its major metabolite
sirolimus (known as rapamycin) is also pharmacological active [227,228]. The conversion from
temsirolimus to sirolimus is mediated by esterase, which is a different metabolism pathway
from CYP-dependent pathways [229–232]. Sirolimus itself is used as an immunosuppressant
and it is suggested to be a dual substrate of CYP3A4 and P-gp in vitro3 [228,233]. However,
the extent of their contributions or interplay in the non-renal clearance of each compound
is unclear [234–237]. Both temsirolimus and sirolimus in the class of mTOR inhibitors have
shown large interindividual variability in drug concentration profiles, which is essential to be
accounted for in drug dosing [236,238,239]. The concern of interindividual variability and the
overlapping dual substrate specificity of the parent drug and its metabolite provide a unique
opportunity to evaluate the contributions of nonrenal elimination pathways in individuals.
We apply iPBPK-R to the drug concentration data of temsirolimus and sirolimus to extract
physiological parameter information and specifically evaluate hepatic enzyme and transporter
activities.
Estimating multiple contributions of drug elimination pathways in the liver is challeng-
ing as we cannot directly access information to measure in vivo activities. We previously
developed and applied iPBPK-R to two cohort datasets of EBT to simultaneously estimate
parameters of non-renal elimination activities, including uptake drug transporter OATPs
and CYP3A4 enzyme [105, 106]. The iPBPK-R method utilizes production rate or the first
derivative measurement of drug concentration data since such data are more sensitive to un-
derlying physiological parameters than drug concentration data [105,134,152]. In this study
3Temsirolimus is intravenously administered due to poor bioavailability [227], and data on bioavailability
and intestinal uptake of temsirolimus are not publicly available.
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we extend the application of iPBPK-R to multiple coupled drug concentration datasets per
individual instead of production rate data. The dataset of intravenously administered tem-
sirolimus and its metabolite sirolimus concentration measurements together provide the rate
information in the model fit with the system of nonlinear ODEs so that multiple parameters
for non-renal elimination activities can be simultaneously estimated. In the application of
iPBPK-R, the overlapping substrate specificity is currently a necessary property.
Classical population PK modeling of temsirolimus and sirolimus was shown by Boni et
al. using the original PK DDI study of temsirolimus with the concomitant drug rifampin
in healthy subjects [240]. Based on the PK analysis of IV temsirolimus and its metabo-
lite sirolimus, rifampin did not change the mean AUC, Cmax, or t1/2 of IV temsirolimus
but decreased the mean AUC by 56%, Cmax by 65%, and t1/2 by 20% of sirolimus. In ad-
dition, they also analyzed PK profiles of PO temsirolimus which differed with and without
rifampin. Rifampin is as well-known in vivo inducer of CYP3A4 and typically used in clinical
DDI studies [241]. For example, rifampin dramatically decrease PK profile of the sensitive
CYP3A4 index substrate midazolam in a healthy cohort [241–243]. Rifampin also serves as
an inducer for CYP2C19, CYP1A2, CYP2B6, CYP2C8, and CYP2C9. Furthermore, P-gp
activity is also reported to be affected by rifampin [244]. As rifampin generally increases
the hepatic and intestinal CYP3A4 activity, Boni et al. concluded that rifampin induces
the hepatic metabolism of sirolimus but not the hepatic metabolism of IV temsirolimus.
In their population PK modeling, only CYP3A4 activity was evaluated without accounting
for other nonrenal elimination pathways. In fact, it is not possible to specifically estimate
in vivo CYP3A4 activity and account for multiple nonrenal elimination pathways by using
population PK modeling applied to just one type of DDI data (i.e., PK study data of IV
temsirolimus alone and IV temsirolimus plus rifampin).
In this chapter, our goal is to simultaneously estimate multiple parameters of the non-
renal elimination activities and demonstrate its feasibility to facilitate the use of iPBPK-R.
By introducing induction and inhibition coefficients as part of scaling factors in iPBPK-R
we evaluated the effect of co-administered rifampin on the nonrenal elimination pathway
activities in healthy individuals. Here, we emphasize that our aim is to conduct multiple
parameter estimation given observed data but not prediction of drug concentration-time
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profiles. The aims of this work were (1) to differentially estimate contributions of nonrenal
clearance pathways to temsirolimus and sirolimus in healthy subjects, and (2) to investigate
the effect of rifampin on these pathways.
5.3 Method
5.3.1 Clinical Data Sources
The whole-blood concentration data of temsirolimus and its metabolite sirolimus were
obtained from clinical literature [240]. Briefly, the study of the observed data was an open-
label sequential study where the effect of multiple oral doses of the potent CYP3A4 inducer
rifampin on the PK profile of a single 25-mg IV dose was evaluated in healthy adults. The
study included two dosing periods; temsirolimus alone (Period 1), followed by temsirolimus
with concomitant rifampin (Period 2). Temsirolimus 25mg was administered as a single
30-minute IV infusion in both periods. Whole blood concentrations of temsirolimus and
sirolimus were serially measured at 13 timepoints (at 0 (as predose), and 0.5, 1, 2, 3, 8, 24,
48, 72, 96, 120, 144, and 168 hours) over 7 days in period 1 and repeated in period 2. All
subjects were to receive daily oral doses (2 × 300mg capsules) of rifampin from Days 15 to 27.
Period 2 began on Day 21 with repeat dosing of temsirolimus 25mg IV. All of the 16 enrolled
subjects were male, and 14 subjects were Caucasian. In iPBPK-R modeling, 15 individual
data were used since one withdrew and did not provide the data in the second period4. In
addition, in order to present the actual observed data and to illustrate the goodness-of-fit of
the iPBPK-R method in Figure 33, mean concentration data of temsirolimus and sirolimus
were digitized from the literature [240] using GetData Digitizer (version 2, www.getdata-
graph-digitizer.com) and they were plotted. Thus, these mean datasets were treated as
individual observed data solely for presenting visual performance of iPBPK-R to supplement
the limitation of the data confidentiality of the original individual data and not for evaluating
4We do not describe the individual data further as this work was conducted during the FDA ORISE
fellowship which is subject to the FDA data confidentiality under the Code of Federal Regulations Title 21
Part 20 [245].
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the parameter estimates in iPBPK-R.
5.3.2 PBPK Model Structure
A PBPK model consisting of seven organ/tissue compartments and sub-compartments
( 1©- 7© in Figure 31) was built with a set of physiological and kinetic parameters (i.e.,
PBPK parameters) for temsirolimus and sirolimus, respectively. The compartments included
were artery (Art), vein, lung (LG), liver (LV), kidney (KD), and combined other organs
(OT). The liver compartment consisted of extracellular space (ES) and liver cell (LC) sub-
compartments. For each compound, total passive diffusion was included to model the drug
transfer between ES and LC. Furthermore, linear CYP3A4 clearance and esterase (EST)
clearance, and non-linear efflux transporter (P-gp) with maximum velocity and Michaelis-
Menten constante were modeled in LC. In LC, temsirolimus gets converted to sirolimus by
EST [229–232] and thus the two sets of models, one for temsirolimus and one for sirolimus, are
linked through the esterification of temsirolimus. Lastly, we also included a non-CYP3A4-
dependent metabolism pathway for the sirolimus model based on the literature [246] where
the metabolites formed by CYP3A4/3A5 approximately represented 10% of the total intrin-
sic clearance observed in in vitro experiments using human liver microsomes. Assuming that
abundance of CYP3A5 is very small and negligible in the liver [246,247], this non-CYP3A4-
dependent intrinsic clearance was denoted as CLNONCYP3A4(m). CLNONCYP3A4(m) was assumed
to be independent of esterase since temsirolimus is an ester analog of sirolimus [248].
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Figure 31: PBPK model structures of temsirolimus and sirolimus in iPBPK-R.
q−−→
W:Z
denotes a mass flow from W compartment to Z compartment and it is represented by an arrow. Similar to the mass
balance in the iPBPK-R application to EBT data (Appendix B.2), the mass balance is retained in the whole system.
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5.3.3 Ordinary Differential Equations, Kinetic Parameters, and Data Input
A set of ODEs describes drug concentration dynamics of all compartments for tem-
sirolimus and sirolimus, respectively. In iPBPK-R, vein and artery compartments were sep-
arately modeled as our previous publication [105]. Permeability-limited liver models were
used in the ODEs associated with ES and LC [101]. Based on the drug mass flows shown
in Figure 31 and following the similar procedure discussed in Chapter 3 (see Appendix
B), the set of ODEs was constructed as in Appendix C. Tables 26 and 27 provide PBPK
parameters for temsirolimus and sirolimus, respectively, some of which were calculated using
IVIVE equations. Note that the calculated IVIVE values of nonrenal elimination pathways
for temsirolimus are not shown in Table 26 due to the FDA data confidentiality under the
Code of Federal Regulations Title 21 Part 20 [245] similar to Section 5.3.1. Accordingly,
initial % contributions of these nonrenal elimination pathways cannot be shown. Derivation
of IVIVE equations for P-gp clearance and passive diffusion for sirolimus are described as
an example in Appendix D. These parameters were used as input values in the estimation
of scaling factors, which is described later.
5.3.4 Coupled Concentration Data and Reduced Order Model
The first derivative of concentration data or production rate data are mathematically
higher information content (i.e., it enables higher accuracy of estimated model parameters)
compared to equivalently sampled concentration data [105, 134, 152]. iPBPK-R was devel-
oped based on this concept and previously applied to breath sample data [105]. In this
chapter, we extend iPBPK-R application to multiple coupled drug concentration datasets
(i.e., temsirolimus and sirolimus blood concentration data) per individual since such coupled
multiple datasets are mathematically high information content via the system of ODEs. The
iPBPK-R model was simultaneously fit to the temsirolimus and sirolimus concentration-time
data of Period 1 and Period 2 (in the absence and presence of rifampin in the system, re-
spectively) via a nested co-optimization procedure. Multiple nonrenal elimination pathways,
i.e., enzymatic metabolism, efflux transport, and total passive diffusion parameters were es-
timated via scaling factors relative to IVIVE using the single IV dose of temsirolimus. The
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types of scaling factors used were: (1) co-optimized adjustment factors, (2) independent ad-
justment factors, and (3) scaling coefficients (induction or inhibition coefficients). To achieve
high precision in the iPBPK-R model fit, we used a reduced order model [198]. Reduced
order models are complex enough to capture the behavior of interest but manageable to be
well-posed, providing estimable parameters. For this mathematical reason, the total number
of compartments and sub-compartments was limited to seven in the same fashion of our
previous application [105].
5.3.5 Model Assumptions
Adopting the concept of reduced order model enabled us to present a goodness-of-fit in
iPBPK-R modeling of temsirolimus and sirolimus and to implement high-dimensional co-
parameter estimation. We performed the iPBPK-R modeling under the assumption listed
in Table 22.
5.3.6 Simulations and Optimizations
Concentration-time curves of temsirolilmus and sirolimus were simulated for individual
patients using the system of ODEs. The ODEs are shown in Appendix D (See Subsec-
tion 5.3.3 for the construction of ODEs).
Prior to conducting the high-dimensional parameter optimization for healthy subjects,
the impactful and/or biologically relevant parameters to shape the concentration-time curves
were identified using manual sensitivity analysis. The identified parameters we detail in outer
and inner loops below were found to be essential for fitting the model to the four series of
blood concentration data simultaneously.
iPBPK-R uses a nested co-optimization procedure, which consists of the inner loop
and outer loop to optimize PBPK parameters (Figure 32). In the outer loop, thirteen
scaling factors for the following PBPK parameters were optimized5: for the temsirolimus
5The number of observed samples per individual in this simultaneous PBPK model fit is 13 time points
× 4 datasets (for parent and metabolite drugs in Period 1 and 2) = 52 data points. Therefore, the number
of functionally dependent parameters to optimize here (i.e., 13 outer loop parameters) is sound since the
same argument in the analysis of iPBPK-R estimation using regularization in Section 2.4.7 applies.
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Table 22: List of assumptions used in iPBPK-R of temsirolimus and sirolimus for healthy
subjects
Number Assumption
1 The duration of intravenous dosing of temsirolimus was 30 minutes.
2 The iPBPK-R model is well-stirred [183, 199]. All compartments except for the
liver compartment are perfusion-limited.
3 Pathways from the extracellular space to the liver cells (ES → LC sub-
compartment)) for temsirolimus and sirolimus are total passive diffusion.
4 In the LC sub-compartment, there are CYP3A4 and esterase-mediated
metabolism pathways for temsirolimus. Esterification (hydrolysis) of tem-
sirolimus by esterase (EST) produces sirolimus. We assumed linearity for the
intrinsic clearance of CYP3A4 and esterase.
5 Sirolimus is metabolized by CYP3A4 [246] In addition, other metabolites of
sirolimus are reported in literature [229, 232, 249, 250]. These enzyme-mediated
pathway(s) were modeled as a meta linear non-CYP3A4 metabolism (i.e., non-
CYP3A4 clearance for sirolimus in the LC sub-compartment).
6 Both temsirolilmus and sirolimus are substrates of efflux drug transporter P-gp.
In the apical side of LC sub-compartment, these drug transport processes are
modeled to be non-linear elimination processes. We assumed that relative activity
factor (RAF) in the IVIVE-based intrinsic clearance of P-gp is commonly shared
between temsirolimus and sirolimus at the beginning of study.
7 Rifampin does not affect EST activity on temsirolimus.
8 As described in 3 to 6, the liver consisting of ES and LC sub-compartments is an
elimination organ. In addition, parameters µ and µ(m) were incorporated in the
OT compartment to explain the exponential decay of temsirolimus and sirolimus,
respectively. We expected that µ and µ(m) would improve the co-model fitting
of four series of datasets per individual. The exponential decay was assumed to
account for any loss or decomposition of the drug before the drug reaches the
liver within the system.
9 The unbound drug was subject to efflux transport, enzymatic metabolism, and
elimination in the liver.
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model, CYP3A4 clearance (CLCYP3A4), esterase clearance (CLEST), and partition coefficient
of the combined other organs to plasma (POT:P); for the sirolimus model, CYP3A4 clearance
(CLCYP3A4(m)), non-CYP3A4-dependent clearance (CLNONCYP3A4(m)), partition coefficient of
the combined other organs to plasma (POT:P(m)), and total passive diffusion between ex-
tracellular space and hepatocyte (QES−LC(m)); for both temsirolimus and sirolimus models,
maximum velocity of P-gp (assuming proportional Jmax,OUT1 and Jmax,OUT1(m)), volume of
total hepatocyte (VLC), arterial blood flow into the combined other organs (QArt,OT), venous
blood flow from the combined other organs (QVein,OT), volume of vein (VVein), and volume
of the combined other organs (VOT). These parameters were assumed to take a common
value between Period 1and Period 2, and thus they were co-optimized across periods within
individuals. These scaling factors are called as co-optimized adjustment factors. In model
fitting, a co-optimized adjustment factor measures the extent of the patient-specific baseline
adjustment from the population IVIVE (or an initial input value) through the entire study.
In the inner loop, one and seven scaling factors were independently optimized in the
respective study period: In Period 1, a scaling parameter for relative activity factor for
P-gp (RAF), which is a linear component of the IVIVE input [68]6, was optimized, and in
Period 2 scaling parameters for maximum velocity of P-gp for temsirolimus and sirolimus
(Jmax,OUT1 and Jmax,OUT1(m)) , CLCYP3A4, CLCYP3A4(m), CLNONCYP3A4(m), POT:P, and POT:P(m)
were optimized. The scaling parameter in Period 1 was included to adjust the IVIVE-based
intrinsic clearance for P-gp under an assumption that the RAF is commonly shared between
temsirolimus and sirolimus. The scaling parameters for P-gp in Period 2 are interpreted as
non-competitive induction or inhibition coefficients in the presence of rifampin. The scaling
coefficients for metabolic enzymes in Period 2 are used to evaluate induction and inhibition
of the enzyme activity in the presence of rifampin. If the coefficient value is estimated to be
within 0 to 1, then the biological activity is considered to be inhibited. If the coefficient value
is estimated to be greater than 1, the activity is considered to be induced. Scaling factors
were estimated via nested co-optimization that minimizes the errors of the fitted model of
temsirolimus and sirolimus.
6RAF is the expression ratio between in vivo and in vitro hepatocytes, which is one of the commonly
used factors appearing in IVIVE equations [68].
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The model fit was evaluated using average normalized residuals between predicted and
observed rates, visual inspection, and plausibility of the parameter estimates. Among the
PBPK parameters in Tables 26 and 27, outer loop and inner loop parameters described above
were selected for optimization.
Simulations and parameter co-optimization were implemented with R 3.4.4. The R pack-
age deSolve was used for solving the set of ODEs, and large-scale simulations were performed
via the Bridges supercomputer at the PSC [126]. Methodological details of iPBPK-R are
described in Chapter 2.
5.3.7 Statistical Analysis
Mean± SD and/or median (range) were used as descriptive statistics. Box plots were
created for visualization of estimation results. No statistical test was powered in advance
since the study explored feasibility and estimability. For comparing parameters between
Period 1 and Period 2, two-sided paired t-tests were conducted in case of normally distributed
measurements. Otherwise, two-sided Wilcoxon signed-rank tests were conducted. In all
comparisons a P-value < 0.05 was considered statistically significant. All statistical analyses
were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
5.4 Results
The iPBPK-R model was simultaneously fit to the four series of observed blood concen-
tration - time data, i.e., concentration data of temsirolimus and sirolimus in the absence of
rifampin (Period 1) and in the presence of rifampin (Period 2) in the 15 healthy subjects
(Figure 33). Due to the FDA data confidentiality under the Code of Federal Regulations
Title 21 Part 20 [245], the individual observed data are not shown (see Section 5.3.1). To
assess the goodness-of-fit of iPBPK-R, we calculated means (SDs) of the average normal-
ized residual of all model fits: 36.2% (9.2%) in Period 1 and 31.4% (10.5%) in Period 2 for
temsirolimus and 0.9% (0.3%) in Period 1 and 1.1% (0.2%) in Period 2 for sirolimus, all
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of which indicated a good model fit. Furthermore, the observed mean concentration-time
curves of temsirolimus and sirolimus were treated as data for one hypothetical individual,
and the observed mean plots and iPBPK-R-based simulated curves are shown in Figure 33.
The PK parameters of the observed and simulated curves in the hypothetical individual
are compared in Table 23. Cmax, t1/2, and AUC indicated that the simulated curves had
an early higher peak than the observed curve for temsirolimus while they indicated that
simulated and observed concentration-time curves are well comparable for sirolimus in both
study periods.
The nested co-optimization procedure yielded parameter estimates for all patients except
for the scaling parameter of RAF for P-gp in two subjects. In these two subjects, the
scaling parameter for RAF was resulted in 0 at baseline, suggesting that P-gp activity did
not mathematically have an essential role in the model. Accordingly, these subjects were
excluded from the analysis on P-gp. Figure 34 provides an example of 3D concentration-time
curve simulations in one healthy subject where the nested co-optimization leads to the final
model fit to temsirolimus and sirolimus in Period 1 and Period 2, simultaneously.
Table 24 shows 13 co-optimized adjustment factors for CLCYP3A4, CLEST, POT:P,
CLCYP3A4(m), CLNONCYP3A4(m), POT:P(m), QES−LC(m), Jmax,OUT1, VLC, QArt,OT, QVein,OT, VVein,
and VOT in the outer loop (Figure 32). The mean co-optimized adjustment factors for P-gp
activity on temsirolimus and sirolimus, CYP3A4 activity on temsirolimus, and the hepato-
cyte volume (Jmax,OUT1, CLCYP3A4, and VLC) were close to 1, respectively, indicating that
little adjustment of IVIVE or population input value was needed. The mean co-optimized
adjustment factors for the volume of blood and the volume of the combined other organs
(VVein, and VOT) were also closed to 1. The co-optimized adjustment factor for esterase
activity on temsirolimus (CLEST) was much higher than 1 (mean ± SD, 13.99 ± 0.05). The
co-optimized adjustment factors for CYP3A4 and non-CYP3A4-dependent enzyme activi-
ties on sirolimus were estimated to be lower than 1 (0.15 ± 0.05 for CLCYP3A4(m) and 0.03
± 0.05 for CLNONCYP3A4(m), respectively) while the co-optimized adjustment factor for the
passive diffusion of sirolimus between extracellular space and hepatocyte was quite large
and inter-individually variable (200.09 ± 0.32 for QES−LC(m)). In the OT compartment, all
co-optimized adjustment factors differed from 1 (0.23 ± 0.05 for POT:P(m), 0.30 ± 0.06 for
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POT:P(m), 0.19 ± 0.04 for QArt,OT, and 0.23 ± 0.04 for QVein,OT) (Table 24). These adjust-
ment factors in the OT compartment do not provide biological implication, but they were
optimized for the purpose of model fitting similarly to our other iPBPK-R studies [105,106].
In the inner loop, a scaling factor for RAF of P-gp in Period 1 and other scaling coeffi-
cients in Period 2 were estimated independently (Table 25 and Figure 32). In Figure 35(A)
and Table 25, P-gp activity on both temsirolimus and sirolimus did not alter by rifampin
since the scaling factors (induction or inhibition coefficients) were not significantly differ-
ent from 1 (0.98 ± 0.07, p=0.95 for temsirolimus; 1.05 ± 0.10, p=0.10 for sirolimus). In
Figure 35(B) and Table 25, the scaling factor for RAF of P-gp was estimated to be lower
than 1 and interindividually variable at Period 1 (0.36 ± 0.31, p<0.0001). In Figure 36
and Table 25, the estimated scaling factors (induction/inhibition coefficients) indicated that
rifampin did not change CYP3A4-mediated clearance of temsirolimus (scaling coefficient
0.95 ± 0.17, p=0.72) but significantly increased the CYP3A4 and non-CYP3A4-dependent
metabolic activities on sirolimus by 73% and 153%, respectively (1.73 ± 0.52, p<0.0001 for
CLCYP3A4(m); 2.53 ± 0.52, p<0.0001 for CLNONCYP3A4(m)). The interindividual variability
of the induction/inhibition coefficient of CYP3A4 activity was also large for sirolimus. Ri-
fampin altered scaling factors for partition coefficient on temsirolimus and sirolimus in OT
(Table 25). These parameters in the combined other organs (i.e., a lumped-up compartment)
were selected for independent optimization between study periods to achieve a good model
fit. The resulted scaling factors indicate that rifampin altered mass flows of temsirolimus
and sirolimus among the non-hepatic compartments.
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Nested 13-parameter estimation for Period 1 
 (temsirolimus and sirolimus in the absence of rifampin) 
Outer loop –  co-optimized IVIVE adjustment factors 
o For the temsirolimus model,  
• CYP3A4 clearance for temsirolimus (CLCYP3A4) 
• Esterase clearance for temsirolimus (CLEST) 
• Partition coefficient of the combined other organs to plasma (POT:P) 
o For the sirolimus model,  
• CYP3A4 clearance for sirolimus (CLCYP3A4(m)) 
• Non-CYP3A4-dependent clearance for sirolimus (CLNONCYP3A4(m)) 
• Partition coefficient of the combined other organs to plasma (POT:P(m)) 
• Total passive diffusion between ES space and LC (QES-LC(m)) 
o For both temsirolimus and sirolimus models,  
• Maximum velocity of P-gp (assuming proportional Vmax, OUT1 and Vmax, OUT1(m)) 
• Volume of hepatocyte (VLC) 
• Arterial blood flow into the combined other organs (QArt,OT) 
• Venous blood flow from the combined other organs (QVein,OT) 
• Volume of vein (Vvein) 
• Volume of the combined other organs (VOT) 
Inner loop –  independent IVIVE adjustment and model fitting 
• Scaling parameter for relative expression factor (REF) for P-gp 
Nested 13-parameter estimation for Period 2  
 (temsirolimus and sirolimus in the presence of rifampin) 
Outer loop –  co-optimized IVIVE adjustment factors 
• The same as Period 1 in all models 
Inner loop –  independent IVIVE adjustment and model fitting 
• Scaling coefficient α1 for Vmax, OUT1 
• Scaling coefficient α2 for CLCYP3A4  
• Scaling factor for POT:P 
• Scaling coefficient α*1 for Vmax, OUT1(m) 
• Scaling coefficient α*2 for CLCYP3A4(m) 
• Scaling coefficient α*3 for CLNONCYP3A4(m) 
• Scaling factor for POT:P(m) 
Individualized PBPK modeling of temsirolimus and sirolimus  
in healthy subjects 
13-parameter co-optimization in outer loop per iteration 
Note: A scaling coefficient 
ranges between 0 and 4. 
0 to 1: inhibition coefficient 
1 to 4: induction coefficient 
Figure 32: Framework of the application of iPBPK-R to the four time series of blood con-
centration data of a drug-drug interaction study of temsirolimus with rifampin in 15 healthy
individuals.
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Figure 33: iPBPK-R simultaneous model fitting to the individual concentration data of temsirolimus and sirolimus in the
absence and presence of rifampin from the 15 healthy subjects.
The black lines and dashed gray lines are modeled curves in Period 1 (without rifampin) and in Period 2 (with rifampin),
respectively. We also showed the simulated curves and observed plots of the mean concentration data treated as a hypothetical
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individual to show the goodness-of-fit of iPBPK-R. Mean observed data are shown with open squares for Period 1 and black
triangles for Period 2. Individual observed plots are not shown due to data confidentiality under the Code of Federal Regulation
Title 21 Part 20 [245].
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Figure 34: An example of 3D blood concentration-time curve simulations for temsirolimus
and sirolimus in one healthy individual.
The nested co-optimization simultaneously leads to the final model fit in Period 1 and Pe-
riod 2. The 3D curves for temsirolimus are shown in the left panel and 3D curves for sirolimus
are shown in the right panel. The curves in the red–yellow–red color transition are the simu-
lated curves in the absence of rifampin (Period 1) and the curves in the blue–green–blue color
transition are the simulated curves in the presence of rifampin (Period 2) during the nested
parameter co-optimization (high-dimensional parameter estimation). Both curves were si-





Relative Activity Factor (RAF) for P-gp activity  
at Baseline (Period 1)  
RAF of P-gp (N=13) 
Figure 35: Box plots of estimated scaling factors.
(A) Estimated scaling factors (induction/inhibition coefficients) for P-gp activity on tem-
sirolimus and sirolimus in the presence of rifampin (Period 2) compared to the baseline
without rifampin (Period 1) in the liver. (B) Estimated scaling factor for relative activity







Figure 36: Box plots of estimated induction/inhibition coefficients for CYP3A4 activity on
temsirolimus, CYP3A4 activity on sirolimus, and non-CYP3A4 activity on sirolimus in the
presence of rifampin (Period 2) compared to the baseline without rifampin (Period 1) in the
liver.
?? indicates a statistically significant difference from 1 at a significance level of 0.01. N = 15
in all box plots.
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Cmax(ng/mL) 512 954 1.86 50.6 52.8 1.04
tmax(hr) 0.53 0.5 NA
c
t1/2(hr) 23.0 13.1 69.4 38.3
AUC (ng·h/mL) 2056 1907 0.93 4564 4911 1.08
With rifampin
Cmax(ng/mL) 532 951 1.79 17.7 26.7 1.51
tmax(hr) 0.47 0.5 NA
c
t1/2(hr) 22.6 14.3 55.1 63.4
AUC (ng·h/mL) 1879 1715 0.91 2004 1940 0.97
aThe PK parameter values were obtained from literature [240]. bThe PK parameters of simulated iPBPK-R data were calculated
using a standard noncompartmental method in Phoenix WinNonlin 8.2. cNot available in the literature. dRatio (relative
difference) of simulated to observed PK parameters.
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Table 24: Co-optimized parameter estimates via the nested co-optimization in the iPBPK-R modeling of temsirolimus and
sirolimus in 15 healthy subjects across two study periods
Co-optimized parameter Drug modeled with the opti-
mized parameter
Mean ± SD Median (Range)
IVIVE or input adjustment for:
CYP3A4 clearancea Temsirolimus 1.01 ± 0.02 1.01 (0.97, 1.04)
Esterase clearancea Temsirolimus 13.99 ± 0.05 13.99 (13.90,14.15)
Partition coefficient in the combined other or-
gans
Temsirolimus 0.23 ± 0.05 0.25 (0.12, 0.31)
CYP3A4 clearancea Sirolimus 0.15 ± 0.05 0.14 (0.08, 0.31)
Non-CYP3A4-dependent clearancea Sirolimus 0.03 ± 0.04 0.02 (0.00, 0.15)
Partition coefficient in the combined other or-
gans
Sirolimus 0.30 ± 0.06 0.28 (0.24, 0.42)
Total passive diffusion between ES and LC Sirolimus 200.09 ± 0.32 200.00 (199.87, 201.23)
P-gp maximum velocityab Temsirolimus and sirolimus 1.02 ± 0.09 1.00 (0.95, 1.32)
Hepatocyte volume Temsirolimus and sirolimus 0.98 ± 0.05 1.00 (0.86, 1.02)
Arterial blood flow in the combined other or-
gans
Temsirolimus and sirolimus 0.19 ± 0.04 0.19 (0.09, 0.28)
Venous blood flow from the combined other
organs
Temsirolimus and sirolimus 0.23 ± 0.04 0.22 (0.18, 0.30)
Volume of blood compartment Temsirolimus and sirolimus 1.04 ± 0.04 1.03 (0.95, 1.16)
Volume of the combined other organs Temsirolimus and sirolimus 1.05 ± 0.15 1.00 (0.93, 1.46)
IVIVE, in-vitro in-vivo extrapolation; CYP3A4, cytochrome P450 3A4; P-gp, P-glycoprotein;
aThe adjustment factor measures the baseline deviation from IVIVE. bThe sample size was 13 since P-gp clearance did not
mathematically have an essential role as a result of iPBPK-R model fit in two healthy subjects.
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Table 25: Independent parameter estimates via the nested co-optimization in the iPBPK-R modeling of temsirolimus and
sirolimus in 15 healthy subjects in Period 1 (without rifampin) and Period 2 (without rifampin), respectively
Independently optimized parameter Drug modeled with the opti-
mized parameter
Mean ± SD Median (Range) P-valuec
Induction/inhibition coefficienta in Period 2
for:
Maximum velocity of nonlinear P-gp
clearanceb
Temsirolimus 0.98 ± 0.07 1.00 (0.82, 1.05) 0.95
CYP3A4 clearance Temsirolimus 0.95 ± 0.17 1.00 (0.38, 1.08) 0.72
Maximum velocity of nonlinear P-gp
clearanceb
Sirolimus 1.05 ± 0.10 1.03 (0.80, 1.28) 0.10d
CYP3A4 clearance Sirolimus 1.73 ± 0.52 1.55 (1.32, 2.77) < 0.0001??
Non-CYP3A4-dependent clearance Sirolimus 2.53 ± 0.11 2.52 (2.24, 2.79) < 0.0001??
Scaling factor for:
Partition coefficient in OT in Period 2 Temsirolimus 1.29 ± 0.70 1.15 (0.84, 3.59) 0.04?
Partition coefficient in OT in Period 2 Sirolimus 2.32 ± 0.05 2.34 (2.20, 2.38) < 0.0001??
RAF for P-gp in Period 1b Temsirolimus and sirolimus 0.36 ± 0.31 0.32 (0.00, 1.11) < 0.0001d??
CYP3A4, cytochrome P450 3A4; P-gp, P-glycoprotein; RAF, relative activity ratio; OT, the combined other organs compart-
ment
aAn induction/inhibition coefficient value < 1.0 means that the biological activity is inhibited. If the value is > 1.0, the activity
is considered to be induced. The value 1.0 was used as a null hypothesis for all statistical testing. bThe sample size was 13
since P-gp clearance did not mathematically have an essential role as a result of iPBPK-R model fit in two healthy subjects.
cWilcoxon signed rank tests were conducted. ; dOne-sampled t-tests were conducted. ? and ?? indicate a statistically difference
from 1.0 in the presence of rifampin at a significance level of 0.05 and 0.01, respectively.
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Table 26: Parameters used for iPBPK-R simulations of temsirolimus for healthy subjects
Description (units) Notation Value Reference/Comments
Intravenous dose of tem-
sirolimus (mg)
25 [240]
Volume of kidney (L) VKD (= V4) 0.270 [184]
Volume of lung (L) VLG (= V1) 0.775 [184]
Volume of vein (L) Vvein (= V2) 2.700 [184]
Volume of the combined other
organs (L)
VOT (= V3) 372.67 Calculated [184,251–254]
Volume of artery (L) Vart (= V5) 2.700 [184]
Volume of extracellular space
in the liver (L)
VES (= V6) 0.340 Calculated [101,184,185]
Effective volume of Extracel-
lular space in the liver (L)
VES,eff (= V
′
6) 0.4313 Calculated with approxi-
mation [101,255]
Volume of hepatocyte (L) VLC (= V7) 1.139 Calculated [101,184,185]
Blood flow of kidney (L/hr) QKD (= Q4) 66 [5]





Calculated based on total
clearance [240] and % re-
nally excreted [256]
Total body blood flow (L/hr) QTotal (= Q1) 300 [5]
Blood flow of the combined
other organs (L/hr)
QOT (= Q3) 136 Calculated [5]
Blood flow of hepatic artery
(L/hr)
QLV,Art (= Q5) 98 Calculated [186]; Portal
blood hepatic artery blood
flow were combined to sim-
plify the model
Blood flow of hepatic vein
(L/hr)
QLV,Vein (= Q2) 98 [186]
Total passive diffusion be-
tween extracellular space and
hepatocyte (L/hr)
QES−LC (= Q67) NA Approximated with a cal-
culated value [5,67,68,227,
257–259]






NA Calculated [5, 67, 159, 227,
259]
Clearance via esterase (L/hr) CLEST CLCYP3A4 Assumed to be the same as
CLCYP3A4 as an initial in-
put
Fraction unbound in blood fu,BL (= fb) 0.15 [261]
Fraction unbound in extracel-
lular space
fu,ES (= f6) 0.261 Calculated Khor et al.
[189]8
8fu,ES was calculated applying the assumption proposed for general physiological PK modeling by Khor
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Table 26: Parameters used for iPBPK-R simulations of temsirolimus for healthy subjects
Description (units) Notation Value Reference/Comments
Fraction unbound in hepato-
cyte
fu,LC (= f7) 0.167 Calculated [262–264]
Volume of distribution at
steady state (L/kg)
VSS NA [259]
Partition coefficient of lung to
plasma
PLG:P 26.28 Calculated [184,195,196]
Partition coefficient of the
combined other organs to
plasma
POT:P 7.58 Calculated [184,195,196]
Partition coefficient of blood
to plasma
PBL:P (= Pb) NA [259]
Partition coefficient of kidney
to plasma
PKD:P 9.565 Calculated [184,195,196]
Partition coefficient of hepa-
tocyte to plasma
PLC:P (= P7p) 6.87 Calculated [184,195,196]
Partition coefficient of extra-
cellular space to plasma
PES:P (= P6p) 6.87 Calculated [184,195,196]
Michaelis constant of P-gp
(mmol/hr)
Km,OUT1 (= Kb) NA Calculated [227,259]
Exponential decay in the com-
bined other organs (L/hr)
µ 12.5 Assumed based on sensi-
tivity analysis
NA, not available due to the FDA data confidentiality under the Code of Federal Regulations
Title 21 Part 20 [245], the individual observed data are not shown.
et al. to our modeling. This assumption was ’the blood protein to which the drug binds is also present in
interstitial fluid and that the association binding constant is the same in both blood and interstitial fluid’
[189]. It is not clear which particular protein binds to temsirolimus (or sirolimus). However, extracellular
space matrix (ECM) is known to have many proteins such as fibrillar collagens, proteoglycans, growth factors,
cytokines, chemokines, enzymes, among others [193]. We treat these proteins in ECM in the liver as a general
protein that can bind to temsirolimus in the modeling.
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Table 27: Parameters used for iPBPK-R simulations of sirolimus for healthy subjects
Description (units) Notation Value Reference/Comments
Volume of kidney (L) VKD (= V4) 0.270 [184]
Volume of lung (L) VLG (= V1) 0.775 [184]
Volume of vein (L) Vvein (= V2) 2.700 [184]
Volume of the combined other or-
gans (L)
VOT(m) (= V3) 271.92 Calculated [184,251–254]
Volume of artery (L) Vart (= V5) 2.700 [184]
Volume of extracellular space in the
liver (L)
VES (= V6) 0.340 Calculated [101,184,185]
Effective volume of Extracellular
space in the liver (L)
VES,eff(m) (= V
′
6) 0.967 Calculated with approxi-
mation [101,255]
Volume of hepatocyte (L) VLC (= V7) 1.139 Calculated [101,184,185]
Blood flow of kidney (L/hr) QKD (= Q4) 66 [5]
Renal clearance of sirolimus (L/hr) CLR(m) 0.0 Assumed [249,265]
Total body blood flow (L/hr) QTotal (= Q1) 300 [5]
Blood flow of the combined other or-
gans (L/hr)
QOT (= Q3) 136 Calculated [5]
Blood flow of hepatic artery (L/hr) QLV,Art (= Q5) 98 Calculated based on [186];
Portal blood hepatic artery
blood flow were combined
to simplify the model
Blood flow of hepatic vein (L/hr) QLV,Vein (= Q2) 98 [186]
Total passive diffusion between ex-




0.921 Calculated [5, 67, 68, 233,
258, 266]; Also see Ap-
pendix D
Clearance via Pgp (L/hr) CLOUT1(m) 74.07 Calculated [5, 67, 68, 233,
258, 266]; Also see Ap-
pendix D
Clearance via CYP3A4 (L/hr) CLCYP3A4(m) (=
Qcyp)
844.7 Calculated [5, 246,247]
Clearance via non-CYP3A4 depen-
dent metabolism (L/hr)
CLNONCYP3A4(m) 3065.67 Calculated assuming that
abundance of CYP3A5 was
very small and negligible
[246,247]
Fraction unbound in blood fu,BL(m) (= fb) NA [259]
Fraction unbound in extracellular
space
fu,ES(m) (= f6) NA [189,259]
9
Fraction unbound in hepatocyte fu,LC(m) (= f7) 0.416 Calculated [249,263]
9fu,ES(m) was calculated applying the assumption proposed for general physiological PK modeling by
Khor et al. to our modeling. See the comments on fu,ES in Table 26. The same argument applies to protein
binding regarding fu,ES(m).
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Table 27: Parameters used for iPBPK-R simulations of sirolimus for healthy subjects
Description (units) Notation Value Reference/Comments
Volume of distribution at steady
state (L/kg)
VSS(m) NA [259]
Partition coefficient of lung to
plasma
PLG:P(m) 21.8 Calculated [184,195,196]
Partition coefficient of the combined
other organs to plasma
POT:P(m) 6.31 Calculated [184,195,196]
Partition coefficient of blood to
plasma
PBL:P(m) (= Pb) NA [259]
Partition coefficient of kidney to
plasma
PKD:P(m) 7.99 Calculated [184,195,196]
Partition coefficient of hepatocyte
to plasma
PLC:P(m) (= P7p) 6.52 Calculated [184,195,196]
Partition coefficient of extracellular
space to plasma
PES:P(m) (= P6p) 6.52 Calculated [184,195,196]





Exponential decay in the combined
other organs (L/hr)
µ(m) 0.0001 Assumed based on sensi-
tivity analysis
NA, not available due to the FDA data confidentiality under the Code of Federal Regulations
Title 21 Part 20 [245], the individual observed data are not shown.
(m) denotes metabolite sirolimus.
5.5 Discussion
Both temsirolimus and sirolimus are mTOR inhibitors [223, 267]. However, water solu-
bility and chemical stability of sirolimus is poorer than those of temsirolimus [201, 224, 265,
267, 268]. Because of the difference in these properties, Ballou et al. discussed that tem-
sirolimus can be administered intravenously and rapidly converted to sirolimus which seems
to be responsible for the difference in pharmacological effects from sirolimus [267]. Although
the exact mechanism of inhibition of mTORC1 complex (a complex formed by mTOR when
it binds to regulatory subunits of lipid kinases of the phosphatidylinositol 3-kinase [PI3K]
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family) by these drugs is unclear [267], temsirolimus clinically exhibits an anti-cancer effect
with a less immunosuppressive effect than the immunosuppressant, sirolimus [223].
Temsirolimus is an ester analog of sirolimus and it gets converted to sirolimus by esterase.
Both temsirolimus and sirolimus undergo CYP3A4- and P-gp-mediated elimination pathways
in the liver [227,229]. There are some metabolism pathways other than CYP3A4 for the two
entities including CYP3A5 and CYP2C8 [246,248–250]. However, CYP3A4 is a predominant
pathway among CYP enzymes [229,246,249]. Furthermore, the abundance of CYP3A5 was
found to be very small and negligible in human hepatocytes [247]10. Accordingly, our focus
was to model CYP3A4 and P-gp activities for which both temsirolimus and sirolimus are
substrates. We also modeled a non-CYP3A4-dependent clearance to describe relatively large
undetermined metabolic pathway(s)11 of sirolimus reported in preclinical literature [246] as
described in Section 5.3.2.
The extent of each contribution of elimination pathways and the effect of rifampin on
the pathways are hard to evaluate when we have the overlapping metabolism of temsirolimus
and sirolimus. It is also essential to consider a potential interplay between CYP3A4 and P-
gp activities with interindividual variabilities. CYP3A4 and P-gp are shown to interplay in
several rifampin-inducing drug-drug interactions (DDIs) [110,270]. A marked interindividual
variation has been also seen in rifampin-induced CYP3A4 expression [271]. On the other
hand, the role of P-gp has been inconsistent in the context of interplay between CYP3A4 and
P-gp. P-gp is less expressed in the human liver compared to the intestine [244,247,272,273].
Rifampin is known to be a strong inducer of CYP3A4 for P450-mediated metabolisms
for concomitant use in clinical DDI studies [241]. For example, rifampin has been shown to
reduce AUC of concentration-time data of the sensitive CYP3A4 index substrate midazolam
10Note that temsirolimus is a relatively recently approved drug and clinical pathway contributions (%)
of esterase and CYP enzymes have not been published. Determining all metabolites of temsirolimus is
analytically difficult and they are not fully determined [232]. As in Section 5.3.3, the initial input parameters
related to these pathways are either not shown due to the FDA data confidentiality or assumed. See Table 26.
11Undetermined metabolic pathway(s) means the metabolic pathway(s) other than CYP3A4, CYP3A5,
and CYP2C8-mediated pathway(s) [250]. The specification regarding these metabolic pathways was not
available for the in vitro data we used for IVIVE calculation. Accordingly, the model structure could not
be specified if we did not limit the hepatic metabolic pathways to evaluate. In addition, multiple metabolic
pathways in iPBPK-R are likely to be indistinguishable mathematically as discussed in the limitations later
in this section. The bioavailability of sirolimus has been reported to be 14% using a two-stage population
analysis of meta-data consisting of single IV, single PO, or multiple PO doses [269], which is not relevant
information in the context of this hepatic model building for sirolimus as a metabolite of temsirolimus.
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(PO, 15mg) by 96% in healthy subjects [241–243]. Strong inducers are defined to decrease
the AUC of sensitive index substrates of a given metabolic pathway by greater than or equal
to 80%. Rifampin serves as a strong inducer for CYP2C19 and as a moderate inducer for
CYP1A2, CYP2B6, CYP2C8, and CYP2C9 for concomitant use in DDI studies as well.
Furthermore, P-gp activity is also reported to be affected by rifampin [244]. In this study,
we applied iPBPK-R to the four series of blood concentration datasets of temsirolimus and
sirolimus. To the best of our knowledge, this is the first study to simultaneously estimate each
contribution of CYP3A4 and P-gp to the nonrenal elimination pathways of temsirolimus and
sirolimus and the effect of rifampin in healthy individuals in an integral fashion via iPBPK-R
modeling.
Compared to our previous applications of iPBPK-R to production rate data [105, 106],
fitting the iPBPK-R model to multiple concentration datasets was a harder problem and
required more computation resources. Model fit took on average 160 times as long as in
our previous work. Accordingly, the model fit was a little compromised. However, we could
observe a good model fit across the four datasets where the average normalized residual means
in Period 1 and Period 2 were 36% and 31% for temsirolimus and 0.9% and 1.1% for sirolimus
(Figure 33) since the general acceptable criterion for PBPK model prediction of mean Cmax
and AUC (thus, not even for individual Cmax or AUC) is 2-fold or 200% of observed Cmax or
AUC (see Section 1.4.5). In our iPBPK-R the relative difference in AUC for the hypothetical
individual ranged from 0.91 to 1.08 (Table 23). Note that fitting Cmax for temsirolimus was
relatively hard in this one hypothetical individual (relative difference: 1.86 without rifampin
and 1.79 with rifampin in Table 23) given the complex model structures for two compounds
being used in the simultaneous high-dimensional parameter optimization. This may be
improved if the parameter dependency relationships are fully established. However, this
requires enormous evaluation time and is out of scope. In addition, these relative differences
are still within the general criterion 2-fold, confirming the overall good performance of the
PBPK model fit.
In this study, 13 co-adjustment factors were selected for nested co-optimization as they
were impactful enough to change the shape of simulated curves and/or biologically rele-
vant. Most of the adjustment factors were closed to 1 including the ones for volumes of
210
compartment and for CYP3A4 and P-gp activities on temsirolimus. Adjustment factors
related to CYP3A4 and non-CYP3A4-dependent pathways of sirolimus were lower than 1.
These are within a reasonable range provided that only a little metabolism information was
available in the literature for calculating IVIVEs due to the complexity and instability of
metabolites [229]. The adjustment factors for esterase activity on temsirolimus and for pas-
sive diffusion of sirolimus resulted in high values. These are not surprising results since the
IVIVE values were not available but assumed value or calculated based on surrogate exper-
imental data (Table 26). Despite the limited input data available, all estimated standard
deviations of adjustment factors were tight, indicating that the performance of iPBPK-R
was consistent across all subjects. Methodologically, iPBPK-R uses a pre-determined model
structure and it does not require a validation step unlike predictive modeling. For this rea-
son, successful high-dimensional parameter optimization across all individuals serves model
validation.
In the inner loop optimization, a total of eight scaling parameters were independently
optimized. The scaling factor for RAF of P-gp at baseline was estimated to be 0 for two
subjects and 0.36 on average for the other subjects, suggesting that P-gp does not have an
essential role on nonrenal clearance of temsirolimus and sirolimus in the model. At the same
time, the scaling factor for RAF of P-gp showed large interindividual variability. There is
no data regarding RAF of P-gp in literature while relative expression factor (REF; relative
expression factor in vivo compared with in vitro) of P-gp has been shown to be variable with
a CV value of 50% in meta-analysis of healthy Caucasian adult database [68]. Under the as-
sumption that the abundance of the transporter is correlated with its activity, our estimated
result of REF was consistent with the literature. In case that this assumption does not hold,
the value of RAF can be only obtained by fitting clinical PK data [68]. In this case, to our
knowledge this is the first study to have estimated RAF of P-gp using model fitting. Ri-
fampin did not affect P-gp activities on temsirolimus and sirolimus according to the estimated
scaling coefficients in Period 2. Rifampin did not significantly affect CYP3A4 activity on
temsirolimus either. However, rifampin significantly increased CYP3A4 activity on sirolimus
by 73% in the estimated coefficient on average with a great interindividual variability. The
asymmetric effect of rifampin on CYP3A4 activities for temsirolimus and for sirolimus may
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be explained by the difference in chemical structure. Temsirolimus is synthesized by intro-
ducing the 2,2-bis-(hydroxymethyl)-propionate side chain at the C40 position (the same C40
position of sirolimus)12 [232]. It is suggested that this structural difference result in signifi-
cant steric hindrance and block CYP3A4 activity on the 39-O-methyl group of temsirolimus.
Cai et al. discussed that sirolimus (or temsirolimus) may alter its structure conformation
after binding to target proteins in vivo and thus changes CYP3A4 action and results in a
different biotransformation profile than that found in vitro [229]. Our iPBPK-R application
quantified the asymmetric role of CYP3A4 on temsirolimus and sirolimus and its alteration
by rifampin, which was consistent with the preclinical literature [229]. The estimated scaling
factor (induction/inhibition coefficient) indicated that rifampin increased not only CYP3A4
activity but also non-CYP3A4 dependent metabolism of sirolimus in the liver. Based on the
abundance of hepatic CYP3A5 which is the shared pathway of temsirolimus and sirolimus,
CYP3A5 activity for sirolimus was assumed to be negligible in Section 5.3.2. Accordingly,
the part of enzymes responsible for the non-CYP3A4-dependent metabolism of sirolimus
may be CYP2C8 as discussed above. The increase of non-CYP3A4-dependent metabolic
activity on sirolimus may be partly explained by that rifampin is a CYP2C8 inducer as
well [241]. However, the literature used for calculating the IVIVE input of non-CYP3A4-
dependent clearance did not provide the full specifications of these non-CYP3A4 enzymes
in vitro [246]. Jacobsen et al. discussed that other than CYP2C8 (and CYP3A4/3A5) there
are likely to be undetermined CYP enzymes responsible for the metabolism of sirolimus in
vivo [250], and thus non-CYP3A4 enzymes other than CYP2C8 cannot be determined as
discussed below.
This study has several limitations. First, among potential CYP-mediated pathways
CYP3A4 alone was modeled for temsirolimus assuming that CYP3A4 clearance is a dominant
metabolism pathway. However, the recently published literature suggested that CYP3A5 and
CYP2C8 are also responsible for metabolizing temsirolimus to a lesser extent [232]. Due to
the nature of the reduced order model structure, multiple CYPs cannot be mathematical dis-
tinguishable in terms of parameter optimization of iPBPK-R. How to add multiple CYPs in
12This numbering in the chemical structure follows the IUPAC nomenclature as Shokati et al. adapted [232]
and it may appear to be different from some literatures which did not follow IUPAC like Cai et al. [229].
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the complex model structure of temsirolimus and sirolimus and how to differentiate parame-
ters in estimation will be investigated in our future studies. Second, population IVIVE values
were calculated for a 70 kg male. The variability in body size may be partly reflected in the
adjustment factors for the volumes of compartments such as hepatocyte compartment and
combined other organs compartment. Third, the fitted iPBPK-R models cannot be validated
against the measurements other than the blood concentration data. We confirmed a good
model fit via visual inspection (observed data not shown due to the data confidentiality) and
average normalized residuals across all individuals. Multiple coupled blood concentrations
were measurements in this study, which added a unique challenge compared to our former
applications where the dynamic first derivative of concentrations was a measurement. How-
ever, the PK parameters (i.e., AUC, Cmax, and t1/2) of the original population PK analysis
of temsirolimus and sirolimus conducted by Boni et al. [240] were overall comparable with
the PK parameters calculated based on the iPBPK-R result of the hypothetical individual
data as discussed above. Thus, our finding on the asymmetric effect of rifampin on CYP3A4
activities aligned with the published result by Boni et al. that rifampin did not change
the hepatic metabolism of temsirolimus but increased the hepatic metabolism of sirolimus.
Fourth, P-gp is known to have single nucleotide polymorphisms associated with altered drug
disposition of P-gp substrates [274]. For the healthy subjects of which we modeled the PK
profiles of temsirolimus and sirolimus, genetic variant data of P-gp was not available. There-
fore, for instance we could not evaluate whether the large variability in the estimated RAF
of P-gp was caused by the P-gp variants or not. Fifth, we did not model esterase activity
of non-hepatic organs since no in vitro literature information of non-hepatic esterase was
available for temsirolimus as well as estimating parameters in iPBPK-R requires a reduced
order model (see Chapter 2). The purpose of this chapter is to present the feasibility of
extending the iPBPK-R method to multiple coupled drug concentrations rather than rate
data and to evaluate the effect of rifampin on hepatic elimination pathways. While esterase
which converts temsirolimus to sirolimus is distributed outside of the liver in humans [275]
and was not explicitly modeled in iPBPK-R, exponential parameters included in combined
other organs compartment may explain the esterase activity outside of the liver. In addi-
tion, rifampin was assumed not to affect esterase activity in Table 22. Therefore, using the
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reduced order model does not critically affect our achieving the objectives.
Regarding goodness-of-fit, the faster transient and higher peak of the simulated curves
for temsirolimus may be improved. One possible approach may be to model the esterase
clearance instead of general exponential decay in the other organs compartment. Another
approach could be to model sub-level compartments for the vein compartment. However,
these approaches require further input values from the literature and extensive evaluation
on the Bridges supercomputer, and it is not immediately implementable. Our future studies
include evaluation of the effect of rifampin on the interplay between CYP3A4 and P-gp in
patients with chronic kidney disease via iPBPK-R since Vitamin D receptor is reported to
affect the CYP3A4 induction [244]. We are also interested in exploring relationships between
nonrenal pathway parameters and uremic toxins as potential biomarkers using iPBPK-R
analysis when uremic toxin data become available.
5.6 Conclusions
In conclusion, parameters related to multiple non-renal elimination pathways of tem-
sirolimus and sirolimus and the effect of rifampin on these pathways were simultaneously
estimated using iPBPK-R in healthy individuals. The iPBPK-R framework was applied
to multiple blood concentration datasets and the potential interplay between CYP3A4 and
P-gp was evaluated for both temsirolimus and sirolimus. iPBPK-R showed a good model
fit to both temsirolimus and sirolimus concentration-time data individually across two study
periods. We found that rifampin did not affect CYP3A4 activity on temsirolimus but in-
creased it for sirolimus by 73% in the estimated coefficient. These results of CYP3A4 activity
aligned with the published results of population PK modeling of the same data by Boni et
al [240] where rifampin did not change the hepatic metabolism of temsirolimus but increased
the hepatic metabolism of sirolimus. However, iPBPK-R allowed us to make further infer-
ences on nonrenal elimination pathways. Thus, the increase of CYP3A4 by rifampin was
also interindividually variable. Rifampin did not affect P-gp activity on temsirolimus or
sirolimus. iPBPK-R enabled estimation of all scaling parameters to measure the effect of
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rifampin on the different nonrenal elimination pathways, which cannot be implemented via
classical population PK modeling of the same datasets. In the future, iPBPK-R will be
applied to a similar type of multiple coupled concentration datasets in patients. This will
facilitate exploring relationships of the mechanistic alteration with pathphysiological states
and identifying the cause and extent of interindividuality in a patient cohort. We anticipate
that iPBPK-R will be a pragmatic tool towards future precision medicine.
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6.0 Conclusions and Future Directions
6.1 Summary and Key Findings
The purpose of this dissertation research was to develop a novel PBPK model and mea-
surement procedure, iPBPK-R, to simultaneously estimate parameters for hepatic drug elim-
ination pathways in individuals and evaluate the effect of kidney impairment on these path-
ways. Furthermore, the potential to extend application of iPBPK-R to drug concentration
data was explored through estimation of nonrenal elimination pathways of parent drug and
its metabolite in healthy subjects.
In Chapter 2 we have mathematically described the iPBPK-R framework. It allows us to
estimate multiple physiological parameters in individuals using a single probe drug. iPBPK-
R is an indirect signal processing-based measurement method for biological quantities in
humans that cannot be directly measured. As guiding example we showed a procedure to
estimate hepatic enzyme and drug transporter activities through breath samples clinically
obtained via EBT: a small dose of radio-labeled erythromycin is intravenously administered
and the subsequent content of radio-labeled CO2 is measured repeatedly in exhaled breath;
the resulting time series was analyzed. We developed a 14-variable non-linear reduced order
dynamical model that describes the behavior of the drug and its metabolites in the human
body well enough to capture all biological phenomena of interest. Based on this system
of coupled non-linear ODEs we treated the measurement problem as inverse problem: we
estimated the ODE parameters in individual subjects from the measured EBT time series.
These estimates then provided a measurement of the hepatic activity of interest. The param-
eters are hard to estimate as the ODEs are stiff1 and the problem needs to be regularized to
ensure stable convergence. In iPBPK-R, regularization was achieved via penalty terms (e.g,
bias, lower bound, drift, and X-shift) in objective functions that are used in nested optimiza-
tion or co-optimization. We developed a formal framework based on operators represented
1”Stiff equation” is a standard numerical analysis term commonly used in pharmacometrics modeling and
simulation and in software/programs including NONMEM, Madonna, and R [276–278]. Certain numerical
methods for solving stiff equations are numerically unstable if the step size is not set to be very small [279].
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as matrices of scalar function to capture and treat the specific non-linearities present, and
perform perturbation analysis to establish properties of the estimation procedure and its
solution. Development of the method required 150,000 CPU hours at a supercomputing
center. Figure 37 depicts the iPBPK-R approach contrasting with general PBPK modeling.
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Figure 37: Comparison between general bottom-up PBPK approaches and the middle-out
iPBPK-R approach.
Scheme and features are highlighted for general bottom-up PBPK approaches (top panel)
and the middle-out iPBPK-R (bottom panel) [280]. The concentration-time plot in the top
panel is reprinted from Jamei et al [101].
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In Chapter 3, a 7-compartment model (a system of nonlinear ODEs) including linear
CYP3A4 clearance and nonlinear transporter clearances were fit to 14CO2 production rate
–time curves obtained from an EBT study in healthy individuals [127]. 14C-erythromycin
in EBT is a substrate of hepatic CYP3A4, OATPs, P-gp, and MRP2. Using a nested pa-
rameter estimation method developed in iPBPK-R, scaling factors called adjustment factors
for IVIVE inputs on maximum velocity (Jmax) of transporters, CYP3A4 clearance, among
others, were simultaneously estimated. Multiple parameter estimation, in particular, esti-
mation on nonlinear transporter clearance in the system of ODEs, is mathematically diffi-
cult [59] [73] [97] [99]. Rate data for 14CO2 production, as the approximate first derivative
of 14CO2 concentration data, turned out to be more dynamic and sensitive data than con-
centration data, allowing iPBPK-R to successfully extract parameter information related
to nonrenal elimination pathways regardless of rate-limiting steps. Sensitivity analysis was
used to show that multiple PK parameters including CYP3A4 and OATPs activities control
the shape of 14CO2 production rate–time curve. Estimated multiple parameters indicated
that CYP3A4 activity is much lower than the baseline IVIVE input (median: 12.2% of the
IVIVE) in 12 healthy subjects2. Females had a higher CYP3A4 activity than males by
11.3%. In addition, the low molecular weight uremic toxin BUN and the adjustment factor
for Jmax of OATPs transporter had a negative correlation in an exploratory analysis.
CKD is known to differentially affect nonrenal clearance (CLNR) pathways [17]. Though
highly variable, generally OATP activity decreases as kidney function declines [30, 92, 93,
209,210,216] while CYP3A4 remains relatively unaffected [210]. In contrast to the accumu-
late evidence regarding the effect of CKD on transporter- and enzyme-mediated activities
in CLNR, the effect of hemodialysis on individual CLNR pathways has not been elucidated.
iPBPK-R and erythromycin breath test data can be leveraged to assess CLNR pathways. In
Chapter 4, iPBPK-R was applied to two sets of 14CO2 production rate data (EBT data) in
12 ESRD patients receiving standard hemodialysis [128]. The iPBPK-R model was fit to the
observed production rate-time curves pre- and post-HD in all patients, showing an excellent
2Note that the IVIVE inputs here are reference values and get optimized. As long as parameter optimiza-
tion in iPBPK-R is sound which is shown in Chapter 2, the initial value of IVIVE × adjustment factor always
captures and estimates the true parameter value for the pre-specified model structure. In this sense, the
validity of the input value is not essential while the consistency in parameter estimates within a reasonable
distributional range self-validates the iPBPK-R method as discussed in Chapter 2.
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model fit. The iPBPK-R parameter estimates indicated that CYP3A4 activity increased
only marginally post-hemodialysis. OATP activity was not increased post-hemodialysis
but showed high interindividual variability. Females had 22.2% and 29.8% higher median
CYP3A4 activity than males pre- and post-hemodialysis, respectively. Thus, the higher
CYP3A4 activity in females than males was consistent with the PBPK analysis in healthy
subjects. No relationship between BUN and activity of CLNR pathways was observed. Ex-
ploratory hierarchical cluster analysis identified two patients with highly improved CYP3A4
activity with decreased iPTH, which was not statistically tested. Considering that in vitro
metabolic clearance tends to have a high interindividual variability [66], estimation of indi-
vidual adjustment factors in iPBPK-R can account for a deviation from a reference IVIVE.
This work provides a proof of principle that iPBPK-R may be used to evaluate the effect of
hemodialysis on CLNR pathways.
In Chapter 5, iPBPK-R application was extended to multiple coupled concentration
datasets rather than production rate data. Our objective was to evaluate the ability of
iPBPK-R to distinguish and simultaneously estimate the contributions of nonrenal elimi-
nation pathways mediated by CYP3A4 and P-gp to the disposition of temsirolimus and its
metabolite sirolimus within healthy individuals. Intravenously administered temsirolimus
gets converted to its metabolite sirolimus by esterase while both temsirolimus and sirolimus
are substrates of hepatic CYP3A4 and P-gp. In a classical PK analysis of a DDI study
of temsirolimus, rifampin did not affect PK profiles of temsirolimus but decreased Cmax
and AUC of sirolimus in a healthy cohort [240]. iPBPK-R was applied to four concen-
tration datasets and each contribution and potential interplay of CYP3A4 and P-gp was
simultaneously evaluated for temsirolimus and sirolimus. iPBPK-R analysis indicated that
rifampin increased CYP3A4 activity on sirolimus by 73% but not temsirolimus or P-gp activ-
ity in healthy individuals. The estimated induction was also interindividually variable. The
iPBPK-R application in this chapter allowed us to quantify the asymmetric role of CYP3A4
on temsirolimus and sirolimus and its alteration by rifampin. This asymmetric result was
consistent with the preclinical literature [229].
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6.2 Clinical Implications and Limitations
6.2.1 Clinical implications
In clinical pharmacology research, EBT was once used as a CYP3A4 probe based on the
premise that the radio-labeled drug 14C-erythromycin undergoes enzymatic metabolism by
CYP3A4 in the liver and a final by-product 14CO2 in this elimination pathway gets released
into the breath. However, erythromycin has overlapping substrate specificity for not only
CYP3A4 but also for uptake and efflux transporters (OATPs, MRP2, and P-gp) so that the
simple interpretation on CYP3A4 activity will be misleading.
In Chapters 3 and 4, iPBPK-R enabled us to distinguish and simultaneously estimate the
activity of multiple non-renal elimination pathways of erythromycin in healthy subjects and
patients with kidney disease receiving hemodialysis. Using iPBPK-R a new interpretation of
EBT data was obtained. We found that production rate data has rich information allowing
estimation of per-person PBPK parameters. These application studies serve as proof of
principle that the iPBPK-R framework is a novel tool for delineating rate-limiting and non-
rate-limiting elimination pathways using a single probe. We anticipate that iPBPK-R will
enable us to evaluate the mechanistic impact of disease or intervention on drug disposition
with individualized multiple parameter estimation.
iPBPK-R can be applied to other rate-derived data like volatile organic compounds col-
lected and measured from breath samples (called breath biopsy samples) [124] beyond EBT,
which was shown theoretically in Chapter 2. Breath biopsy analysis is an emerging area since
breath tests can be used non-invasively for biomarker research and conducted efficiently with
advanced technology [125,131]. Breath tests are also potentially cost-effective. As the latest
topic, some volatile organic compounds (VOCs) that can be measured in breath samples are
studied to see if they can be biomarkers for detecting individuals infected with Coronavirus
Disease 2019 (COVID-19) [125]. Including this current pandemic example, potential areas
to apply iPBPK-R in breath biopsy research are drug-drug interaction, pathophysiological
effects on drug disposition, among others. In kidney disease, the role of biomarkers on
hemodialysis efficiency can be evaluated by exploring correlations between iPBPK-R-based
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parameter estimates and uremic toxin concentrations.
iPBPK-R has a potential to be a tool to evaluate candidate biomarkers. Although it
is an exploratory analysis, BUN was negatively correlated with hepatic OATP activity in
healthy subjects but not in ESRD patients. This may suggest that BUN is well dialyzable
and not a good candidate biomarker to evaluate nonrenal drug disposition in patients on
hemodialysis. When a panel of uremic toxin data is available, iPBPK-R analysis enables us
to identify uremic toxins that have altered relationships with nonrenal elimination pathways
in patients with kidney disease compared to healthy subjects. Such uremic toxins may be
found to be good biomarker candidates to identify kidney disease at an early stage.
In Chapter 5, the asymmetric effect of rifampin on CYP3A4 activity, which was estimated
using two scaling parameters to specifically measure the changes of CYP3A4 clearance for
temsirolimus and for sirolimus in iPBPK-R, may be explained by the difference in chemical
structure. In an article published this year Shokati et al. discussed that temsirolimus having
the 2,2-bis-(hydroxymethyl)-propionate side chain at the C40 position (the same C40 position
of sirolimus)3 may block CYP3A4 activity on the 39-O-methyl group of temsirolimus due to a
steric hindrance [232]. As a result, a different biotransformation profile between temsirolimus
and sirolimus may have been found in vivo. This is the first PBPK model-based estimation
work that quantified the asymmetric effect of temsirolimus and sirolimus in vivo. This
presents an ability of iPBPK-R to allow us to evaluate physiologically dependent data of
clinical pharmacology studies and gain mechanistical insights in vivo.
Throughout the dissertation research, iPBPK-R provided a solution with high accuracy
in model fit and biological plausibility. This may enable iPBPK-R to facilitate drug dosing
based on measured personalized parameter value after extensive clinical research to iden-
tify appropriate substrate probe(s) and validate them using the method. The estimated
personalized parameters cannot be measured without the mechanistic model fitting. Thus,
personalized parameter estimation could be seen as one candidate approach, individualized
modeling, suggested to use for precision dosing [281] [282].
3This numbering in the chemical structure follows the IUPAC nomenclature as Shokati et al. adapted [232]
and it may appear to be different from some literatures which did not follow IUPAC like Cai et al. [229].
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6.2.2 Limitations
There are also limitations in the method and applications of iPBPK-R. First, iPBPK-R
uses pre-specified reduced order models. Determining the model structure and the param-
eters to be optimized require sufficient prior knowledge about system- and drug-properties
and various sensitivity tests to make it work. When two transporters have the same role
in the system of nonlinear ODEs, they need to be treated as one global transporter so that
its combined parameters can be optimized. Accordingly, it is important to initially evaluate
whether a substrate is a good candidate to apply iPBPK-R based on the detailed mechanism
of drug disposition (i.e., the the enzymes and transporters) involved.
Second, when PBPK modeling is conducted, it may not be possible to obtain all necessary
in vitro experimental data in the literature to calculate IVIVE values, especially for newer
drugs. For example, we could not obtain in vitro clearance value of esterase for temsirolimus,
and its IVIVE value was a best assumed value. However, this would be a more critical
problem for population PBPK modeling to predict PK profiles but not so much for iPBPK-
R to estimate parameters since the parameters are to be optimized in iPBPK-R while the
assumed IVIVE value is treated as a reference value. When an experimental in vitro data
becomes available, the assumed reference can be replaced with a newly calculated IVIVE
using the in vitro data. Then, the original estimated parameters (e.g., adjustment factors
estimated in iPBPK-R) can be simply recalculated and updated by multiplying the original
parameter estimates with the ratio of the original and new references if needed.
Third, the sample sizes of the clinical studies in Chapters 3 and 4 were small. Although
the sample sizes are typical for clinical pharmacology studies, all correlation analyses with
uremic toxins had an exploratory nature due to a lack of statistical power. Our conclusions
on uremic toxin require validation with large-scaled clinical trials. Note that the actual
minimum number of required sample size can be calculated based on a pre-determined effect
size of a particular uremic toxin between females and males, for example, as well as based
on the statistical power one wants to achieve. The sample size calculation is not derived by
iPBPK-R modeling itself. Therefore, the minimum sample size cannot be generalized and it
needs to determined at a stage of designing a clinical study according to its specific study
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objectives.
Fourth, no genetic variant data of OATPs was available for the application studies of
iPBPK-R in Chapters 3 and 4. Therefore for instance, we cannot conclude whether CYP3A4
activity solely had a sex difference or this finding was biased by the interplay with OATP
variants. However, the sex difference in CYP3A4 activity was consistent between healthy
subjects and patients with kidney disease and further investigation on the sex difference is
warranted.
Fifth, CYP3A4 and transporter activity estimates derived from iPBPK-R modeling were
not compared to or validated using substrate specific probes as controls. The fitted model
cannot be validated against the measurements beyond the breath data although visual in-
spection and normalized residuals calculated from predicted and observed curves indicated
excellent model fit across all individuals. When clinical studies will be designed to apply
iPBPK-R, it is also essential to plan to collect different samples (e.g., plasma or urine sam-
ples) in order to validate the simulation results with observed PK parameters and build
confidence on the applications of iPBPK-R. Similarly, in Chapter 5 the fitted iPBPK-R
models were not validated against the measurements other than the blood concentration
data. We confirmed a good model fit via average normalized residuals across all individu-
als. In addition, simulated PK parameters were within 2-fold of observed ones for the mean
data (which was used as a hypothetical individual). However, the overall goodness-of-fit
of the EBT studies seemed to be better than that in the application of iPBPK-R to the
coupled concentration datasets of temsirolimus and sirolimus. Improving the model fit for
the drug concentration data under mathematical constraints may be further investigated.
Potential avenues of exploration include speeding up optimization procedures that will en-
able understanding functional dependency in the system of nonlinear ODEs for temsirolimus
and sirolimus. Another avenue may be to account for the minor enzyme-mediated pathways
(e.g., CYP3A5, CYP2C8, etc.) in the model for which pharmacometrics research on how to
distinguished the same type of clearance terms of ODEs is required and for which the IVIVE
values for temsirolimus are not available in literature.
In terms of the iPBPK-R method development, simulations and parameter optimization
demanded high computational resources (the Bridges supercomputer) because it was imple-
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mented in R. To make it a useful tool for clinical practice, an efficient programming language
like C++ would need to be used to shorten the simulation time enormously and improve the
efficiency of iPBPK-R. This would require substantial development effort and cost.
6.3 Future Directions
We anticipate that iPBPK-R can become a step towards precision drug dosing and per-
sonalized medicine. iPBPK-R is a mechanistic and indirect measurement approach so that
for instance in vivo CYP3A4 activity can be estimated for a particular individual using a
single probe given the individual’s high resolution measurement data. In such estimation,
other physiological activities are simultaneously accounted for via iPBPK-R. CYP3A4 ac-
tivity can be repeatedly estimated before and after intervention or disease progression, so
not only inter-individual comparisons but also longitudinal individual monitoring can be im-
plemented. This indicates that sources of inter-individual variability can be mechanistically
identified and that iPBPK-R may also provide a means of personalized dosing of narrow
therapeutic drugs based on the particular individual’s physiological activity. For example,
if the source of inter-individual variability is identified to be a particular uremic toxin and if
the corresponding individuals who exhibit a great increase in estimated activity of nonrenal
elimination pathway (e.g., CYP3A4) are identified post-hemodialysis (as an intervention), a
higher dosage of CYP3A4 substrate drug could be considered to optimize the drug dosing for
these patients (after iPBPK-R is validated with necessary clinical studies). Alternatively, the
uremic toxin may be used as a biomarker for evaluating the activity of the associated nonre-
nal elimination pathway in the individuals and thus used for dose optimization based on the
evaluated pathway activity. Potential fields of application of iPBPK-R includes nephrology,
oncology, pediatrics, and other health conditions where exact knowledge of patient would be
of high value.
In Chapters 3 and 4, we could show exploratory results of correlations between uremic
toxins and nonrenal elimination-related parameters in healthy individuals and CKD patients.
Our next step is to design exploratory and confirmatory clinical trials in a sequential fashion
225
where many subjects with different CKD severity are evaluated for their nonrenal elimination
pathways and the effect of kidney disease on these pathways. Furthermore, uremic solutes
as candidate biomarkers will be investigated using iPBPK-R analysis and one or some of
them will be identified as early diagnostic biomarker(s) for kidney disease.
To establish iPBPK-R as a feasible method with clinical utility, we need to validate the
method with applications in appropriate large-scale clinical trials using breath test samples.
In the past decade, development of breath sampler tool kits has been advanced [125] and
breath biopsy/biomarker research is emerging as well [124,131]. Given this environment, we
anticipate that there will be opportunities to apply iPBPK-R. To facilitate use of iPBPK-R,
substrate probes with preferable properties would need to be explored. The substrate probes
will be or converted to VOCs to be measured in breath samples. VOCs should originate
from exogenous compounds since they can be directly used as probes [124]. VOC probes can
have multiple substrate specificity but they should be distinguishable in high-dimensional
parameter estimation. For example, 13C-methacetin breath test has been under development
as a VOC breath test for assessment of maximal liver function as 13CO2 is its by-product
in the CYP1A2-mediated metabolism pathway that is altered in liver dysfunction [283].
Some VOC probes could be partially converted to generate radio-labeled CO2 by oxidation
if CYP3A4 is responsible for the biotransformation [284].
Another future direction for the iPBPK-R methodology is to explore its utility for drug
concentration data since concentration data is a common measurement in Clinical Pharma-
cology research. In Chapter 5, we presented the application of iPBPK-R to multiple coupled
drug concentration data series of temsirolimus and its metabolite sirolimus in healthy sub-
jects. In this application, intravenously administered temsirolimus can be viewed as a single
probe. One of the findings was the asymmetric effect of rifampin on the activity of CYP3A4
for the two compounds as estimated using the scaling parameters in iPBPK-R. Our future
studies include evaluation of the effect of rifampin on the interplay between CYP3A4 and
P-gp in patients with CKD via iPBPK-R since Vitamin D receptor is reported to affect the
CYP3A4 induction [244]. iPBPK-R will allow us to quantify such induction or inhibition and
show mechanistic relationships of disease or intervention, potential biomarkers (e.g., uremic
toxins or Vitamin D), and in vivo activities related to nonrenal clearance. Similarly, iPBPK-
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R may be broadly applied to the same type of multiple coupled concentration datasets in
patients to establish its utility. Ideal drugs that provide such concentration data may have
following properties: (1) multiple disposition pathways are known, (2) two different types
of concentration data are available and they can be coupled through a system of nonlinear
ODEs, (3) elimination half-life is relatively long to differentiate parameter estimates, (4)
concentrations are frequently measured in samples collected in the early phase of PK profile,
(5) In vitro data is sufficiently available to calculate IVIVE values, (6) IV dosing is preferable
to use reduced order models (PO dosing is theoretically possible but actual application of
iPBPK-R requires extensive research starting with specification of model structure), and (7)
individual concentration data are available in both healthy subjects and patients. Defining
specific criteria for these properties will require further methodological research. Success in
establishing use of iPBPK-R for drug concentration data will also lead to exploring relation-
ships of mechanistic alterations in nonrenal clearance with disease severity and eventually
identifying diagnostic biomarkers as well as the cause and extent of interindividuality in a pa-
tient cohort. We anticipate that iPBPK-R will be a pragmatic tool towards future precision
medicine or personalized dosing as described above.
In all iPBPK-R applications, simulations and parameter optimization demanded high
computational resources (the Bridges supercomputer) because it was implemented in R. The
execution time depends on the difficulty of the optimization problem. By switching to a more
efficient programming language like C++ and targeting modern computer platforms with
multicore CPUs and GPUs, it would be possible to shorten the simulation time enormously
and improve the efficiency of iPBPK-R. This would come at substantial development effort
and cost but such development is also essential to make the method more widely applicable.
It may be possible to make a user-friendly (cloud based) phone application of iPBPK-R when
simulations can be implemented much faster with a more efficient programming language.
Lastly, regardless of the data type used in iPBPK-R (i.e., rate or coupled concentration
data series), conducting optimal clinical studies to obtain clinical data will be enormously
costly and it may not be realistic to conduct them in the immediate future. To overcome this
issue, machine-learning and deep learning (ML/DL) or artificial intelligence (AI) can help
to generate approximate clinical data based on literature so that iPBPK-R can be applied
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to the generated datasets and be evaluated for its utility. In Appendix E we outline a
procedure to generate a clinical dataset using neural ODEs [285], which is one of the latest
ML methods that can capture and extrapolate a data series. For example, the limitation of
presenting observed clinical data due to confidentiality (e.g., Figure 33) can be supplemented
along with this type of ML/DL and AI research, and the application of iPBPK-R can be
further facilitated.
In summary, we anticipate that iPBPK-R will serve as a tool to estimate parameters on
both rate-limiting step and non-rate-limiting steps in nonrenal clearance of a single probe
with multiple substrate specificity utilizing clinical rate measurement. It allows us to study
the correlation of nonrenal elimination pathways and uremic solutes and to differentiate pa-
tients with difference in uremic solutes. It may eventually provide clinical utility to evaluate
alterations of drug disposition caused by disease or intervention as well as inter-individuality.
It may identify unique subgroups based on potential uremic solute biomarkers in a patient
population with CKD. It may facilitate drug dosing based on personalized parameter esti-
mation. This can lead to an innovative approach of precision medicine.
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Appendix A
Mass Balance Theorem and Quality Analysis
A.1 Proof of Theorem 1
Here we provide the proof of theorem 1.
Proof We use


























































To establish correctness of mass balance for the model eq. (2.45)–eq. (2.51) used in
iPBPK-R we have to show that eq. (2.45)–eq. (2.51) is an instance of eq. (2.9) and that indeed
eq. (2.11) holds for all edges eij ∈ V × V, and that eq. (2.12) holds for all compartments
Vi, 1 ≤ i ≤ n. Careful inspection of eq. (2.45)–eq. (2.51) establishes this, which proves that
the invariant eq. (2.10) holds for eq. (2.45)–eq. (2.51). Note that in eq. (2.45)–eq. (2.51) as
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instances of eq. (2.9), qij and −qji may be used interchangeably. The choice between qij and
−qji is determined by the arrow in a graph.
A.2 EBT Analysis
In this section we analyze the operator (2.25) to derive its eigendecomposition and thus
be able to make statements about estimable parameters. We pick one (healthy) individual
from the first example from section 2.6.4 and pick concentration ~C = ~0, i.e., no drug in
the system as operating point. At this point all Michaelis Menten non-linearities are fully
linear. Thus we are computing A+ = (X + Y+). The same analysis can be done for the
fully saturated case A−. The resulting matrix is given by
A =

−2003.519 387.097 0 0 387.097 0 0 0 0 0 0 0 0 0
287.542 −185.926 2.860 93.612 0 28.179 0 0 0 0 0 0 0 0
0 2.599 −0.404 0 3.177 0 0 0 0 0 0 0 0 0
0 244.444 0 −189.179 244.444 0 0 0 0 0 0 0 0 0
287.542 0 3.497 9.361 −197.144 −36.296 0 0 0 0 0 0 0 0
0 0 0 0 180.479 −430.361 57.137 0 0 0 0 0 0 0
0 0 0 0 0 223.407 −3.957 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0.076 0 0 0 0 0 0 0 0 0 0 0
0 0 0 1.954 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0.423 0 0 0 0 0 0 0
0 0 0 0 0 0 0.003 0 0 0 0 0 0 0
0 0 0 0 0 0 0.423 0 0 0 0 0 −12.72 0
0 0 0 0 0 0 0 0 0 0 0 0 12.72 0

(A.1)
The matrix A has eigenvalues
θi = 0.0, 0.0, 0.0, 0.0, 0.0, −12.7, −2119.7, −434.0, −290.5, −221.4, 23.7, 32.1, −0.7, 0.0
(A.2)
The spectrum contains two positive eigenvalues 32.1 and 23.7 responsible for the initial
spike in the concentration-time curve. The dominant negative eignevalue is −2119.7 which
captures the initial decay. The terminal slope is driven by the three negative eigenvalues
of similar magnitude, −434.0, −290.5, and −221.4. The dimension of the null space of the
matrix A is 6, capturing the source and sink compartments.
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The eigenbasis of A in ordered according to the eigenvalues is given by
C =

0 0 0 0 0 0 0.977 0.007 0.071 0.003 −0.009 −0.070 −0.019 0
0 0 0 0 0 0 −0.147 −0.097 0.542 0.590 −0.054 −0.284 −0.082 0
0 0 0 0 0 0 0.000 0.000 −0.002 0.001 −0.005 −0.031 0.909 0
0 0 0 0 0 0 0.037 −0.030 −0.754 −0.117 −0.056 −0.405 −0.130 0
0 0 0 0 0 0 −0.146 0.127 −0.229 −0.574 0.006 −0.083 −0.019 0
0 0 0 0 0 0 0.016 0.876 −0.224 −0.387 −0.122 −0.137 0.001 0
0 0 0 0 0 0 −0.002 −0.455 0.175 0.398 −0.989 −0.850 0.066 0
0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 1 0 0 0 0 0 0 0 0 0 0.000 −0.099 0
0 0 1 0 0 0 0 0.000 0.005 0.001 −0.005 −0.025 0.362 0
0 0 0 1 0 0 0 0.000 0.000 −0.001 −0.018 −0.011 −0.040 0
0 0 0 0 1 0 0 0 0 0 0.000 0.000 0.000 0
0 0 0 0 0 0.707 0 0.001 0.000 −0.001 −0.012 −0.008 0.002 0
1 0 0 0 0 −0.707 0 0 0 0 −0.006 −0.003 −0.042 0

(A.3)
This shows that A indeed is a simple matrix and has eigendecomposition (2.42).
Further, factorizing out the null space of A shows that the basis vectors have sufficiently
large angles between them so that the problem does not degenerate. The (i, j) entry of the
matrix below shows the scalar product of projected normalized eigenvector i with projected
normalized eigenvector j of the column space:
1 0.016 −0.009 −0.011 −0.004 −0.030 −0.010
0.016 1 −0.334 −0.646 0.351 0.295 −0.022
−0.009 −0.334 1 0.696 −0.135 0.048 0.072
−0.011 −0.646 0.696 1 −0.375 −0.358 0.005
−0.004 0.351 −0.135 −0.375 1 0.897 −0.063
−0.030 0.295 0.048 −0.358 0.897 1 −0.006
−0.010 −0.022 0.072 0.005 −0.063 −0.006 1

(A.4)
The scalar product of two normalized eigenvectors is between 0.004 and 0.897, which indicates
that all vectors are sufficiently pairwise non-parallel. This together provides evidence that
the EBT problem indeed follows the assumptions of section 2.4.7. To fully establish a proof
of soundness one would have to analyze A+ and A− for all twelve individuals. The results
shown in section 2.6.3 provide further experimental evidence that the analysis holds, as the
modes computed in this section are visible in the results shown in Figure 15 of chapter 3.
This overall adds to the soundness of our approach.
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Appendix B
Detailed ODEs and Proof of Mass Balance for Healthy Subjects
We detail the set of ordinary differential equations (ODEs) used in Chapter 3, our PBPK
model of EBT for healthy subjects. These are actual examples of ODEs in Tables 7 and
table:6 in Chapter 2 using the notation in Table 12. Furthermore, C, C?, and C?? stand for




B.1 ODEs for Concentration Change




































































where µ is a parameter of exponential decay that explains loss or decomposition of the
parent drug.
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where δ is the fraction of the drug filtered via the glomerulus.
































































































































− (kpool1 + kresp)C?LC + kpool2C?pool,BL
(B.8)
where C?pool,BL is the concentration of H
14CO
−





solved in the blood) in the same fashion of equation (5) in Sugiyama et al. 2011. We
referred to their in vivo rat PBPK study and set both parameters kpool1 and kpool2 to 0.










where A??LG is the exhaled amount of
14CO2 in breath, and φ is a conversion factor of
14CO2
from its molecular weight to Ci (a unit of radioactivity) (φ = 1 in our simulations since all
the calculations of concentrations were done in molar base). dA??LG/dt is the radioactivity




14CO2 have a one-to-one molar relationship (no rate-limiting step)
in Equation ( B.9).
B.2 Mass Balance
Similarly to all other pharmacokinetics models, our model uses approximation of physi-
ological behavior. Importantly, we do not intend that our model is a classical PBPK model
that is usually used for prediction. iPBPK-R is rather different, mathematically correct, and
useful for our research purpose of estimating the parameters related to non-renal elimination
pathways after observed data is obtained (i.e., not for prediction). Here we provide a proof
that the mass balance of 14C-erythromycin is retained in our iPBPK-R. As presented in the
application of Chapter 3 (and Chapter 4), the model served our goal well as an application
of the novel approach.
Figure 38 depicts the masses and mass flows of the drug (14C-erythromycin) in the sys-
tem. The system is closed, i.e., no drug mass is created or lost. The system consists of
12 compartments. Among 12 compartments, there is one source compartment (IV dosing
compartment colored with light orange in the figure) and three waste compartments (Ex-
ponential decay in OT, Urine, Metabolism, and Bile compartments colored with light gray
in the figure). Note that seven-compartmental iPBPK-R in Chapter 3 is the result of not
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showing the five input and waste compartments from 12 compartments. In each compart-
ment, there is one state variable, m, which denotes drug mass. q−−→
W:Z
denotes a mass flow
from W compartment to Z compartment and it is represented by an arrow in Figure 38.
In this closed system, at any time the total amount of the drug is constant m0 which is a
system invariant. This drug content m0 is in the source compartment (IV dosing compart-
ment) at time 0 and in the waste compartments at infinite time. Each flow is a directed
and anti-symmetric quantity, which means what flows out of one compartment flows into
the other compartment. The two compartments are connected with an arrow. We assume
that the type of each flow is one or a combination of the following:
- with diffusion (proportional to difference in concentrations between two compartments)
- without diffusion (proportional to concentration of one compartment)
- proportional to non-linear Michaelis–Menten clearance
- proportional to linear clearance
B.3 Equations Depicting Mass Flow as Shown in Figure 38
Then, mass flows in the figure are defined as below where non-linear kinetics are described















































































































Generally, state equation per compartment can be defined as:
change in mass = sum of all inflows of mass− sum of all outflows of mass.
Accordingly, using the above defined mass flows q−−→
W:Z
, the state equation (mass balance
equation) for each compartment in the closed system (Figure 38) can be written as Equations






































Thus, when summed up, all terms on the right hand sides of these equations cancel out,
which indicates that the mass balance is held.
B.4 ODEs for Mass Change










































































































The ODE equations for change in drug concentrations, Equations (1) to (7), can be derived
by dividing both sides of each equation of Equations (11) to (17) by the volume of the
corresponding compartment, VLG, VVein, VOT, VKD, VArt, VES,eff , and VLC, respectively.
Note that q−−−−→
IV:VN
is omitted from the ODE equation of Vein compartment, i.e., Equation (2).
In addition, we assume that the mass flow q−−−−→
Art:ES
from Artery to ES compartment is fast
and thus modeled instantaneous as
CArt = CES. (B.22)
For the mass flow q−−−−→
ES:VN






provided by the well-stirred model assumption in our 2-blood compartment model for the
blood tissue (i.e., Vein and Artery compartments are modeled separately in iPBPK-R). In
other words, Equations (22) and (23) are necessary assumptions in iPBPK-R to approximate
the drug flows between the blood tissue and liver organ when the blood is modeled with two
separate compartments, Artery and Vein, while retaining the well-stirred model assumption
for the blood tissue. This 2-blood compartment model is described in Chapter 2 under
preparation (Franchetti et al. In preparation) as well.
In summary, (i) no drug mass is created or lost in the system (the mass invariant holds)
since all terms of the right hand sides of Equations (10) - (21) cancel out, (ii) all arrows in
Figure 38 align with the signs of the respective flows in the state equations, (iii) all flows
are anti-symmetric since an in-flow on one compartment is the same as the out-flow on
the other compartment, and (iv) all drug flows and compartments correspond to Figure 38.
Our purpose is to estimate the parameters related to non-renal elimination pathways with
observed clinical data. While its set-up may differ from a conventional PBPK model, the
iPBPK-R model served this goal well. Our model is mathematically consistent and correct
given the mathematical principle of mass balance in a closed system established by (i)-(iv).
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③ Lung (LG) ④ Artery (Art) ② Vein (VN) 
Liver (LV) ⑨ Extracellular Space (ES) 
⑩ Liver Cell (LC) 
⑤ Combined  
 other organs (OT) 
⑦ Kidney (KD) 
⑫ Bile (B) 
⑥ Exponential  
 Decay in OT (D) 
⑧ Urine (U) 
① IV dosing (IV) 
⑪ Metabolism (M) 
Figure 38: Mass balance in iPBPK-R
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Appendix C
Nonlinear Systems of ODEs for Temsirolimus and Sirolimus in Healthy
Subjects
We detail the set of ODEs used in Chapter 5, i.e., the PBPK models of temsirolimus
and sirolimus for healthy subjects. These were built following the procedure to set up the
PBPK model of 14C-erythromycin as shown in Tables 7 and 9 in Chapter 2.
C.1 ODEs for Concentration Change
C.1.1 Parent drug: Temsirolimus
A set of ODEs to model the rate of change in parent drug concentrations for healthy
subjects in Period 1 (IV dosing of temsirolimus alone) or Period 2 (IV dosing of temsirolimus
with orally administered rifampin) are listed below. C stands for the blood concentrations of
temsirolimus. Note that initial concentrations (at time 0) in all compartments are 0 except
Vein compartment. Other related notation are shown in Table 24.

















































+ infusion rate (µmol/L/time)
(C.2)






















where µ is a parameter of exponential decay that explains loss or decomposition of the
parent drug (temsirolimus).























where CLR is overall renal clearance so fraction unbound in the kidney compartment is
not accounted for.












































where QES−LC,LV is the clearance by passive diffusion and VES,eff is the effective volume of
extracellular space defined as VES,eff = VES +
VVS
KEW:B
. VS and EW stand for vascular space
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and extracellular water, respectively.

































where OUT1 stands for P-gp efflux transporter while CYP3A4 and EST stand for metabolism
by CYP3A4 and esterase, respectively. α1 and α2 are scaling factors (inhibition and/or
induction coefficients) when rifampin is co-administered in period 2.
C.1.2 Active metabolite: Sirolimus
A set of ODEs to model the rate of change in active metabolite concentrations for healthy
subjects in Period 1 (IV dosing of temsirolimus alone) or Period 2 (IV dosing of temsirolimus
with orally administered rifampin) are listed below. C? stands for the blood concentrations
of sirolimus and ? denotes sirolimus. Note that initial concentrations (at time 0) in all com-
partments are 0. Other related notation are shown in Table 24.























































































where µ? is a parameter of exponential decay that explains loss or decomposition of the
active metabolite drug (sirolimus).





























where CL?R is overall renal clearance so fraction unbound in the kidney compartment is
not accounted for.






















































where Q?ES−LC,LV is the clearance by passive diffusion and VES,eff is the effective volume of
extracellular space defined as V?ES,eff = VES +
VVS
K?EW:B
. VS and EW stand for vascular space
and extracellular water, respectively.






































where OUT1 stands for P-gp efflux transporter while CYP3A4 and NONCYP3A4 stand
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for metabolism by CYP3A4 and non-CYP3A4 dependent enzyme, respectively. α?1, α
?
2,
and α?3 are scaling factors (inhibition and/or induction coefficients) when rifampin is co-
administered in period 2.
We assume that the metabolized amount of temsirolimus by esterase and generation of




Derivation of IVIVE Values based on MDR1-MDCK Data for sirolimus
In this appendix, derivations of surrogate IVIVE values for intrinsic clearance of P-gp
and total passive diffusion between extracellular space and hepatocyte are shown. These
surrogate IVIVEs were used as initial inputs in the iPBPK-R modeling for sirolimus (Ta-
ble 27). The surrogate IVIVE values for temsirolimus (Table 26) were calculated in a similar
fashion.
D.1 In vivo intrinsic clearance of P-gp for sirolimus CLOUT1(m)
The in vitro P-gp clearance data for sirolimus from literature [233] was used to calculate
the surrogate in vivo intrinsic clearance of P-gp for sirolimus (CLOUT1(m) in Table 27). The
cell culture system of this in vitro experiment was based on MDR1-transfected MDCK cells
but not hepatocytes. Therefore, the IVIVE calculation was adjusted by multiplying an
IVIVE equation in literature with the ratio of cell volumes between MDCK and hepatocyte.
First, adopting Burt et al. [68], an IVIVE equation to calculate in vivo intrinsic clearance of
P-gp transpoter in the liver for sirolimus can be expressed as
CLOUT1(m)[L/hr] = CLint(m) × RAF× F× HPGL× Liver Weight× 60−6, (D.1)
where CLint(m) is the in vitro intrinsic clearance for P-gp [µL/(min· million hepatocytes)],
RAF is the activity ratio of P-gp between in vivo and in vitro hepatocytes, F is the relative
abundance for the phenotype of P-gp, HPGL is the number of hepatocytes per gram of the
human liver, and Liver Weight is the human liver weight in gram.
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For convenience, we convert the units in the above equation as follows.
CLOUT1(m)[L/hr] = CLint,cell(m) × RAF× F× HPGL× Liver Weight, (D.2)
where CLint,cell(m) is the in vitro intrinsic clearance for P-gp [µL/(hr· hepatocytes)]. Next,








where β is the in vitro intrinsic transporter clearance per cell for P-gp in MDR1-MDCK,
2.08 × 10−9[cm3] is the typical cell volume of MDCK [266], 3.4 × 10−9[cm3] is the typical
cell volume of hepatocyte [258], and Ncells is the number of cells per insert in the in vitro
experiment. Note that the typical cell volumes of MDCK and MDR1-MDCK cells are
assumed to be the same in the above equation.
Let us assume that RAF = 1 and F = 1 in eq. ( D.2) since RAF for P-gp activity was
designed to be estimated as part of the iPBPK-R modeling (see section 5.3.6, Figure 32, and
Table 22). Furthermore, HPGL = 99× 106[cells/gLiver] [67] and Liver Weight for a 70-kg male
is 2.3% of the body weight [5]. Therefore, by replacing CLint,cell(m) with the above equation






× 1× 1× (99× 106)[cells/gLiver]× (70[kg]× 0.023× 103)[gLiver],
(D.3)
D.2 In vivo total passive diffusion between extracellular space and
hepatocyte for sirolimus QES−LC(m)
In the calculation of the surrogate IVIVE of total passive diffusion for sirolimus (QES−LC(m)
in Table 27), the same MDR1-MDCK experimental data above was used [233]. Therefore,






× 1× 1× (99× 106)[cells/gLiver]× (70[kg]× 0.023× 103)[gLiver],
(D.4)
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where α is the in vitro intrinsic passive diffusion in MDR1-MDCK and Ncells is the number
of cells per insert in the in vitro experiment. Similar to the RAF for P-gp, this surrogate
IVIVE of passive diffusion for sirolilmus was optimized based on the sensitivity analysis of
the iPBPK-R modeling (see section 5.3.6 and Figure 32).
D.3 Calculation of in vitro values for sirolimus from literature
In this subsection, we derive the in vitro intrinsic transporter clearance for P-gp in
MDR1-MDCK (β in eq. ( D.3)) and the in vitro intrinsic passive diffusion in MDR1-MDCK
(α in eq. ( D.4)) from the experimental data in literature [233]. Ncells that is commonly used
in these equations will be also calculated.
Let us suppose that the transwell cell culture system used in the literature can be illus-
trated with parameters as in Figure 39. A and B denote the apical side and basolateral side
of the MDR1-MDCK cell monolayer, respectively. The left panel of the figure shows the cell
monolayer model with parameters used when we consider the permeability from A to B (i.e.,
PAPP(A→B)), while the right panel shows the same cell monolayer model with parameters
when we consider the permeability from B to A (i.e., PAPP(B→A)).
In the left panel of Figure 39, C1, C2, and C3 denote concentrations of sirolimus in A,
in the cell monolayer, and in B, respectively. In the right panel of Figure 39, C ′1, C
′
2, and
C ′3 denote concentrations of sirolimus in B, in the cell monolayer, and in A, respectively. In
both panels, γ1, γ2, and γ3 denote the observed fluxes (i.e., velocities or observed amounts
transferred per time) of sirolimus via P-gp, passive diffusion at A, and passive diffusion at
B, respectively. Both panels show the direction of each γ with a red arrow for setting up
equations of flux shortly.
Using the literature data [233], let C1 = C
′
1 = 1[µM], and C3 = C
′
3 = 0[µM] at time
0 [sec]. C2 and C
′
2 are unknown and assumed to be consistent at steady-state. Note that
all fluxes are assumed to be linear in time in this calculation. Then, to each of the net
fluxes with permeability PAPP(A→B) and PAPP(B→A) in Figure 39, we apply a general net flux
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= PAPP · A · (Cout − Cin), (D.5)
where J is a net flux, V is volume of flux, A is surface area of the membrane, Cout is the
drug concentration at the side where the drug is applied in the transwell experiment, and
Cin is the drug concentration at the other side of the transwell (based on fluid dynamics).
Accordingly, based on the left and right panels of Figure 39, the net fluxes of A to B and B
to A (denoting K1 and K2, respectively) are calculated as
K1 = PAPP(A→B) · A · (C1 − C3)




= 1.806× 10−10[µmol/s], and
(D.6)
K2 = PAPP(B→A) · A · (C ′1 − C ′3)






Then, each observed flux γ can be expressed with α, β and C, and from the constructed
equations α and β can be eventually calculated. First, based on the left panel of Figure 39,
the net flux K1 in eq. ( D.6) is expressed with γ as
K1 = γ1 = γ2 − γ3. (D.8)
Since each observed flux γ is
γ1 = α(C2 − C3) = αC2, (D.9)
γ2 = α(C1 − C2) = α(1[µM] − C2), and (D.10)
γ3 = βC2, (D.11)






Similarly, based on the right panel of Figure 39, we set up
K2 = γ1 = γ2 + γ3, where (D.13)
γ1 = α(C
′
1 − C ′2) = α(1[µM] − C ′2), (D.14)
γ2 = α(C
′









Solving the eq. ( D.12) and eq. ( D.17) for α and β,






Plugging the values of K1 and K2 in eq. ( D.6)–eq. ( D.7) into eq. ( D.18) and eq. ( D.19),
the in vitro P-gp clearance (β) and total passive diffusion (α) are calculated as
α = 1.48806× 10−8[L/s] = 5.357× 10
−5
[L/hr] and
β = 1.196331× 10−6[L/s] = 4.3068× 10
−3
[L/hr].
Lastly, in this in vitro MDR1-MDCK transwell experiment [233], 250,000 [cells/insert]
were seeded into inserts of diameter 4.2 [cm2], and experiments were conducted after main-
taining the culture for 4 to 5 days. Assuming that the cell cycle was 24 [hrs] on average,
Ncells is approximated as
Ncells = 250, 000× 24.5[days] = 5.67× 106[cells/insert].
Thus, the surrogate IVIVE values of intrinsic P-gp and total passive diffusion in the liver can
be calculated by plugging the above β, α and Ncells into eq. ( D.3) and eq. ( D.4), respectively.
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Figure 39: MDR1-MDCK monolayer models for calculating in vitro values for sirolimus.
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Appendix E
A Procedure to Conduct Deep Learning Simulations for Evaluating iPBPK-R
Presenting individual observed data may not be always possible due to data confidential-
ity, for instance. To address this issue and demonstrate the performance of iPBPK-R model
fit, we outline a procedure to simulate individual clinical datasets using the neural ordinary
differential equation approach [285], which is one of the latest machine learning techniques.
For instance, individual datasets of temsirolimus and sirolimus can be simulated based on
the mean and standard deviation of the same published data [240] used in Chapter 5. The
procedure to simulate the individual datasets is as follows.
1. Conduct iPBPK-R model fit to the mean value of the healthy cohort as a virtual
person.
2. Obtain 16 optimized parameter values from the iPBPK-R model fit.
3. Randomly sample 10,000 parameter sets from the ± 10% of the parameter values.
4. Use the PBPK models of temsirolimus and sirolimus to simulate 10,000 curves using
the 10,000 parameter sets.
5. Train the neural ODE model with the 10,000 curves.
6. Pick independent values randomly at 3 to 5 of 13 sampling time points within the
distributional range of the published data (defined with the observed mean ± SD).
Then, let the system predict the curve based on the picked values. Take values at the
13 time points from the predicted curve as a simulated data series.
7. Repeat 6. so that a data series can be simulated for N individuals. All simulated
datasets will be within the distributional range of the published data.
Using the simulated datasets for N subjects, iPBPK-R model fit can be conducted similar to
the study in Chapter 5. Simulating clinical datasets via ML/DL or AI research will facilitate
not only the evaluation of iPBPK-R but also overall clinical pharmacology research.
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